WO2010031735A1 - Piperazine d3 and 5-ht2a receptor modulators - Google Patents

Piperazine d3 and 5-ht2a receptor modulators Download PDF

Info

Publication number
WO2010031735A1
WO2010031735A1 PCT/EP2009/061788 EP2009061788W WO2010031735A1 WO 2010031735 A1 WO2010031735 A1 WO 2010031735A1 EP 2009061788 W EP2009061788 W EP 2009061788W WO 2010031735 A1 WO2010031735 A1 WO 2010031735A1
Authority
WO
WIPO (PCT)
Prior art keywords
trans
piperazin
ethyl
benzo
isoxazol
Prior art date
Application number
PCT/EP2009/061788
Other languages
French (fr)
Inventor
Luca Gobbi
Georg Jaeschke
Rosa Maria Rodriguez Sarmiento
Lucinda Steward
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Priority to ES09782901T priority Critical patent/ES2402875T3/en
Priority to CA2735400A priority patent/CA2735400A1/en
Priority to EP09782901A priority patent/EP2334657B1/en
Priority to MX2011002628A priority patent/MX2011002628A/en
Priority to BRPI0918949A priority patent/BRPI0918949A2/en
Priority to KR1020117006453A priority patent/KR101329548B1/en
Priority to CN2009801369519A priority patent/CN102159557A/en
Priority to JP2011527297A priority patent/JP5367824B2/en
Priority to AU2009294695A priority patent/AU2009294695B2/en
Publication of WO2010031735A1 publication Critical patent/WO2010031735A1/en
Priority to IL210769A priority patent/IL210769A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Definitions

  • the present invention relates to compounds of the general formula (I)
  • the compounds of formula (I) according to the invention are dual modulators of the serotonin 5-HT 2a and dopamine D 3 receptors.
  • the compounds of the invention have high affinity for the dopamine D 3 and serotonin (5-Hydroxytryptamine; 5-HT) 5-HT 2 A receptors and are effective in the treatment of psychotic disorders, as well as other diseases such as depression and anxiety, drug dependence, dementias and memory impairment.
  • Psychotic disorders encompass a variety of diseases, which include schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and other psychoses involving paranoia and delusions.
  • schizophrenia is characterized by complex symptomatology including positive symptoms, (i.e. delusions and hallucinations), and negative symptoms, (i.e. anhedonia, restricted fluency and productivity of thought and speech).
  • cognitive impairment is the third major diagnostic category of schizophrenia, characterized by loss in working memory as well as other deficits.
  • Other symptoms include aggressiveness, depression and anxiety (Stahl, S. M. (2000) Essential Psychopharmacology. Neuro scientific Basis and Practical Applications. Cambridge University Press, second edition, Cambridge, UK).
  • the different categories and the clinical features of the disorder are defined in diagnostic schemes such as DSM-IV (Diagnostic and statistical manual of mental disorders, 4 th edition) or ICD-IO (International classification of diseases, 10 th edition).
  • Dopamine a major catecholamine neurotransmitter, is involved in the regulation of a variety of functions which include emotion, cognition, motor functions, and positive reinforcement, (Purves, D. et al. (2004) Neuroscience. Sinauer, third edition, Sunderland, Massachusetts).
  • GPCRs G protein- coupled receptors
  • Di-D 5 five different dopamine receptors Di-D 5 have been identified, where the D 2 -like receptors (D 2 , D 3 and D 4 ) couple to the G-protein G ⁇ i (Missale, C. et al.. (1998) Dopamine receptors: from structure to function. Physiol. Rev. 78, 189-225).
  • the D 3 dopamine receptor is most highly expressed in the nucleus accumbens (Gurevich, E. V., Joyce, J. N. (1999) Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuropsychopharmacology 20, 60-80), and is proposed to modulate the mesolimbic pathway consisting of neuronal projections from the ventral tegmental area, hippocampus and amygdala to the nucleus accumbens, which projects to the prefrontal and cingulate cortices as well as various thalamic nuclei.
  • D 3 receptor antagonists are proposed to modulate psychotic symptoms such as hallucinations, delusions and thought disorder (Joyce, J. N. and Millan, M. J., (2005) Dopamine D3 receptor antagonists as therapeutic agents. Drug Discovery Today, 1 JuI, Vol. 10, No. 13, 917-25), while these antagonists spare the D 2 modulated striatal extrapyramidal system (associated with EPS induction).
  • drug naive schizophrenic patients show altered levels of D 3 receptor expression (Gurevich, E. V. et al. (1997) Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study.
  • the neurotransmitter serotonin is implicated in several psychiatric conditions including schizophrenia (Kandel, E. R. et al. (eds.; 2000) Principles of Neural Science, 3 rd edition Appleton & Lange, Norwalk, CT).
  • the involvement of serotonin in psychotic disorders is suggested by multiple studies which include treatment in humans with the psychotropic drug Lysergic acid (LSD; a serotonin agonist) which can induce schizophrenia-like symptoms such as hallucinations (Leikin, J. B. et al. (1989) Clinical features and management of intoxication due to hallucinogenic drugs. Med. Toxicol. Adverse Drug Exp. 4, 324-350).
  • the 5-HT 2 A receptor is most prominently expressed in the prefrontal cortex and at lower levels in the basal ganglia and the hippocampus in human brain (Pompeiano, M. et al. (1994) Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors. Brain Res. MoI. Brain Res. 23, 163-178; Pazos, A., Probst, A., Palacios, J. M. (1987) Serotonin receptors in the human brain ⁇ IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience 21, 123-139), and is coupled predominantly to the G-protein G ⁇ q (Roth, B. L. et al.
  • 5-HT 2 A receptor (Porras, G. et al. 5-HT2A and 5-HT2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum. Neuropsychopharmacology 26, 311-324 - 2002). Overall 5-HT 2 A receptor antagonists are proposed to be suitable for the treatment of disorders associated with dysfunctional dopaminergic systems. Moreover, 5-HT 2A receptor antagonism has been recognized as beneficial for the treatment of psychosis (reviewed in de Angelis, L. (2002) 5- HT2A antagonists in psychiatric disorders. Curr. Opin. Investig.
  • Drugs 3, 106-112 are one of the defining features of so-called atypical antipsychotic drugs which are characterized by a relatively high affinity for the 5-HT 2A - relative to the D 2 receptor (Meltzer, H. Y. et al. (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-I, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 251, 238- 246).
  • the compounds of the invention have high affinity for the dopamine D 3 and serotonin 5-HT 2A receptors and are expected to be effective in the treatment of psychotic disorders which include schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and other psychoses involving paranoia and delusions (Reavill-C, et al. (2000) Pharmacological actions of a novel, high-affinity, and selective human dopamine D3 receptor antagonist, SB-277011-A. JPET 294:1154-1165; Harrison, P. J. (1999) Neurochemical alterations in schizophrenia affecting the putative receptor targets of atypical antipsychotics. Focus on dopamine (Dl, D3, D4) and 5-HT2A receptors.
  • the dopamine D3 receptor antagonist SB27701 IA antagonizes nicotine-enhanced brain-stimulation reward in rat. Soc. Neurosci. Abstr., 322.8; Ashby, et al. (2003) Acute administration of the selective D3 receptor antagonist SB-277011-A blocks the acquisition and expression of the conditioned place preference response to heroin in male rats. Synapse, 48, 154-156); anxiety, and depression (Reavill-C et al. (2000) Pharmacological actions of a novel, high-affinity, and selective human dopamine D3 receptor antagonist, SB-277011- A. JPET 294:1154-1165; Drescher, K. et al.
  • substituted unless specifically defined otherwise, means that the specified group or moiety can bear 1, 2, 3, 4, 5 or 6 substituents. Where any group may carry multiple substituents and a variety of possible substituents is provided, the substituents are independently selected and need not to be the same.
  • unsubstituted means that the specified group bears no substituents.
  • optionally substituted means that the specified group is unsubstituted or substituted by one or more substituents, independently chosen from the group of possible substituents.
  • one or more means from one substituent to the highest possible number of substitution, i.e. replacement of one hydrogen up to replacement of all hydrogens by substituents. Thereby, one, two or three substituents are preferred.
  • Compounds of formula (I) can form pharmaceutically acceptable acid addition salts.
  • pharmaceutically acceptable salts are salts of compounds of formula (I) with physiologically compatible mineral acids, such as hydrochloric acid, sulphuric acid, sulphurous acid or phosphoric acid; or with organic acids, such as methanesulphonic acid, p-toluenesulphonic acid, acetic acid, lactic acid, trifluoro acetic acid, citric acid, fumaric acid, maleic acid, tartaric acid, succinic acid or salicylic acid.
  • physiologically compatible mineral acids such as hydrochloric acid, sulphuric acid, sulphurous acid or phosphoric acid
  • organic acids such as methanesulphonic acid, p-toluenesulphonic acid, acetic acid, lactic acid, trifluoro acetic acid, citric acid, fumaric acid, maleic acid, tartaric acid, succinic acid or salicylic acid.
  • a COOH group can further form salts with bases.
  • salts examples of such salts are alkaline, earth-alkaline and ammonium salts such as e.g. Na-, K-, Ca- and trimethylammoniumsalt.
  • pharmaceutically acceptable salts also refers to such salts.
  • Preferred are the hydrochloride salts. Also solvates and hydrates of compounds of formula (I) and their salts form part of the present invention.
  • esters embraces compounds of formula (I) in which hydroxy groups have been converted to the corresponding esters with inorganic or organic acids such as, nitric acid, sulphuric acid, phosphoric acid, citric acid, formic acid, maleic acid, acetic acid, succinic acid, tartaric acid, methanesulphonic acid, p- toluenesulphonic acid and the like, which are non toxic to living organisms.
  • inorganic or organic acids such as, nitric acid, sulphuric acid, phosphoric acid, citric acid, formic acid, maleic acid, acetic acid, succinic acid, tartaric acid, methanesulphonic acid, p- toluenesulphonic acid and the like, which are non toxic to living organisms.
  • the compounds of general formula (I) in this invention may be derivatized at functional groups to provide derivatives which are capable of conversion back to the parent compound in vivo.
  • Physiologically acceptable and metabolically labile derivatives, which are capable of producing the parent compounds of general formula (I) in vivo are also within the scope of this invention.
  • Compounds of formula (I) can have one or more asymmetric carbon atoms and can exist in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates or mixtures of diastereoisomeric racemates.
  • the optically active forms can be obtained for example by resolution of the racemates, by asymmetric synthesis or asymmetric chromatography (chromatography with a chiral adsorbens or eluant). The invention embraces all of these forms.
  • Ci- 6 -alkyl denotes monovalent linear or branched saturated hydrocarbon moiety, consisting solely of carbon and hydrogen atoms, having from 1 to 6 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, n-butyl, ⁇ o-butyl, sec-butyl, tert-butyl and the like.
  • Preferred alkyl groups are groups with 1, 2, 3 or 4 carbon atoms.
  • Particularly preferred Ci- 6 -alkyl are methyl, ethyl and n-propyl. Most preferred is methyl and ethyl.
  • Ci-6-alkoxy denotes a group -O-R' wherein R' is Ci-6-alkyl as defined above.
  • Preferred Ci-6-alkoxy are methoxy, ethoxy and isopropoxy. Most preferred is methoxy.
  • halo or halogen denotes chloro, iodo, fluoro and bromo. Preferred halo are fluoro, chloro and bromo, more preferred are fluoro and chloro. Most preferred is fluoro.
  • Ci- 6 -haloalkyl denotes an Ci- 6 -alkyl group as defined above wherein at least one of the hydrogen atoms of the alkyl group is replaced by a halogen atom, preferably fluoro or chloro, most preferably fluoro.
  • a halogen atom preferably fluoro or chloro, most preferably fluoro.
  • Examples of Ci-6-haloalkyl include but are not limited to methyl, ethyl, propyl, isopropyl, isobutyl, sec-butyl, tert-butyl, pentyl or n-hexyl wherein one or more hydrogen atoms are replaced by Cl, F, Br or I atom(s), as well as those Ci-6-haloalkyl groups specifically illustrated by the examples herein below.
  • Ci- 6 -haloalkyl groups are monofluoro-, difluoro- or trifluoro -methyl, -ethyl or - propyl, for example 3,3,3-trifluoropropyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, fluoromethyl, trifluoromethyl. Most preferred are 3,3,3-trifluoropropyl and 2,2,2-trifluoroethyl.
  • Ci- 6 -hydroxyalkyl denotes an Ci- 6 -alkyl group as defined above wherein at least one of the hydrogen atoms of the alkyl group is replaced by a hydroxy group.
  • Examples of Ci- 6 -hydroxyalkyl include but are not limited to methyl, ethyl, propyl, isopropyl, isobutyl, sec-butyl, tert-butyl, pentyl or n-hexyl wherein one or more hydrogen atoms are replaced by OH, as well as those Ci-6-hydroxyalkyl groups specifically illustrated by the examples herein below.
  • the preferred Ci-6-hydroxyalkyl groups are hydroxymethyl, hydroxyethyl and 2-hydroxypropyl.
  • 3 to 10-membered cycloalkyl refers to a monovalent saturated monocyclic or bicyclic hydrocarbon radical of 3 to 10 ring carbon atoms.
  • Bicyclic means consisting of two saturated carbocycles having two carbon atoms in common, i.e. the bridge separating the two rings is either a single bond or a chain of preferably one or two carbon atoms.
  • Examples for monocyclic 3 to 10-membered cycloalkyl are cyclopropyl, cyclobutanyl, cyclopentyl, cyclohexyl or cycloheptyl.
  • bicyclic 3 to 10-membered cycloalkyl examples include bicyclo[2.2.1]heptanyl, and bicyclo[2.2.2]octanyl.
  • Preferred 3 to 10-membered cycloalkyl is a monocyclic hydrocarbon radical of 3 to 6 ring carbon atoms, and preferred examples are cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • 3 to 6-membered cycloalkyl refers to a monovalent saturated monocyclic hydrocarbon radical of 3 to 6 ring carbon atoms. Preferred examples are cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • the term "4 to 10-membered hetero cycloalkyl” refers to a monovalent saturated 4 to 10-membered monocyclic or bicyclic ring system containing one, two or three ring heteroatoms selected from N, O or S, the remaining ring atoms being carbon atoms.
  • the ring is preferably 4- or 6-membered
  • the bicyclic ring is preferably 7-, 8- or 9-membered.
  • 4 to 10-membered hetero cycloalkyl may be unsubstituted or substituted as described herein.
  • substituents on 4 to 10-membered hetero cycloalkyl are independently selected from Ci- 6 -alkyl, hydroxy, Ci- 6 -hydroxyalkyl, benzyl, oxo, -C(O)O-Ci- 6 -alkyl, 3 to 10-membered cycloalkyl, alkylene-O-Ci_ 6 -alkyl, -C(O)-Ci_ 6 -haloalkyl, -C(O)- alkylene-O-Ci_6-alkyl, cyano-Ci_ 6 -alkyl, alkylene-S(O) x -Ci_ 6 -alkyl, -alkylene-C(O)N(Ci_6- alkyl) 2 , halo, Ci-6-haloalkyl or Ci-6-alkoxy, wherein x is 0, 1, or 2.
  • 4- to 10-membered hetero cycloalkyl are oxetanyl, tetrahydrofuranyl, tetrahydro-furanyl, tetrahydropyranyl, tetrahydropyranyl, piperidinyl, [l,3]dioxanyl, [l,4]dioxanyl and 7-oxa-bicyclo[2.2.1]heptyl.
  • 4 to 7-membered hetero cycloalkyl refers to a monovalent saturated monocycle or bicycle as defined above.
  • 4 to 7-membered hetero cycloalkyl is a monovalent saturated monocyclic or bicyclic ring containing one or two ring heteroatoms selected from N, O, or S.
  • 4 to 7-membered heterocycloalkyl moieties are tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, imidazolidinyl, morpholinyl, thiomorpholinyl, piperidinyl, and piperazinyl.
  • Preferred examples are oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, [l,3]dioxanyl, [l,4]dioxanyl and 7-oxa-bicyclo[2.2.1]heptyl. Most preferred is
  • 5 to 10-membered heteroaryl denotes an aromatic monocyclic or bicyclic ring of 5 to 10 ring atoms containing one, two, three or four heteroatoms selected from N, O, or S, the remaining ring atoms being C.
  • the monocyclic 5 to 10-membered heteroaryl ring is 5 or 6 membered and the bicylcic 5 to 10-membered heteroaryl ring is 9 or 10 membered.
  • the one, two, three or four heteroatoms of the bicyclic 5 to 10-membered heteroaryl moiety are located in either one or both rings.
  • Examples for 5 or 6-membered monocyclic heteroaryl include but are not limited to pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, or tetrazolyl.
  • 9 or 10-membered bicyclic heteroaryl examples include but are not limited to indolyl, benzo furanyl, benzo thiophenyl, benzimidazolyl, benzoxyzolyl, benzoisoxazolyl, benzo thiazolyl, benzoisothiazolyl, benzo triazo IyI, purinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, quinoxalinyl, phtalazinyl, or pteridinyl.
  • Preferred examples for 5- or 6-membered monocyclic heteroaryl are are thiophenyl and isoxazolyl.
  • a preferred example for a 9-membered bicyclic heteroaryl is benzoisoxazolyl. 5 to 10-membered heteroaryl is optionally substituted as described herein.
  • phenyl can be unsubstituted or substituted with one or more substituents selected from Ci-6-alkyl, 3 to 10-membered cycloalkyl, Ci_ 6 -alkoxy, halo-Ci_ 6 -alkoxy, Ci_ 6 -haloalkyl, halo, OH, CN, or an anellated bridge being selected from -0-CH 2 CH 2 O-, -0-CHCH 3 CH 2 -, or -O-C(CH 3 ) 2 CH 2 -, however, wherein phenyl is not para-substituted with halo.
  • Preferred substituents on phenyl are Ci_6- alkoxy, or an anellated bridge being selected from -0-CHCH 3 CH 2 -, or -O-C(CH 3 ) 2 CH 2 -.
  • Trans-configuration denotes the orientation of functional groups within a molecule. Trans-configuration indicates an orientation, wherein a pair of substituents is
  • X is independently of each other halogen or Ci- 6 -alkyl
  • n 0, 1, or 2;
  • R 1 is -CO-R 2 or -SO 2 -Ci_ 6 -alkyl
  • R 2 is Ci- 6 -alkyl, Ci- 6 -haloalkyl, Ci- 6 -hydroxyalkyl, Ci- 6 -alkoxy, 3 to 10 membered cycloalkyl, 4 to 10 membered heterocycloalkyl, or 5 to 10 membered heteroaryl, which are optionally substituted by one or more substituents selected from the group consisting of: halo, hydroxy,
  • Ci- 6 -haloalkyl Ci- 6 -hydroxyalkyl
  • Ci-6-alkoxy optionally substituted by one or more R a ,
  • R a is selected from the group consisting of: halo, hydroxy, C ⁇ -alkyl, Ci- 6 -hydroxyalkyl, Ci- 6 -haloalkyl, and Ci-6-alkoxy;
  • the compounds of formula (I) can have one or more asymmetric Carbon atoms and can exist in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates or mixtures of diastereoisomeric racemates.
  • the optically active forms can be obtained for example by resolution of the racemate, by asymmetric synthesis or asymmetric chromatography (chromatography with a chiral adsorbens or eluant). The invention embraces all of these forms.
  • Particularly preferred compounds of formula (I) are those, wherein the piperazinyl-ethyl moiety and the N-amide moiety are attached to the cyclohexyl-ring in a transconfiguration.
  • X is fluoro or methyl.
  • n 1 or 2.
  • R 1 is -CO-R 2 .
  • R 2 is Ci- 6 -alkyl, Ci- 6 -haloalkyl, Ci- 6-hydroxyalkyl, Ci-6-alkoxy, 3 to 6-membered cycloalkyl, 4 to 7-membered heterocycloalkyl, or 5 membered heteroaryl, which are optionally substituted by one or more substituents selected from the group consisting of halo, hydroxy, Ci_ 6 -alkyl, Ci_ 6 -hydroxyalkyl, Ci_ 6 -alkoxy, -S-Ci_ 6 -alkyl, -SO 2 -Ci_ 6 -alkyl, -CONH 2 , 3 to 6- membered cycloalkyl optionally substituted by one or more R a , 4 to 7-membered heterocycloalkyl optionally substituted by one or more R a , and 5 membered heteroaryl optionally substituted by one or more R a , wherein R a
  • R 2 is Ci- 6 -alkyl which is optionally substituted by one substituent selected from the group consisting of Ci-6-alkoxy, -SO 2 -Ci_ 6 -alkyl and 6 membered heterocycloalkyl.
  • R 2 is methyl, methyl substituted by methanesulfonyl or [l,4]dioxin-2-yl or ethyl substituted by methoxy.
  • Another preferred embodiment of the instant invention relates to a compound of formula (Ia):
  • X and n are defined as given above;
  • R 4 is hydrogen, hydroxyl, d_ 6 -alkyl, Ci- 6 -hydroxyalkyl, Ci-6-alkoxy,
  • R b is selected from the group consisting of: hydroxy, Ci-e-alkyl,
  • Ci- 6 -hydroxyalkyl Ci-6-alkoxy.
  • Especially preferred compounds of formula (Ia') include the following compounds:
  • X and n are defined as given above;
  • R 4 is 3 to 6-membered cycloalkyl optionally substituted by one or more R b , or 4 to 7-membered hetero cycloalkyl optionally substituted by one or more R b ;
  • R b is selected from the group consisting of: hydroxy, d_ 6 -alkyl,
  • Ci- 6 -hydroxyalkyl Ci-6-alkoxy.
  • Another preferred embodiment of the instant invention relates to a compound of formula (Ib):
  • X and n are defined as given above;
  • R 5 is 4 to 7-membered heterocycloalkyl
  • Especially preferred compounds of formula (Ib') include the following compounds: 4-Methoxy-cyclohexanecarboxylic acid N-trans-(4- (2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl] -ethyl ⁇ -cyclohexyl)-amide;
  • Tetrahydro-pyran-4-carboxylic acid N-trans-(4- (2-[4-(5,6-difluoro-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl] -ethyl ⁇ -cyclohexyl)-amide;
  • Tetrahydro-pyran-4-carboxylic acid N-trans-(4- (2-[4-(5,6-dichloro-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl] -ethyl ⁇ -cyclohexyl)-amide;
  • Particularly preferred compounds of formula (I) include the following compounds:
  • Tetrahydro-pyran-4-carboxylic acid N-trans-(4- (2-[4-(6-chloro-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl] -ethyl ⁇ -cyclohexyl)-amide; N-trans-(4- ⁇ 2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl ⁇ -cyclohexyl)-rac-
  • Tetrahydro-pyran-4-carboxylic acid N-trans-(4- (2-[4-(5,6-difluoro-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl]-ethyl ⁇ -cyclohexyl)-amide;
  • Tetrahydro-pyran-4-carboxylic acid N-trans-(4- (2-[4-(5,6-dichloro-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl] -ethyl ⁇ -cyclohexyl)-amide; N-trans-(4- ⁇ 2-[4-(5,6-Dichloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl ⁇ -cyclohexyl)-
  • a further aspect of the present invention relates to the process for the manufacture of compounds of formula (I) as defined above.
  • the compounds of formula (I) can be manufactured by the methods given below, by the methods given in the examples or by analogous methods. Appropriate reaction conditions for the individual reaction steps are known to a person skilled in the art. Starting materials are either commercially available or can be prepared by methods analogous to the methods given below, by methods described in references cited in the description or in the examples, or by methods known in the art.
  • a preferred embodiment of the process for preparing a compound of formula (I) comprises one of the following steps:
  • N- ⁇ 4-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-l-yl)-ethyl]-cyclohexyl ⁇ -amide derivates of formula (I'-A), wherein X, n and R 2 are as defined above, can be prepared as depicted in scheme 1 starting from 4-nitro-phenylacetic acid (1) that was hydrogenated using Raney nickel as catalyst. The hydro genation with nickel leads preferentially to the desired trans- isomer (according to Journal of Medicinal Chemistry, 1998, 41, 760-771). Preparing the ethyl ester according to methods known to those skilled in the art and described in the mentioned literature (e.g.
  • N,N-carbonyldiimidazole CDI
  • 1 -hydroxy- 1,2,3- benzotriazole HOBT
  • O-benzotriazol-l-yl-N,N,N,N-tetramethyluronium tetrafluoroborate TBTU
  • suitable solvent like, e.g. dimethylformamide (DMF) or dioxane
  • a base e.g. triethylamine or diisopropylethylamine (DIPEA)
  • DIPEA diisopropylethylamine
  • an acid chloride can also be used in the presence of a base (e.g. triethylamine or diisopropylethylamine) in a solvent like dichloromethane.
  • a 3-piperazin-l-yl-l,2-benzisoxazole of formula (4), wherein X and n are as defined above, can be obtained starting from an appropriately substituted benzaldehyde containing a leaving group such as for example F in ortho position.
  • the benzaldehyde can be converted to the corresponding oxime with a reagent such as NH 2 OH. HCl in the presence of a base such as NaOH in a solvent mixture like water and EtOH.
  • the intermediate (6) wherein X and n are as defined above, can also react with a sulfonyl chloride in the presence of a base like triethylamine to give the corresponding sulfonyl derivative of the formula (F-B), wherein X and n are as defined above and R 3 is Ci-6-alkyl.
  • the corresponding salts with acids can be obtained by standard methods known to the person skilled in the art, e.g. by dissolving the compound of formula (I) in a suitable solvent such as e.g. dioxan or THF and adding an appropriate amount of the corresponding acid.
  • a suitable solvent such as e.g. dioxan or THF
  • the products can usually be isolated by filtration or by chromatography.
  • the conversion of a compound of formula (I) into a pharmaceutically acceptable salt with a base can be carried out by treatment of such a compound with such a base.
  • One possible method to form such a salt is e.g. by addition of 1/n equivalents of a basic salt such as e.g.
  • a suitable solvent e.g. ethanol, ethanol-water mixture, tetrahydrofuran- water mixture
  • the conversion of compounds of formula (I) into pharmaceutically acceptable esters can be carried out e.g. by treatment of a suitable hydro xyl group present in the molecule with a acid using e.g. a condensating reagent such as benzotriazol-1- yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP), N 5 N- dicylohexylcarbodiimide (DCC), N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDCI) or O-(l,2-dihydro-2-oxo-l-pyridyl)-N,N,N,N-tetra-methyluronium- tetrafluoroborate (TPTU), or by direct reaction with a suitable acid under acidic conditions, as for example in the presence of a strong mineral acid like hydrochloric acid, sulfuric acid and the like.
  • the compounds of formula (I) as well as all intermediate products can be prepared according to analogous methods or according to the methods set forth above. Starting materials are commercially available, known in the art or can be prepared by methods known in the art or in analogy thereto. It will be appreciated that the compounds of general formula (I) in this invention may be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compound in vivo.
  • novel compounds of the present invention and their pharmaceutically usable salts and esters possess valuable pharmacological properties and have been found to be selective dual modulators of the serotonin 5-HT 2a and dopamine D 3 receptors.
  • the compounds of the present invention can therefore be used, either alone or in combination with other drugs, for the treatment or prevention of diseases which are modulated by ligands for serotonin 5-HT 2a and dopamine D 3 receptors.
  • diseases include, but are not limited to cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions.
  • the invention likewise embraces a compound of formula (I) for the use as a medicament.
  • the invention also relates to medicaments comprising one or more compounds as defined above and pharmaceutically acceptable excipients for treatment and/or the prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions.
  • the invention also relates to pharmaceutical compositions comprising a compound as defined above and a pharmaceutically acceptable carrier and/or adjuvant, prefereably for the use in the treatment and/or the prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions.
  • the invention likewise embraces compounds as described above as well as its pharmaceutically acceptable salt for use as therapeutically active substances, especially as therapeutically active substances for the treatment or prevention of diseases which are related to the serotonin 5-HT 2a and dopamine D 3 receptors, particularly for the treatment and/or the prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions.
  • the invention relates to a method for the treatment or prevention of diseases which are related to the serotonin 5-HT 2a and dopamine D 3 receptors, particularly for the treatment and/or the prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions, which method comprises administering a compound as described above as well as its pharmaceutically acceptable salt to a human being or animal.
  • the invention likewise embraces compounds as described above as well as its pharmaceutically acceptable salt for use in the for use in treatment and/or the prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions.
  • the invention also embraces the use of compounds as defined above as well as its pharmaceutically acceptable salt for the manufacture of medicaments for the treatment or prevention of diseases which are modulated by ligands for serotonin 5-HT 2a and dopamine D 3 receptors.
  • the invention also embraces the use of compounds as defined above as well as its pharmaceutically acceptable salt for the manufacture of medicaments for the treatment and/or the prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions.
  • the ability of the compounds to bind to the 5-HT 2 A, D 3 and D 2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.
  • HEK-293 EBNA cells were transiently transfected with expression plasmids encoding for the human D 2 or D 3 dopamine- or for the human 5-HT 2A serotonin receptor, respectively.
  • the cells were harvested 48 h post-transfection, washed three times with cold PBS and stored at -80 0 C prior to use.
  • the pellet was suspended in cold 50 mM Tris-HCl buffer containing 10 mM EDTA (pH 7.4) and homogenized with a Polytron (Kinematica AG, Basel, Switzerland) for 20-30 sec at 12.000 rpm.
  • the pellet was resuspended in cold 10 mM Tris-HCl buffer containing 0.1 mM EDTA (pH 7.4), homogenized, and centrifuged as above. This pellet was further resuspended in a smaller volume of ice cold 10 mM Tris-HCl buffer containing 0.1 mM EDTA (pH 7.4) and homogenized with a Polytron for 20-30 sec at 12.000 rpm.
  • the protein content of this homogenate was determined with the Bio-Rad (Bradford) Protein Assay (Biorad Laboratories GmbH, M ⁇ nchen, Germany) according to the instructions of the manufacturer using gamma globulin as the standard. This homogenate was stored at -80 0 C in aliquots and thawed immediately prior to use.
  • the binding affinity (K 1 ) of the compounds was determined using radioligand binding.
  • Membranes were incubated in a total volume of 200 ⁇ l with a fixed concentration of radioligand (final concentration approximately 0.7 nM [ 3 H] -spiperone for D 2 , 0.5 nM [ 3 H]- spiperone for D 3 , and 1.1 nM [ 3 H]-ketanserin for 5-HT 2A ) and ten concentrations of test compound in ranging between 10 ⁇ M -0.1 nM for 1 h at RT.
  • reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters (Packard BioScience, Zurich, Switzerland; preincubated for 1 h in 0.1% polyethylenimine (PEI) in assay buffer) with a Filtermate 196 harvester (Packard BioScience) and washed 3 times with cold assay buffer.
  • PEI polyethylenimine
  • Filtermate 196 harvester Packard BioScience
  • Microscint 40 Perkin Elmer, Schwerzenbach, Switzerland
  • a Topcount Microplate Scintillation Counter Canberra Packard SA, Zurich, Switzerland
  • the compounds of the present invention are selective dual modulators of the serotonin 5-HT 2 A and dopamine D 3 receptors as this is shown with the activity table hereinafter which gives the K 1 values in ⁇ M for the human serotonin 5-HT 2 A, human dopamine D 3 and human dopamine D 2 receptors for some examples of the compounds of the present invention:
  • the compounds of formula (I) and pharmaceutically acceptable salts thereof can be used as medicaments, e.g. in the form of pharmaceutical preparations.
  • the pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions.
  • the administration can also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.
  • the compounds of formula (I) and pharmaceutically acceptable salts thereof can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations.
  • Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts and the like can be used, for example, as such as carriers for tablets, coated tablets, dragees and hard gelatine capsules.
  • Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like; depending on the nature of the active substance no carriers are, however, usually required in the case of soft gelatine capsules.
  • Suitable carriers for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar, glucose and the like.
  • Adjuvants such as alcohols, polyols, glycerol, vegetable oils and the like, can be used for aqueous injection solutions of water-soluble salts of compounds of formula (I), but as a rule are not necessary.
  • Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.
  • the pharmaceutical preparations can contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
  • medicaments containing a compound of formula (I) or pharmaceutically acceptable salts thereof and a therapeutically inert excipient are also an object of the present invention, as is a process for the production of such medicaments which comprises bringing one or more compounds of formula (I) or pharmaceutically acceptable salts thereof and, if desired, one or more other therapeutically valuable substances into a galenical dosage form together with one or more therapeutically inert carriers.
  • the dosage can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case.
  • the effective dosage for oral or parenteral administration is between 0.01-20 mg/kg/day, with a dosage of 0.1-10 mg/ kg/day being preferred for all of the indications described.
  • Film coated tablets containing the following ingredients can be manufactured in a conventional manner:
  • the active ingredient is sieved and mixed with micro crystalline cellulose and the mixture is granulated with a solution of polyvinylpyrrolidone in water.
  • the granulate is mixed with sodium starch glycolate and magnesiumstearate and compressed to yield kernels of 120 or 350 mg respectively.
  • the kernels are lacquered with an aqueous solution / suspension of the above mentioned film coat.
  • Capsules containing the following ingredients can be manufactured in a conventional manner:
  • Example C The components are sieved and mixed and filled into capsules of size 2.
  • Example C The components are sieved and mixed and filled into capsules of size 2.
  • Injection solutions can have the following composition:
  • Soft gelatin capsules containing the following ingredients can be manufactured in a conventional manner:
  • Example E The active ingredient is dissolved in a warm melting of the other ingredients and the mixture is filled into soft gelatin capsules of appropriate size.
  • the filled soft gelatin capsules are treated according to the usual procedures.
  • Sachets containing the following ingredients can be manufactured in a conventional manner:
  • the active ingredient is mixed with lactose, microcrystalline cellulose and sodium carboxymethyl cellulose and granulated with a mixture of polyvinylpyrrolidone in water.
  • the granulate is mixed with magnesium stearate and the flavoring additives and filled into sachets.
  • Step 1 trans- ⁇ 4-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-l-yl)-ethyl]-cyclohexyl ⁇ - carbamic acid tert-butyl ester
  • Step 3 N-trans- ⁇ 4-[2-(4-benzo[d]isoxazol-3-yl-piperazin- 1 -yl)-ethyl]-cyclohexyl ⁇ -3- methoxy-propionamide
  • trans-(3-Methoxy-cyclopentyl)-acetic acid methyl ester ⁇ intermediate C) (71 mg, 0.41 mmol) was dissolved in 2 ml dichloromethane. Potassium trimethylsilanolate KO l SiMe3 (105 mg, 0.82 mmol) was added and the suspension stirred for 16 hours at room temperature. The solvent was evaporated and trans-4-[2-(4-benzo[d]isoxazol-3-yl- piperazin-l-yl)-ethyl]-cyclohexylamine hydrochloride (examplel, step 2) (150 mg, 0.41 mmol) in 1 ml DMF was added.
  • the title compound can be prepared in accordance with the literature in the patent WO 2007107566, description 42.
  • Trimethylphosphono acetate 700 mg, 3.87 mmol was solved in 10 ml of THF and added into a cold (0-5 0 C) mixture of sodium hydride (169 mg, 3.87 mmol, 55%) in 10 ml THF. After 1 hour stirring at 0-5 0 C 4-isopropoxy-cyclohexanone (550 mg, 3.5 mmol) in 5 ml THF was added drop wise. The reaction mixture was quenched after 1 hour at room temperature with saturated NaHCO3-solution and extracted two times with ethyl acetate. The organic extracts were washed with brine, dried with sodium sulfate, filtered and evaporated.
  • Step 3 rac-(4-Isopropoxy-cyclohexyl)-acetic acid methyl ester
  • Step 4 N-trans-(4- ⁇ 2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl ⁇ - cyclohexyl)-2-(4-isopropoxy-cyclohexyl)-acetamide
  • Step 1 ri,41Dioxan-2-yl-acetic acid ethyl ester
  • Step 2 2-[1.41Dioxan-2-yl-N-trans-(4-(2-[4-(5-fluoro-benzo[dlisoxazol-3-yl)- piperazin- 1 -yll -ethyl) -cyclohexyD-acetamide
  • Step 1 7-Oxa-bicyclo[2.2.1]hept-5-en-2-one
  • the title compound can be prepared in accordance with literature Lit. : Helvetica Chimica ACTA -Vol. 66, Fasc.6(1983-Nr.l82), S1865-1871.
  • Step 3 (lS.4R)-(7-Oxa-bicvclor2.2.11hept-2-yl)-acetic acid methyl ester
  • Step 4 N-trans-(4- ⁇ 2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl ⁇ - cyclohexyl)-2-(lR,4S)-7-oxa-bicyclo[2.2.1]hept-2-yl-acetamide
  • Oxetan-3-one (commercially available) (50 mg, 0.69 mmol) was solved in 1 ml dichloromethane and cooled to 0-5 0 C. (Methoxycarbonylmethylene) triphenylphosphorane (255 mg, 0.76 mmol) was added and the mixture stirred for 15 minutes. The mixture was directly purified with column chromatography on silica gel using heptane : ethyl acetate 100:0 -> 0:100. The product fractions were concentrated to give 57 mg (64% yield) of a white solid.
  • Step 3 N-trans-(4- ⁇ 2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin- 1 -yl]-ethyl ⁇ - cvclohexyl)-2-(3 -methyl-oxetan-3 -yl)-acetamide
  • Step 2 2-[1.31Dioxan-2-yl-N-trans-(4-(2-[4-(5-fluoro-benzo[dlisoxazol-3-yl)- piperazin- 1 -yl] -ethyl ⁇ -cyclohexyD-acetamide
  • Step 1 (4-Hydroxy-piperidin-l-yl)-acetic acid methyl ester x ⁇ , ( 0
  • the title compound can be prepared in accordance with the literature in the patent WO2007127726, preparation 34.
  • the title compound can be prepared in accordance with the general method of intermediate B, step 3 from (4-hydroxy-piperidin-l-yl)-acetic acid methyl ester.
  • Step 2 N-trans-(4- ⁇ 2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl ⁇ - cyclohexyl)-2-(4-methoxy-piperidin- 1 -yl)-acetamide
  • Step 1 3-Methoxy-butyric acid methyl ester o o ⁇
  • the title compound can be prepared in accordance with the preparation described in the literature Journal of Organic Chemistry (1995), 60(11), 3529-32.
  • Step 2 N-trans-(4- ⁇ 2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl ⁇ - cyclohexyl)-3 -methoxy-butyramide
  • Step 1 (4-Methoxy-4-methyl-cyclohexyl)-acetic acid methyl ester
  • Step 2 N-trans-(4- ⁇ 2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl ⁇ - cvclohexyl)-2-(4-methoxy-4-methyl-cvclohexyl)-acetamide
  • Oxetan-3-one (commercially available) (50 mg, 0.69 mmol) was solved in 1 ml dichloromethane and cooled to 0-5 0 C. (Methoxycarbonylmethylene) triphenylphosphorane (255 mg, 0.76 mmol) was added and the mixture stirred for 15 minutes. The mixture was directly purified with column chromatography on silica gel using heptane : ethyl acetate 100:0 -> 0:100. The product fractions were concentrated to give 57 mg (64% yield) of a white solid.
  • the title compound can be prepared in accordance with the general method of example 10, step 2 from oxetan-3-ylidene-acetic acid methyl ester.
  • Step 3 N-trans-(4- ⁇ 2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin- 1 -yl]-ethyl ⁇ - cvclohexyl)-2-oxetan-3-yl-acetamide
  • Step 1 N-trans-(4- ⁇ 2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl ⁇ - cyclohexyl)-2-tetrahydro-pwan-2-yl-acetamide
  • Step 2 N-trans-(4- ⁇ 2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl ⁇ - cyclohexyl)-2-(R)-tetrahydro-pyran-2-yl-acetamide
  • Example 66 4-Methoxy-cvclohexanecarboxylic acid N-trans(4- ⁇ 2-[4-(5.,6-difluor()- benzordlisoxazol-3-yl)-piperazin-l-yll-ethyl ⁇ -cvclohexyl)-amide
  • Step 1 trans-(4-Amino-cyclohexyl)- acetic acid
  • the autoclave is flushed again with nitrogen and then pressurized to 115 bar and the vessel is heated to 130 0 C while stirring (a maximum pressure of 130 bars is observed). Hydro genation is continued for 5 days to 130 0 C.
  • the autoclave is then cooled, vented and flushed with nitrogen and the contents are removed and filtered through filter aid to remove catalyst. After removal of the solvent 74g of crude material was obtained. The intermediated is used directly in the next step without purification. MS (m/e): 158.3 (M+H + ).
  • a solution of the trans-(4-amino-cyclohexyl)- acetic acid obtained (74g, 476mmol) is adjusted to pH 5 with 25% HCl.
  • the mixture was evaporated to dryness and dried under vacuum overnight.
  • the residue was suspended in 146mL of a 6.5N ethanolic HCl solution and 0.6L of ethanol were added to the mixture. After 4 h refluxing, the mixture is cooled and filtered and the filtrate is concentrated to dryness under vacuum.
  • Step 3 trans-(4-tert-Butoxycarbonylamino-cyclohexyl)-acetic acid ethyl ester
  • Step 4 trans-[4-(2-Oxo-ethyl)-cyclohexyl]-carbamic acid tert-butyl ester
  • Step 1 trans-(4-Hydroxy-cyclohexyl)-acetic acid
  • the title compound can be prepared in accordance with literature Journal of the American Chemical Society (1948), 70 1898-9.
  • the ester can be prepared by refluxing the corresponding acid in methanol and catalytic sulfuric acid for 4 hours.
  • Step 3 trans-(4-Methoxy-cyclohexyl)-acetic acid methyl ester
  • trans-(4-Hydroxy-cyclohexyl)-acetic acid methyl ester 500 mg, 2.90 mmol
  • Sodium hydride 190 mg, 4.35 mmol, 55%) and iodomethane (3.62 ml, 23.2 mmol) were added and the reaction mixture stirred for 4 hours at 0-5 0 C.
  • the reaction mixture was quenched with saturated NaHCO3-solution and extracted with dichloromethane. The organic extract was washed with brine, dried with sodium sulfate, filtered and evaporated.
  • the crude product (561 mg, quant.) was obtained as a colourless oil and used without any further purification for the next step.
  • Step 1 Trans-(3 -Hydro xy-cyclopentyl)-acetic acid methyl ester
  • the title compound can be prepared in accordance with literature Helvetica Chimica Acta - Vol. 75 (1992) Page 1945 and 1950.
  • 2,5-Difluorobenzaldehyde (28.5 g, 0.20 mol) was dissolved in 30 ml EtOH. 80 ml water, 80 g crushed ice and hydroxylamine hydrochloride (15.3 g, 0.22 mol) were added. 250 ml (0.50 mol) 2N NaOH were added drop wise and the yellow solution was stirred for 3 hours at room temperature. The reaction mixture was neutralized to pH 6 with acetic acid. The formed suspension was diluted with water and filtered. The crystals were washed with water and dried 2 hours at 50 0 C and ⁇ 20mbar to obtain the desired product as a white solid (26.1 g, 83%). MS (m/e): 156.0 (M-H + ).
  • Step 2 4- ⁇ (2,5-Difluoro-phenyl)-[(E)-hydroxyimino]-methyl ⁇ -piperazine-l- carboxylic acid tert-butyl ester
  • Step 3 4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazine-l-carboxylic acid tert-butyl ester
  • Step 5 Trans-(4- ⁇ 2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin- 1 -yl]-ethyl ⁇ - cvclohexyD-carbamic acid tert-butyl ester
  • Step 6 4-Trans- ⁇ 2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl ⁇ - cyclohexylamine hydrochloride
  • the title compound can be prepared in accordance with the literature in the patent WO2006063281.
  • the title compound can be prepared in accordance with the general method of intermediate B, step 3 from trans-(3 -hydro xymethyl-cyclobutyD-acetic acid methyl ester.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The present invention relates to compounds of the general formula (I) (I) wherein X, n and R1 are as described herein, as well as pharmaceutically acceptable salts and esters thereof, as well as their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are dual modulators of the serotonin 5-HT2a and dopamine D3 receptors, useful in the treatment and/or the prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions.

Description

PIPERAZINE D3 AND 5-HT2A RECEPTOR MODULATORS
The present invention relates to compounds of the general formula (I)
Figure imgf000002_0001
(I)
wherein X, n and R1 are as described below and in the claims.
It has been surprisingly found that the compounds of formula (I) according to the invention are dual modulators of the serotonin 5-HT2a and dopamine D3 receptors.
The compounds of the invention have high affinity for the dopamine D3 and serotonin (5-Hydroxytryptamine; 5-HT) 5-HT2A receptors and are effective in the treatment of psychotic disorders, as well as other diseases such as depression and anxiety, drug dependence, dementias and memory impairment. Psychotic disorders encompass a variety of diseases, which include schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and other psychoses involving paranoia and delusions.
In particular schizophrenia is characterized by complex symptomatology including positive symptoms, (i.e. delusions and hallucinations), and negative symptoms, (i.e. anhedonia, restricted fluency and productivity of thought and speech). In addition it is now well recognized that cognitive impairment is the third major diagnostic category of schizophrenia, characterized by loss in working memory as well as other deficits. Other symptoms include aggressiveness, depression and anxiety (Stahl, S. M. (2000) Essential Psychopharmacology. Neuro scientific Basis and Practical Applications. Cambridge University Press, second edition, Cambridge, UK). The different categories and the clinical features of the disorder are defined in diagnostic schemes such as DSM-IV (Diagnostic and statistical manual of mental disorders, 4th edition) or ICD-IO (International classification of diseases, 10th edition). Currently used medications to treat schizophrenia, bipolar mania and other psychoses, include antipsychotics both typical (D2ZD3 preferring) or the more recent atypicals, which exhibit polypharmacology interacting at multiple receptors (eg., Di, D2, D3, D4, 5-HTIA, 5-HT2A, 5-HT2C, Hh M1, M2, M4, etc; Roth, B. L. et al. (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov. 3, 353-359). These antipsychotics, although relatively successful (some patients exhibit treatment resistance) at treating the positive symptoms of schizophrenia, are less effective at treating negative symptoms, cognitive deficits, and associated depression and anxiety, all of which lead to reduced patient quality of life and socioeconomic problems (Lieberman, J. A. et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353, 1209-1223). Furthermore, patient compliance is compromised by prevalent side effects such as weight gain, extrapyramidal symptoms (EPS), and cardiovascular effects (Lieberman, J. A. et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353, 1209-1223). In the current invention, compounds with high affinity and greater selectivity for D3 and 5-HT2A receptors are described and are proposed to treat psychoses and other diseases, with fewer associated side affects.
Dopamine, a major catecholamine neurotransmitter, is involved in the regulation of a variety of functions which include emotion, cognition, motor functions, and positive reinforcement, (Purves, D. et al. (2004) Neuroscience. Sinauer, third edition, Sunderland, Massachusetts). The biological activities of dopamine are mediated through G protein- coupled receptors (GPCRs) and in human, five different dopamine receptors Di-D5 have been identified, where the D2-like receptors (D2, D3 and D4) couple to the G-protein Gαi (Missale, C. et al.. (1998) Dopamine receptors: from structure to function. Physiol. Rev. 78, 189-225). The D3 dopamine receptor is most highly expressed in the nucleus accumbens (Gurevich, E. V., Joyce, J. N. (1999) Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuropsychopharmacology 20, 60-80), and is proposed to modulate the mesolimbic pathway consisting of neuronal projections from the ventral tegmental area, hippocampus and amygdala to the nucleus accumbens, which projects to the prefrontal and cingulate cortices as well as various thalamic nuclei. The limbic circuit is thought to be important for emotional behavior and thus D3 receptor antagonists are proposed to modulate psychotic symptoms such as hallucinations, delusions and thought disorder (Joyce, J. N. and Millan, M. J., (2005) Dopamine D3 receptor antagonists as therapeutic agents. Drug Discovery Today, 1 JuI, Vol. 10, No. 13, 917-25), while these antagonists spare the D2 modulated striatal extrapyramidal system (associated with EPS induction). In addition, it has been reported that drug naive schizophrenic patients show altered levels of D3 receptor expression (Gurevich, E. V. et al. (1997) Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Arch. Gen. Psychiatry 54, 225-232) and dopamine release (Laruelle, M. (2000) Imaging dopamine dysregulation in schizophrenia: implication for treatment. Presented at Workshop Schizophr.: Pathol. Bases and Mech. Antipsychotic Action, Chicago), indicating that a disturbed homeostasis of dopamine plays an important role in the etiology of schizophrenic symptoms.
The neurotransmitter serotonin is implicated in several psychiatric conditions including schizophrenia (Kandel, E. R. et al. (eds.; 2000) Principles of Neural Science, 3rd edition Appleton & Lange, Norwalk, CT). The involvement of serotonin in psychotic disorders is suggested by multiple studies which include treatment in humans with the psychotropic drug Lysergic acid (LSD; a serotonin agonist) which can induce schizophrenia-like symptoms such as hallucinations (Leikin, J. B. et al. (1989) Clinical features and management of intoxication due to hallucinogenic drugs. Med. Toxicol. Adverse Drug Exp. 4, 324-350). Furthermore, altered brain distribution of serotonin receptors as well as an altered serotonergic tone, have been detected in schizophrenic patients (Harrison, P. J. (1999) Neurochemical alterations in schizophrenia affecting the putative receptor targets of atypical antipsychotics. Focus on dopamine (Dl, D3, D4) and 5-HT2A receptors. Br. J. Psychiatry Suppl. 38, 12-22). In mammals serotonin exerts its biological activities through a family of 14 5-HT GPCRs (Barnes, N. M., Sharp, T. (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38, 1083- 1152). The 5-HT2A receptor is most prominently expressed in the prefrontal cortex and at lower levels in the basal ganglia and the hippocampus in human brain (Pompeiano, M. et al. (1994) Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors. Brain Res. MoI. Brain Res. 23, 163-178; Pazos, A., Probst, A., Palacios, J. M. (1987) Serotonin receptors in the human brain~IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience 21, 123-139), and is coupled predominantly to the G-protein Gαq (Roth, B. L. et al. (1998) 5- Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5- hydro xytryptamine2C): where structure meets function. Pharmacol. Ther. 79, 231-257). Genetic linkage studies of a 5-HT2A polymorphism to schizophrenia (Spurlock, G. et al. (1998) A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter. MoI. Psychiatry 3, 42-49), as well as responsiveness to antipsychotic drugs (Arranz, M. J. et al. (2000) Pharmaco genetic prediction of clozapine response. Lancet 355, 1615-1616), further suggests a role for the 5-HT2A receptor both in the treatment and pathology of psychosis. In addition, dopaminergic neurotransmission appears to be under the afferent regulation of the - A -
5-HT2A receptor (Porras, G. et al. 5-HT2A and 5-HT2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum. Neuropsychopharmacology 26, 311-324 - 2002). Overall 5-HT2A receptor antagonists are proposed to be suitable for the treatment of disorders associated with dysfunctional dopaminergic systems. Moreover, 5-HT2A receptor antagonism has been recognized as beneficial for the treatment of psychosis (reviewed in de Angelis, L. (2002) 5- HT2A antagonists in psychiatric disorders. Curr. Opin. Investig. Drugs 3, 106-112) and indeed is one of the defining features of so-called atypical antipsychotic drugs which are characterized by a relatively high affinity for the 5-HT2A - relative to the D2 receptor (Meltzer, H. Y. et al. (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-I, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 251, 238- 246).
As mentioned hereinabove, the compounds of the invention have high affinity for the dopamine D3 and serotonin 5-HT2A receptors and are expected to be effective in the treatment of psychotic disorders which include schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and other psychoses involving paranoia and delusions (Reavill-C, et al. (2000) Pharmacological actions of a novel, high-affinity, and selective human dopamine D3 receptor antagonist, SB-277011-A. JPET 294:1154-1165; Harrison, P. J. (1999) Neurochemical alterations in schizophrenia affecting the putative receptor targets of atypical antipsychotics. Focus on dopamine (Dl, D3, D4) and 5-HT2A receptors. Br. J. Psychiatry Suppl. 38, 12-22; de Angelis, L. (2002) 5-HT2A antagonists in psychiatric disorders. Curr. Opin. Investig. Drugs 3, 106-112; Joyce, J. N. and Millan, M. J., (2005) Dopamine D3 receptor antagonists as therapeutic agents. Drug Discovery Today, 1 JuI, Vol. 10, No. 13, P. 917-25); drug dependency and abuse and withdrawal (Vorel, S. R. et al. (2002) Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. J. Neurosci., 22, 9595-9603; Campos, A. C. et al. (2003) The dopamine D3 receptor antagonist SB27701 IA antagonizes nicotine-enhanced brain-stimulation reward in rat. Soc. Neurosci. Abstr., 322.8; Ashby, et al. (2003) Acute administration of the selective D3 receptor antagonist SB-277011-A blocks the acquisition and expression of the conditioned place preference response to heroin in male rats. Synapse, 48, 154-156); anxiety, and depression (Reavill-C et al. (2000) Pharmacological actions of a novel, high-affinity, and selective human dopamine D3 receptor antagonist, SB-277011- A. JPET 294:1154-1165; Drescher, K. et al. (2002) In vivo effects of the selective dopamine D3 receptor antagonist A-437203. Am. Soc. Neurosci. 894.6). Unless otherwise indicated, the following definitions are set forth to illustrate and define the meaning and scope of the various terms used to describe the invention herein.
The following definitions of the general terms apply irrespective of whether the terms in question appear alone or in combination.
The term "substituted", unless specifically defined otherwise, means that the specified group or moiety can bear 1, 2, 3, 4, 5 or 6 substituents. Where any group may carry multiple substituents and a variety of possible substituents is provided, the substituents are independently selected and need not to be the same. The term "unsubstituted" means that the specified group bears no substituents. The term "optionally substituted" means that the specified group is unsubstituted or substituted by one or more substituents, independently chosen from the group of possible substituents.
When indicating the number of subsituents, the term "one or more" means from one substituent to the highest possible number of substitution, i.e. replacement of one hydrogen up to replacement of all hydrogens by substituents. Thereby, one, two or three substituents are preferred.
Compounds of formula (I) can form pharmaceutically acceptable acid addition salts. Examples of such pharmaceutically acceptable salts are salts of compounds of formula (I) with physiologically compatible mineral acids, such as hydrochloric acid, sulphuric acid, sulphurous acid or phosphoric acid; or with organic acids, such as methanesulphonic acid, p-toluenesulphonic acid, acetic acid, lactic acid, trifluoro acetic acid, citric acid, fumaric acid, maleic acid, tartaric acid, succinic acid or salicylic acid. The term "pharmaceutically acceptable salts" refers to such salts. Compounds of formula (I) which comprise an acidic group, such as e.g. a COOH group, can further form salts with bases. Examples of such salts are alkaline, earth-alkaline and ammonium salts such as e.g. Na-, K-, Ca- and trimethylammoniumsalt. The term "pharmaceutically acceptable salts" also refers to such salts. Preferred are the hydrochloride salts. Also solvates and hydrates of compounds of formula (I) and their salts form part of the present invention.
The term "pharmaceutically acceptable esters" embraces compounds of formula (I) in which hydroxy groups have been converted to the corresponding esters with inorganic or organic acids such as, nitric acid, sulphuric acid, phosphoric acid, citric acid, formic acid, maleic acid, acetic acid, succinic acid, tartaric acid, methanesulphonic acid, p- toluenesulphonic acid and the like, which are non toxic to living organisms.
It will be appreciated, that the compounds of general formula (I) in this invention may be derivatized at functional groups to provide derivatives which are capable of conversion back to the parent compound in vivo. Physiologically acceptable and metabolically labile derivatives, which are capable of producing the parent compounds of general formula (I) in vivo are also within the scope of this invention.
Compounds of formula (I) can have one or more asymmetric carbon atoms and can exist in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates or mixtures of diastereoisomeric racemates. The optically active forms can be obtained for example by resolution of the racemates, by asymmetric synthesis or asymmetric chromatography (chromatography with a chiral adsorbens or eluant). The invention embraces all of these forms.
As used herein, the term "Ci-6-alkyl" denotes monovalent linear or branched saturated hydrocarbon moiety, consisting solely of carbon and hydrogen atoms, having from 1 to 6 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, n-butyl, ώo-butyl, sec-butyl, tert-butyl and the like. Preferred alkyl groups are groups with 1, 2, 3 or 4 carbon atoms. Particularly preferred Ci-6-alkyl are methyl, ethyl and n-propyl. Most preferred is methyl and ethyl.
The term "Ci-6-alkoxy" denotes a group -O-R' wherein R' is Ci-6-alkyl as defined above. Preferred Ci-6-alkoxy are methoxy, ethoxy and isopropoxy. Most preferred is methoxy.
The term "halo or halogen" denotes chloro, iodo, fluoro and bromo. Preferred halo are fluoro, chloro and bromo, more preferred are fluoro and chloro. Most preferred is fluoro.
The term "Ci-6-haloalkyl" denotes an Ci-6-alkyl group as defined above wherein at least one of the hydrogen atoms of the alkyl group is replaced by a halogen atom, preferably fluoro or chloro, most preferably fluoro. Examples of Ci-6-haloalkyl include but are not limited to methyl, ethyl, propyl, isopropyl, isobutyl, sec-butyl, tert-butyl, pentyl or n-hexyl wherein one or more hydrogen atoms are replaced by Cl, F, Br or I atom(s), as well as those Ci-6-haloalkyl groups specifically illustrated by the examples herein below. Among the preferred Ci-6-haloalkyl groups are monofluoro-, difluoro- or trifluoro -methyl, -ethyl or - propyl, for example 3,3,3-trifluoropropyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, fluoromethyl, trifluoromethyl. Most preferred are 3,3,3-trifluoropropyl and 2,2,2-trifluoroethyl.
The term "Ci-6-hydroxyalkyl" denotes an Ci-6-alkyl group as defined above wherein at least one of the hydrogen atoms of the alkyl group is replaced by a hydroxy group. Examples of Ci-6-hydroxyalkyl include but are not limited to methyl, ethyl, propyl, isopropyl, isobutyl, sec-butyl, tert-butyl, pentyl or n-hexyl wherein one or more hydrogen atoms are replaced by OH, as well as those Ci-6-hydroxyalkyl groups specifically illustrated by the examples herein below. Among the preferred Ci-6-hydroxyalkyl groups are hydroxymethyl, hydroxyethyl and 2-hydroxypropyl.
The term "3 to 10-membered cycloalkyl" refers to a monovalent saturated monocyclic or bicyclic hydrocarbon radical of 3 to 10 ring carbon atoms. Bicyclic means consisting of two saturated carbocycles having two carbon atoms in common, i.e. the bridge separating the two rings is either a single bond or a chain of preferably one or two carbon atoms. Examples for monocyclic 3 to 10-membered cycloalkyl are cyclopropyl, cyclobutanyl, cyclopentyl, cyclohexyl or cycloheptyl. Examples for bicyclic 3 to 10-membered cycloalkyl are bicyclo[2.2.1]heptanyl, and bicyclo[2.2.2]octanyl. Preferred 3 to 10-membered cycloalkyl is a monocyclic hydrocarbon radical of 3 to 6 ring carbon atoms, and preferred examples are cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
The term "3 to 6-membered cycloalkyl" refers to a monovalent saturated monocyclic hydrocarbon radical of 3 to 6 ring carbon atoms. Preferred examples are cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
The term "4 to 10-membered hetero cycloalkyl" refers to a monovalent saturated 4 to 10-membered monocyclic or bicyclic ring system containing one, two or three ring heteroatoms selected from N, O or S, the remaining ring atoms being carbon atoms. In case of monocyclic 4 to 10-membered hetero cycloalkyl, the ring is preferably 4- or 6-membered, in case of bicyclic 4 to 10-membered hetero cycloalkyl, the bicyclic ring is preferably 7-, 8- or 9-membered. 4 to 10-membered hetero cycloalkyl may be unsubstituted or substituted as described herein. Examples for substituents on 4 to 10-membered hetero cycloalkyl are independently selected from Ci-6-alkyl, hydroxy, Ci-6-hydroxyalkyl, benzyl, oxo, -C(O)O-Ci- 6-alkyl, 3 to 10-membered cycloalkyl, alkylene-O-Ci_6-alkyl, -C(O)-Ci_6-haloalkyl, -C(O)- alkylene-O-Ci_6-alkyl, cyano-Ci_6-alkyl, alkylene-S(O)x-Ci_6-alkyl, -alkylene-C(O)N(Ci_6- alkyl)2, halo, Ci-6-haloalkyl or Ci-6-alkoxy, wherein x is 0, 1, or 2. Among the preferred examples of 4- to 10-membered hetero cycloalkyl are oxetanyl, tetrahydrofuranyl, tetrahydro-furanyl, tetrahydropyranyl, tetrahydropyranyl, piperidinyl, [l,3]dioxanyl, [l,4]dioxanyl and 7-oxa-bicyclo[2.2.1]heptyl.
The term "4 to 7-membered hetero cycloalkyl" refers to a monovalent saturated monocycle or bicycle as defined above. Preferably, 4 to 7-membered hetero cycloalkyl is a monovalent saturated monocyclic or bicyclic ring containing one or two ring heteroatoms selected from N, O, or S. Examples for 4 to 7-membered heterocycloalkyl moieties are tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, imidazolidinyl, morpholinyl, thiomorpholinyl, piperidinyl, and piperazinyl. Preferred examples are oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, [l,3]dioxanyl, [l,4]dioxanyl and 7-oxa-bicyclo[2.2.1]heptyl. Most preferred is
[l,4]dioxanyl. The 4 to 7-membered heterocycloalkyl moiety is optionally substituted as described herein.
The term "5 to 10-membered heteroaryl" denotes an aromatic monocyclic or bicyclic ring of 5 to 10 ring atoms containing one, two, three or four heteroatoms selected from N, O, or S, the remaining ring atoms being C. Preferably, the monocyclic 5 to 10-membered heteroaryl ring is 5 or 6 membered and the bicylcic 5 to 10-membered heteroaryl ring is 9 or 10 membered. The one, two, three or four heteroatoms of the bicyclic 5 to 10-membered heteroaryl moiety are located in either one or both rings. Examples for 5 or 6-membered monocyclic heteroaryl include but are not limited to pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, or tetrazolyl. Examples for 9 or 10-membered bicyclic heteroaryl include but are not limited to indolyl, benzo furanyl, benzo thiophenyl, benzimidazolyl, benzoxyzolyl, benzoisoxazolyl, benzo thiazolyl, benzoisothiazolyl, benzo triazo IyI, purinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, quinoxalinyl, phtalazinyl, or pteridinyl. Preferred examples for 5- or 6-membered monocyclic heteroaryl are are thiophenyl and isoxazolyl. A preferred example for a 9-membered bicyclic heteroaryl is benzoisoxazolyl. 5 to 10-membered heteroaryl is optionally substituted as described herein.
Analogously to the 5 to 10-membered heteroaryl system, phenyl can be unsubstituted or substituted with one or more substituents selected from Ci-6-alkyl, 3 to 10-membered cycloalkyl, Ci_6-alkoxy, halo-Ci_6-alkoxy, Ci_6-haloalkyl, halo, OH, CN, or an anellated bridge being selected from -0-CH2CH2O-, -0-CHCH3CH2-, or -O-C(CH3)2CH2-, however, wherein phenyl is not para-substituted with halo. Preferred substituents on phenyl are Ci_6- alkoxy, or an anellated bridge being selected from -0-CHCH3CH2-, or -O-C(CH3)2CH2-.
The term "trans-configuration" denotes the orientation of functional groups within a molecule. Trans-configuration indicates an orientation, wherein a pair of substituents is
attached on opposite sides of a stereoisomeric group, as for example Ry""C^~RX , wherein Rx and Ry can be any kind of functional groups as described herein. In detail, the present invention relates to compounds of the general formula (I)
Figure imgf000010_0001
wherein:
X is independently of each other halogen or Ci-6-alkyl;
n is 0, 1, or 2;
R1 is -CO-R2 or -SO2-Ci_6-alkyl;
R2 is Ci-6-alkyl, Ci-6-haloalkyl, Ci-6-hydroxyalkyl, Ci-6-alkoxy, 3 to 10 membered cycloalkyl, 4 to 10 membered heterocycloalkyl, or 5 to 10 membered heteroaryl, which are optionally substituted by one or more substituents selected from the group consisting of: halo, hydroxy,
Ci_6-alkyl,
Ci-6-haloalkyl, Ci-6-hydroxyalkyl,
Ci-6-alkoxy,
Ci-6-alkoxy optionally substituted by one or more Ra,
-S-Ci_6-alkyl,
-SO2-Ci_6-alkyl, -CONH2,
-CHO,
3 to 10 membered cycloalkyl optionally substituted by one or more Ra,
4 to 10 membered heterocycloalkyl optionally substituted by one or more Ra, and
5 to 10 membered heteroaryl optionally substituted by one or more Ra;
wherein Ra is selected from the group consisting of: halo, hydroxy, C^-alkyl, Ci-6-hydroxyalkyl, Ci-6-haloalkyl, and Ci-6-alkoxy;
as well as pharmaceutically acceptable salts or esters thereof.
The compounds of formula (I) can have one or more asymmetric Carbon atoms and can exist in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates or mixtures of diastereoisomeric racemates. The optically active forms can be obtained for example by resolution of the racemate, by asymmetric synthesis or asymmetric chromatography (chromatography with a chiral adsorbens or eluant). The invention embraces all of these forms.
Further, it is to be understood that every embodiment relating to a specific residue X, R1 or R2 as disclosed herein may be combined with any other embodiment relating to another residue X, R1 or R2 as disclosed herein.
Particularly preferred compounds of formula (I) are those, wherein the piperazinyl-ethyl moiety and the N-amide moiety are attached to the cyclohexyl-ring in a transconfiguration.
In certain preferred embodiments of the compound of formula (I), X is fluoro or methyl.
In certain preferred embodiments of the compound of formula (I), n is 1 or 2.
In certain preferred embodiments of the compound of formula (I), R1 is -CO-R2.
In certain embodiments of the compound of formula (I), R2 is Ci-6-alkyl, Ci-6-haloalkyl, Ci- 6-hydroxyalkyl, Ci-6-alkoxy, 3 to 6-membered cycloalkyl, 4 to 7-membered heterocycloalkyl, or 5 membered heteroaryl, which are optionally substituted by one or more substituents selected from the group consisting of halo, hydroxy, Ci_6-alkyl, Ci_6-hydroxyalkyl, Ci_6-alkoxy, -S-Ci_6-alkyl, -SO2-Ci_6-alkyl, -CONH2, 3 to 6- membered cycloalkyl optionally substituted by one or more Ra, 4 to 7-membered heterocycloalkyl optionally substituted by one or more Ra, and 5 membered heteroaryl optionally substituted by one or more Ra, wherein Ra is selected from the group consisting of hydroxy, Ci-6-alkyl, Ci-6-hydroxyalkyl, and Ci-6-alkoxy. Even more preferred compounds of the present invention are those, wherein R2 is Ci-6-alkyl which is optionally substituted by one substituent selected from the group consisting of Ci-6-alkoxy, -SO2-Ci_6-alkyl and 6 membered heterocycloalkyl. Most preferred are compounds of the present invention, wherein R2 is methyl, methyl substituted by methanesulfonyl or [l,4]dioxin-2-yl or ethyl substituted by methoxy.
Preference is given to a compound of formula (F):
Figure imgf000013_0001
wherein X, R1 and n are defined as given above.
Special preference is also given to a compound of formula (F) wherein R1 is -COR2; and wherein X, R2 and n are defined as given above.
Another preferred embodiment of the instant invention relates to a compound of formula (Ia):
Figure imgf000013_0002
wherein:
X and n are defined as given above;
R4 is hydrogen, hydroxyl, d_6-alkyl, Ci-6-hydroxyalkyl, Ci-6-alkoxy,
3 to 6-membered cycloalkyl optionally substituted by one or more Rb, or
4 to 7-membered hetero cycloalkyl optionally substituted by one or more Rb,
wherein Rb is selected from the group consisting of: hydroxy, Ci-e-alkyl,
Ci-6-hydroxyalkyl, and Ci-6-alkoxy.
Also preferred is a compound of formula (Ia'):
Figure imgf000014_0001
Xn (Ia')
wherein X, R4 and n are defined as given above.
Special preference is given to a compound of formula (Ia') wherein X and n are defined as given above; and R4 is Ci_6-alkoxy or Ci_6-alkoxy-Ci_6-alkyl.
Especially preferred compounds of formula (Ia') include the following compounds:
N-trans- {4- [2-(4-benzo [d]isoxazol-3 -yl-piperazin- 1 -yl)-ethyl] -cyclohexyl} -3 -methoxy- propionamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-3- methoxy-propionamide; N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2- methoxy-acetamide;
2-Ethoxy-N-trans-(4-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-3,3- dimethoxy-propionamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-4,4- dimethoxy-butyramide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-3- methoxy-propionamide; N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-3- methoxy-butyramide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-3,3- dimethoxy-propionamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)- 3-methoxy-propionamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-
2-methoxy-acetamide;
N-trans-(4-{2-[4-(6-Chloro-5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3-methoxy-propionamide; N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3-methoxy-propionamide; N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3,3-dimethoxy-propionamide;
N-trans-(4-{2-[4-(5,6-Dichloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-
3 -methoxy-propionamide; 3 -Methoxy-N-trans-(4- {2- [4-(6-methyl-benzo [d]isoxazol-3 -yl)-piperazin- 1 -yl] -ethyl} - cyclohexyl)-propionamide;
3,3-Dimethoxy-N-trans-(4-{2-[4-(6-methyl-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-propionamide;
3 -Methoxy-N-trans-(4- {2- [4-(5 -methyl-benzo [d]isoxazol-3 -yl)-piperazin- 1 -yl] -ethyl} - cyclohexyl)-propionamide;
N-trans-(4-{2-[4-(6-Fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-methoxy-acetamide;
N-trans-(4-{2-[4-(6-Fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3 -methoxy-propionamide; and 2-Ethoxy-N-trans-(4-{2-[4-(6-fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-l-yl]- ethyl} -cyclohexyl)-acetamide.
Also preferred is a compound of formula (Ia') wherein:
X and n are defined as given above;
R4 is 3 to 6-membered cycloalkyl optionally substituted by one or more Rb, or 4 to 7-membered hetero cycloalkyl optionally substituted by one or more Rb;
wherein Rb is selected from the group consisting of: hydroxy, d_6-alkyl,
Ci-6-hydroxyalkyl, and Ci-6-alkoxy.
Further preferred compounds of formula (Ia') include the following compounds: N-trans- {4- [2-(4-Benzo [d]isoxazol-3 -yl-piperazin- 1 -yl)-ethyl] -cyclohexyl} -2-trans-(3 - methoxy-cyclopentyl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2- trans-(4-methoxy-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2- (tetrahydro-pyran-4-yl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2-(4- isopropoxy-cyclohexyl)-acetamide; 2-[ 1 ,4]Dioxan-2-yl-N-trans-(4- {2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)-piperazin- 1 -yl]- ethyl} -cyclohexyl)-acetamide;
Rac-2-(2,2-Dimethyl-tetrahydro-pyran-4-yl)-N-trans-(4-{2-[4-(5-fluoro-benzo[d]isoxazol-
3 -yl)-piperazin- 1 -yl] -ethyl} -cyclohexyl)-acetamide; N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2-
(lR,4S)-7-oxa-bicyclo[2.2.1]hept-2-yl-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2- trans-(3-hydroxymethyl-cyclobutyl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2-(3- methyl-oxetan-3-yl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2-
((S)-2,2,4-trimethyl-tetrahydro-pyran-4-yl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2-
((R)-2,2,4-trimethyl-tetrahydro-pyran-4-yl)-acetamide; 2-[ 1 ,3]Dioxan-2-yl-N-trans-(4- {2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)-piperazin- 1 -yl]- ethyl} -cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2-(4- methoxy-piperidin- 1 -yl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2- trans-(3 -methoxymethyl-cyclobuty^-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2- trans-(4-methoxy-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2-
(tetrahydro-pyran-2-yl)-acetamide; N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2- trans-(3-methoxy-cyclopentyl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2-(4- methoxy-4-methyl-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2- (tetrahydro-pyran-4-yl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2- trans-(4-hydroxy-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2- oxetan-3 -yl-acetamide; N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2- trans-(3-methoxymethyl-cyclobutyl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2- (R)-tetrahydro-pyran-2-yl-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2-
(S)-tetrahydro-pyran-2-yl-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2-(4- isopropoxy-cyclohexyFj-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2- cyclopropyl-acetamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-
2-trans-(4-methoxy-cyclohexyl)-acetamide; N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-
2-(4-hydroxy-tetrahydro-pyran-4-yl)-acetamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-
2-(4-methoxy-tetrahydro-pyran-4-yl)-acetamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)- 2-(tetrahydro-pyran-4-yl)-acetamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-
2-trans-(3-methoxy-cyclopentyl)-acetamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-
2-[ 1 ,3]dioxan-2-yl-acetamide; N-trans-(4-{2-[4-(6-Chloro-5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(tetrahydro-pyran-4-yl)-acetamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-cyclopropyl-acetamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2- [ 1 ,4] dioxan-2-yl-acetamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-[ 1 ,3]dioxan-2-yl-acetamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-trans-(3-hydroxymethyl-cyclobutyl)-acetamide; N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-trans-(3-methoxymethyl-cyclobutyl)-acetamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-trans-(4-methoxy-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(5,6-Dichloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)- 2-trans-(4-methoxy-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(5,6-Dichloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-
2-(tetrahydro-pyran-4-yl)-acetamide; 2-trans-(4-Methoxy-cyclohexyl)-N-trans-(4-{2-[4-(6-methyl-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl] -ethyl} -cyclohexyFj-acetamide;
2-[ 1 ,3]Dioxan-2-yl-N-trans-(4- {2-[4-(6-methyl-benzo[d]isoxazol-3-yl)-piperazin- 1 -yl]- ethyl} -cyclohexyl)-acetamide; 2-[ 1 ,4]Dioxan-2-yl-N-trans-(4- {2-[4-(6-methyl-benzo[d]isoxazol-3-yl)-piperazin- 1 -yl]- ethyl} -cyclohexyl)-acetamide;
2-Cyclopropyl-N-trans-(4-{2-[4-(6-fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-l-yl]- ethyl} -cyclohexyl)-acetamide;
2-[l,3]Dioxan-2-yl-N-trans-(4-{2-[4-(6-fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin- 1-yl] -ethyl} -cyclohexyFj-acetamide; and
N-trans-(4-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2- (tetrahydro-pyran-4-yl)-acetamide.
Another preferred embodiment of the instant invention relates to a compound of formula (Ib):
Figure imgf000018_0001
wherein:
X and n are defined as given above; and
R5 is 4 to 7-membered heterocycloalkyl; or
3 to 6-membered cycloalkyl optionally substituted by one or more halogen, hydroxyl or Ci-6-alkoxy.
Also preferred is a compound of formula (Ib'):
Figure imgf000018_0002
wherein X, R5 and n are defined as given above.
Especially preferred compounds of formula (Ib') include the following compounds: 4-Methoxy-cyclohexanecarboxylic acid N-trans-(4- (2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide;
3-Methoxy-cyclohexanecarboxylic acid N-trans-(4- (2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide; Tetrahydro-pyran-4-carboxylic acid N-trans-(4-{2-[4-(6-chloro-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide;
Tetrahydro-furan-3-carboxylic acid N-trans-(4- (2-[4-(6-chloro-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide;
1 -Hydro xy-cyclopropanecarboxylic acid N-trans-(4-{2-[4-(6-chloro-benzo[d]isoxazo 1-3- yl)-piperazin- 1 -yl]-ethyl} -cyclohexyl)-amide;
(S)-Tetrahydro-furan-3-carboxylic acid (4- (2-[4-(6-chloro-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide;
4-trans-Methoxy-cyclohexanecarboxylic acid N-trans-(4- {2-[4-(6-chloro-benzo[d]isoxazol-
3 -yl)-piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide; 4-Methoxy-cyclohexanecarboxylic acid N-trans(4-{2-[4-(5,6-difluoro-benzo[d]isoxazol-3- yl)-piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide;
Tetrahydro-pyran-4-carboxylic acid N-trans-(4- (2-[4-(5,6-difluoro-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide;
1 -Chloro-cyclobutanecarboxylic acid N-trans-(4- {2-[4-(5-chloro-6-fluoro- benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-amide;
Cyclobutanecarboxylic acid N-trans-(4- (2-[4-(5-chloro-6-fluoro-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide;
Tetrahydro-pyran-4-carboxylic acid N-trans-(4- (2-[4-(5,6-dichloro-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide;
Particularly preferred compounds of formula (I) include the following compounds:
N-trans- {4- [2-(4-benzo [d]isoxazol-3 -yl-piperazin- 1 -yl)-ethyl] -cyclohexyl} -3 -methoxy- propionamide;
N-trans- {4-[2-(4-benzo[d]isoxazol-3-yl-piperazin-l-yl)-ethyl]-cyclohexyl}-acetamide;
N-trans- {4- [2-(4-Benzo [d]isoxazo 1-3 -yl-piperazin- 1 -yl)-ethyl] -cyclohexyl} -2-trans-(3 - methoxy-cyclopentyl)-acetamide;
N-trans- {4-[2-(4-Benzo[d]isoxazol-3-yl-piperazin- l-yl)-ethyl] -cyclohexyl} -2-hydroxy- acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-3- methoxy-propionamide; N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2- trans-(4-methoxy-cyclohexyl)-acetamide;
Tetrahydro-pyran-4-carboxylic acid-trans-(4-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2-
(tetrahydro-pyran-4-yl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2- methoxy-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2-(4- isopropoxy-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-3- hydroxy-3 -methyl-butyramide; 2-Ethoxy-N-trans-(4-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-acetamide;
4-Methoxy-cyclohexanecarboxylic acid N-trans-(4- (2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)- methanesulfonamide;
2-[ 1 ,4]Dioxan-2-yl-N-trans-(4- {2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)-piperazin- 1 -yl]- ethyl} -cyclohexyl)-acetamide;
3-Methoxy-cyclohexanecarboxylic acid N-trans-(4- (2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide; N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)- malonamide;
Rac-2-(2,2-Dimethyl-tetrahydro-pyran-4-yl)-N-trans-(4-{2-[4-(5-fluoro-benzo[d]isoxazol-
3 -yl)-piperazin- 1 -yl] -ethyl} -cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2- (lR,4S)-7-oxa-bicyclo[2.2. l]hept-2-yl-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2- trans-(3-hydroxymethyl-cyclobutyl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2-(3- methyl-oxetan-3 -yl)-acetamide; 2-((S)-2,2-Dimethyl-tetrahydro-pyran-4-yl)-N-trans-(4-{2-[4-(5-fluoro-benzo[d]isoxazol-3- yl)-piperazin- 1 -yl] -ethyl} -cyclohexyl)-acetamide;
2-((R)-2,2-Dimethyl-tetrahydro-pyran-4-yl)-N-trans- (4-{2-[4-(5-fluoro-benzo[d]isoxazol-
3 -yl)-piperazin- 1 -yl] -ethyl} -cyclohexyl)-acetamide;
2-[ 1 ,3]Dioxan-2-yl-N-trans-(4- {2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)-piperazin- 1 -yl]- ethyl} -cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2-(4- methoxy-piperidin- 1 -yl)-acetamide; N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-3,3- dimethoxy-propionamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2- trans-(3-methoxymethyl-cyclobutyl)-acetamide; N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-4,4- dimethoxy-butyramide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-3- methoxy-propionamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)- acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2- trans-(4-methoxy-cyclohexyl)-acetamide;
Tetrahydro-pyran-4-carboxylic acid N-trans-(4- (2-[4-(6-chloro-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide; N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-rac-
3,3,3-trifluoro-2-hydroxy-propionamide;
Tetrahydro-furan-3-carboxylic acid N-trans-(4- (2-[4-(6-chloro-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2- (tetrahydro-pyran-2-yl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2- trans-(3-methoxy-cyclopentyl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-3- methoxy-butyramide;
11 --HHyyddrroo xxyy--cyclopropanecarboxylic acid N-trans-(4-{2-[4-(6-chloro-benzo[d]isoxazo 1-3- yl)-piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2-(4- methoxy-4-methyl-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2- (tetrahydro-pyran-4-yl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)- propionamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2- hydroxy-acetamide; N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2- trans-(4-hydroxy-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-3- hydro xy-3 -methyl-butyramide;
(S)-N-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-3- hydroxy-butyramide;
(S)-Tetrahydro-furan-3-carboxylic acid (4- (2-[4-(6-chloro-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2- oxetan-3 -yl-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2- trans-(3-methoxymethyl-cyclobutyl)-acetamide; N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2-
(R)-tetrahydro-pyran-2-yl-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2-
(S)-tetrahydro-pyran-2-yl-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2-(4- isopropoxy-cyclohexy^-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2- cyclopropyl-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-
3,3,3 -trifluoro -propionamide; 4-trans-Methoxy-cyclohexanecarboxylic acid N-trans-(4-{2-[4-(6-chloro-benzo[d]isoxazol-
3 -yl)-piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-3,3- dimethoxy-propionamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)- acetamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-
3 -methoxy-propionamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-
2-trans-(4-methoxy-cyclohexyl)-acetamide; N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)- propionamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-
2-methoxy-acetamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)- 2-(4-hydroxy-tetrahydro-pyran-4-yl)-acetamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-
2-(4-methoxy-tetrahydro-pyran-4-yl)-acetamide; N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-
2-(tetrahydro-pyran-4-yl)-acetamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-
3 -hydro xy-3 -methyl-butyramide; N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-
2-trans-(3-methoxy-cyclopentyl)-acetamide;
4-Methoxy-cyclohexanecarboxylic acid N-trans(4- {2-[4-(5,6-difluoro-benzo[d]isoxazol-3- yl)-piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide;
Tetrahydro-pyran-4-carboxylic acid N-trans-(4- (2-[4-(5,6-difluoro-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl]-ethyl} -cyclohexyl)-amide;
Ethanesulfonic acid N-trans-(4-{2-[4-(5,6-difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]- ethyl} -cyclohexyl)-amide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-
2-[ 1 ,3]dioxan-2-yl-acetamide; N-trans-(4-{2-[4-(6-Chloro-5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-propionamide;
N-trans-(4-{2-[4-(6-Chloro-5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3-methoxy-propionamide;
N-trans-(4-{2-[4-(6-Chloro-5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(tetrahydro-pyran-4-yl)-acetamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3-methoxy-propionamide; N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-cyclopropyl-acetamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-[ 1 ,4]dioxan-2-yl-acetamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-[ 1 ,3]dioxan-2-yl-acetamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3,3-dimethoxy-propionamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-trans-(3-hydroxymethyl-cyclobutyl)-acetamide; N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-trans-(3-methoxymethyl-cyclobutyl)-acetamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3-methylsulfanyl-propionamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(3-methyl-isoxazol-5-yl)-acetamide;
3-Chloro-cyclobutanecarboxylic acid N-trans-(4- {2-[4-(5-chloro-6-fluoro- benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-amide;
5-Chloro-thiophene-2-carboxylic acid N-trans-(4- {2-[4-(5-chloro-6-fluoro- benzo[d]isoxazol-3-yl)-piperazin- 1 -yl]-ethyl} -cyclohexyl)-amide;
5-Methoxy-thiophene-2-carboxylic acid N-trans-(4- {2-[4-(5-chloro-6-fluoro- benzo[d]isoxazol-3-yl)-piperazin- 1 -yl]-ethyl} -cyclohexyl)-amide; N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-propionamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-hydroxy-acetamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-trans-(4-methoxy-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-methanesulfonyl-acetamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3-methanesulfonyl-propionamide; N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-carbamic acid methyl ester;
Cyclobutanecarboxylic acid N-trans-(4- (2-[4-(5-chloro-6-fluoro-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3,3,3-trifluoro-propionamide;
N-trans-(4-{2-[4-(5,6-Dichloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-
3 -methoxy-propionamide;
Tetrahydro-pyran-4-carboxylic acid N-trans-(4- (2-[4-(5,6-dichloro-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide; N-trans-(4-{2-[4-(5,6-Dichloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-
2-trans-(4-methoxy-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(5,6-Dichloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-
2-(tetrahydro-pyran-4-yl)-acetamide;
3 -Methoxy-N-trans-(4- {2- [4-(6-methyl-benzo [d]isoxazol-3 -yl)-piperazin- 1 -yl] -ethyl} - cyclohexyl)-propionamide;
N-trans-(4-{2-[4-(6-Methyl-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)- propionamide; 2-trans-(4-Methoxy-cyclohexyl)-N-trans-(4-{2-[4-(6-methyl-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl] -ethyl} -cyclohexyFj-acetamide;
2-[ 1 ,3]Dioxan-2-yl-N-trans-(4- {2-[4-(6-methyl-benzo[d]isoxazol-3-yl)-piperazin- 1 -yl]- ethyl} -cyclohexyl)-acetamide; 2-[ 1 ,4]Dioxan-2-yl-N-trans-(4- {2-[4-(6-methyl-benzo[d]isoxazol-3-yl)-piperazin- 1 -yl]- ethyl} -cyclohexyl)-acetamide;
3,3-Dimethoxy-N-trans-(4-{2-[4-(6-methyl-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-propionamide;
3 -Methoxy-N-trans-(4- {2- [4-(5 -methyl-benzo [d]isoxazol-3 -yl)-piperazin- 1 -yl] -ethyl} - cyclohexyl)-propionamide;
2-Methanesulfonyl-N-trans-(4-{2-[4-(6-methyl-benzo[d]isoxazol-3-yl)-piperazin-l-yl]- ethyl} -cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(6-Fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-acetamide; N-trans-(4-{2-[4-(6-Fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-methoxy-acetamide;
N-trans-(4-{2-[4-(6-Fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3-methoxy-propionamide;
2-Cyclopropyl-N-trans-(4-{2-[4-(6-fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-l-yl]- ethyl} -cyclohexyTj-acetamide;
2-Ethoxy-N-trans-(4-{2-[4-(6-fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-l-yl]- ethyl} -cyclohexyl)-acetamide;
2-[l,3]Dioxan-2-yl-N-trans-(4-{2-[4-(6-fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-
1 -yl] -ethyl} -cyclohexyl)-acetamide; N-trans-(4-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2-
(tetrahydro-pyran-4-yl)-acetamide;
2-[l,4]Dioxan-2-yl-N-trans-(4-{2-[4-(6-fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-
1 -yl] -ethyl} -cyclohexyl)-acetamide;
2-(R)-[l,4]Dioxan-2-yl-N-trans-(4-{2-[4-(6-fluoro-5-methyl-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl] -ethyl} -cyclohexyl)-acetamide;
2-(S)-[l,4]Dioxan-2-yl-N-trans-(4-{2-[4-(6-fluoro-5-methyl-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl] -ethyl} -cyclohexyl)-acetamide;
(S)-4,4,4-Trifluoro-N-trans-(4-{2-[4-(6-fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-
1 -yl] -ethyl} -cyclohexyl)-3 -hydro xy-butyramide; N-trans-(4-{2-[4-(6-Fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(tetrahydro-pyran-2-yl)-acetamide;
N-trans-(4-{2-[4-(6-Fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(tetrahydro-furan-2-yl)-acetamide; and
N-trans-(4-{2-[4-(6-Fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-methoxy-propionamide.
Even more preferred compounds of formula (I) of present invention are those selected from the group consisting of:
2-Methanesulfonyl-N-trans-(4-{2-[4-(6-methyl-benzo[d]isoxazol-3-yl)-piperazin-l-yl]- ethyl} -cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(6-Fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-acetamide; N-trans-(4-{2-[4-(6-Fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3 -methoxy-propionamide; and
2-(R)-[l,4]Dioxan-2-yl-N-trans-(4-{2-[4-(6-fluoro-5-methyl-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl]-ethyl} -cyclohexyl)-acetamide.
A further aspect of the present invention relates to the process for the manufacture of compounds of formula (I) as defined above.
The preparation of compounds of formula (I) of the present invention may be carried out in sequential or convergent synthetic routes. Syntheses of the invention are shown in the following schemes. The skills required for carrying out the reaction and purification of the resulting products are known to those skilled in the art. The substituents and indices used in the following description of the processes have the significance given herein before unless indicated to the contrary.
In more detail, the compounds of formula (I) can be manufactured by the methods given below, by the methods given in the examples or by analogous methods. Appropriate reaction conditions for the individual reaction steps are known to a person skilled in the art. Starting materials are either commercially available or can be prepared by methods analogous to the methods given below, by methods described in references cited in the description or in the examples, or by methods known in the art.
A preferred embodiment of the process for preparing a compound of formula (I) comprises one of the following steps:
a) reductive amination of aldehyde of formula (1-1) with 3-piperazine-l-yl-l,2- benzisoxazole of formula (1-2) in the presence of a reducing agent, and
Figure imgf000027_0001
removing the protecting group G under acidic conditions to yield amine intermediate of formula (1-3),
Figure imgf000027_0002
Xn (1-3)
b) and coupling of amine intermediate of formula (1-3) with a carboxylic acid R2-COOH, acid chloride R2-COC1, or sulfonyl chloride R3-SO2C1 to yield compounds of formula (I), wherein X, n and R2 are as defined above and R3 is Ci-6-alkyl.
Scheme 1
Figure imgf000028_0001
N- {4-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-l-yl)-ethyl]-cyclohexyl} -amide derivates of formula (I'-A), wherein X, n and R2 are as defined above, can be prepared as depicted in scheme 1 starting from 4-nitro-phenylacetic acid (1) that was hydrogenated using Raney nickel as catalyst. The hydro genation with nickel leads preferentially to the desired trans- isomer (according to Journal of Medicinal Chemistry, 1998, 41, 760-771). Preparing the ethyl ester according to methods known to those skilled in the art and described in the mentioned literature (e.g. by treatment with ethanol on the presence of an acid such as HCl) and crystallizing the HCl salt leads to the resolution of the cis/trans mixture yielding the pure trans amino ester chloride (2). Introduction of a protecting group with a reagent such as tert-butyl dicarbonate (BOC) on the presence of a base like triethylamine and a catalyst like dimethylaminopyridine (DMAP) and reduction with diisobutylaluminium hydride (DIBAL-H) in an appropriate solvent such as, e.g. toluene at -78°C gives the aldehyde (3) which can be used without purification on the next step. Reductive amination of aldehyde (3) with a substituted 3-piperazin-l-yl-l,2-benzisoxazole (4) either commercially available or accessible by methods described in references, by methods described in this patent or by methods known in the art in the presence of a solvent like dichloromethane and a reducing agent such as sodium triacetoxy borohydride yields intermediate (5). Removal of the BOC protective group under acidic conditions such as trifluoro acetic acid in dichloromethane or hydrochloric acid in dioxane yields the trans-amino cyclohexyl ethyl intermediate (6) (usually the HCl salt). The coupling of the amine intermediate (6) with carboxylic acids (either commercially available or accessible by methods described in references or by methods known in the art) is widely described in literature (e.g. Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 2nd Edition, Richard C. Larock. John Wiley & Sons , New York, NY. 1999) and can be accomplished by employing the coupling reagents such as, e.g. N,N-carbonyldiimidazole (CDI), 1 -hydroxy- 1,2,3- benzotriazole (HOBT) or O-benzotriazol-l-yl-N,N,N,N-tetramethyluronium tetrafluoroborate (TBTU) in a suitable solvent like, e.g. dimethylformamide (DMF) or dioxane in the presence of a base (e.g. triethylamine or diisopropylethylamine (DIPEA)) to yield compounds of formula (F-A), wherein X, n and R2 are as defined above. In other cases an acid chloride can also be used in the presence of a base (e.g. triethylamine or diisopropylethylamine) in a solvent like dichloromethane.
Scheme 2
Figure imgf000029_0001
A 3-piperazin-l-yl-l,2-benzisoxazole of formula (4), wherein X and n are as defined above, can be obtained starting from an appropriately substituted benzaldehyde containing a leaving group such as for example F in ortho position. The benzaldehyde can be converted to the corresponding oxime with a reagent such as NH2OH. HCl in the presence of a base such as NaOH in a solvent mixture like water and EtOH. Chlorination of the oxime with a reagent such as N-chlorosuccinimide (NCS) in a solvent like acetonitrile (ACN) and reaction with piperazine-1-carboxylic acid tert-butyl ester yields the corresponding phenyl- piperazin-1-yl-methanone oxime derivative. Deprotonation of the oxime with a base such as KOH in water and a solvent like dioxane and intramolecular cyclization leads to the benzo[d]isoxazole derivative. Removal of the BOC protective group under acidic conditions such as hydrochloric acid in dioxane yields the 3-piperazin-l-yl-l,2-benzisoxazole of formula (4), wherein X and n are as defined above.
Scheme 3
2a CDI, THF -OH reflux, 2Oh
Figure imgf000030_0001
reflux, 60%
Figure imgf000030_0002
Figure imgf000030_0003
An alternative to the procedure mentioned before to prepare a 3-piperazin-l-yl-l,2- benzisoxazole of formula (4), wherein X and n are as defined above, is to start with an appropriate substituted 2-hydroxybenzoate derivative and prepare the hydroxylamide that can be cyclized using CDI to the substituted hydroxy benzo-isoxazol. Replacement of the hydroxyl group for a chloro can be performed using a chlorinating agent like phosphorus oxychloride. Reaction with piperazine-1-carboxylic acid tert-butyl ester and removal of of the BOC protective group under acidic conditions yields the corresponding 3-piperazin-l- yl-l,2-benzisoxazole of formula (4), wherein X and n are as defined above.
Figure imgf000031_0001
In other examples the intermediate (6), wherein X and n are as defined above, can also react with a sulfonyl chloride in the presence of a base like triethylamine to give the corresponding sulfonyl derivative of the formula (F-B), wherein X and n are as defined above and R3 is Ci-6-alkyl.
The corresponding salts with acids can be obtained by standard methods known to the person skilled in the art, e.g. by dissolving the compound of formula (I) in a suitable solvent such as e.g. dioxan or THF and adding an appropriate amount of the corresponding acid. The products can usually be isolated by filtration or by chromatography. The conversion of a compound of formula (I) into a pharmaceutically acceptable salt with a base can be carried out by treatment of such a compound with such a base. One possible method to form such a salt is e.g. by addition of 1/n equivalents of a basic salt such as e.g. M(OH)n, wherein M = metal or ammonium cation and n = number of hydroxide anions, to a solution of the compound in a suitable solvent (e.g. ethanol, ethanol-water mixture, tetrahydrofuran- water mixture) and to remove the solvent by evaporation or lyophilisation.
The conversion of compounds of formula (I) into pharmaceutically acceptable esters can be carried out e.g. by treatment of a suitable hydro xyl group present in the molecule with a acid using e.g. a condensating reagent such as benzotriazol-1- yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP), N5N- dicylohexylcarbodiimide (DCC), N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDCI) or O-(l,2-dihydro-2-oxo-l-pyridyl)-N,N,N,N-tetra-methyluronium- tetrafluoroborate (TPTU), or by direct reaction with a suitable acid under acidic conditions, as for example in the presence of a strong mineral acid like hydrochloric acid, sulfuric acid and the like.
Insofar as their preparation is not described in the examples, the compounds of formula (I) as well as all intermediate products can be prepared according to analogous methods or according to the methods set forth above. Starting materials are commercially available, known in the art or can be prepared by methods known in the art or in analogy thereto. It will be appreciated that the compounds of general formula (I) in this invention may be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compound in vivo.
As described above, the novel compounds of the present invention and their pharmaceutically usable salts and esters possess valuable pharmacological properties and have been found to be selective dual modulators of the serotonin 5-HT2a and dopamine D3 receptors. The compounds of the present invention can therefore be used, either alone or in combination with other drugs, for the treatment or prevention of diseases which are modulated by ligands for serotonin 5-HT2a and dopamine D3 receptors. These diseases include, but are not limited to cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions.
The invention likewise embraces a compound of formula (I) for the use as a medicament.
The invention also relates to medicaments comprising one or more compounds as defined above and pharmaceutically acceptable excipients for treatment and/or the prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions.
The invention also relates to pharmaceutical compositions comprising a compound as defined above and a pharmaceutically acceptable carrier and/or adjuvant, prefereably for the use in the treatment and/or the prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions.
The invention likewise embraces compounds as described above as well as its pharmaceutically acceptable salt for use as therapeutically active substances, especially as therapeutically active substances for the treatment or prevention of diseases which are related to the serotonin 5-HT2a and dopamine D3 receptors, particularly for the treatment and/or the prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions.
In another preferred embodiment, the invention relates to a method for the treatment or prevention of diseases which are related to the serotonin 5-HT2a and dopamine D3 receptors, particularly for the treatment and/or the prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions, which method comprises administering a compound as described above as well as its pharmaceutically acceptable salt to a human being or animal.
The invention likewise embraces compounds as described above as well as its pharmaceutically acceptable salt for use in the for use in treatment and/or the prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions.
The invention also embraces the use of compounds as defined above as well as its pharmaceutically acceptable salt for the manufacture of medicaments for the treatment or prevention of diseases which are modulated by ligands for serotonin 5-HT2a and dopamine D3 receptors.
The invention also embraces the use of compounds as defined above as well as its pharmaceutically acceptable salt for the manufacture of medicaments for the treatment and/or the prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions.
The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.
Membrane preparation for human D2, human D3 and human 5 -HT2A receptors
HEK-293 EBNA cells were transiently transfected with expression plasmids encoding for the human D2 or D3 dopamine- or for the human 5-HT2A serotonin receptor, respectively. The cells were harvested 48 h post-transfection, washed three times with cold PBS and stored at -800C prior to use. The pellet was suspended in cold 50 mM Tris-HCl buffer containing 10 mM EDTA (pH 7.4) and homogenized with a Polytron (Kinematica AG, Basel, Switzerland) for 20-30 sec at 12.000 rpm. After centrifugation at 48.000 X g for 30 min at 4°C, the pellet was resuspended in cold 10 mM Tris-HCl buffer containing 0.1 mM EDTA (pH 7.4), homogenized, and centrifuged as above. This pellet was further resuspended in a smaller volume of ice cold 10 mM Tris-HCl buffer containing 0.1 mM EDTA (pH 7.4) and homogenized with a Polytron for 20-30 sec at 12.000 rpm. The protein content of this homogenate was determined with the Bio-Rad (Bradford) Protein Assay (Biorad Laboratories GmbH, Mϋnchen, Germany) according to the instructions of the manufacturer using gamma globulin as the standard. This homogenate was stored at -800C in aliquots and thawed immediately prior to use.
Radioligand binding assay conditions
Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein / well (D2, D3) and 15 μg protein / well (5- HT2A), respectively.
The binding affinity (K1) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H]- spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM -0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters (Packard BioScience, Zurich, Switzerland; preincubated for 1 h in 0.1% polyethylenimine (PEI) in assay buffer) with a Filtermate 196 harvester (Packard BioScience) and washed 3 times with cold assay buffer. The nonspecific binding was determined with equally composed reaction mixtures in the presence of 10 μM unlabelled spiperone. Per well 45 μl of Microscint 40 (Perkin Elmer, Schwerzenbach, Switzerland) was added, plates for sealed, shaken for 20 min and counted for 3 min on a Topcount Microplate Scintillation Counter (Canberra Packard SA, Zurich, Switzerland) with quenching correction.
Data calculation
The CPM value for each duplicate of a concentration of competing compound was averaged (yl), then the % specific binding was calculated according to the equation (((yl - non-specific)/(total binding-non-specific))xlOO). Graphs were plotted with the % specific binding using XLfit, a curve fitting program that iteratively plots the data using Levenburg Marquardt algorithm. The single site competition analysis equation used was y = A + ((B- A)/(l+((x/C)D))), where y is the % specific binding, A is the minimum y, B is the maximum y, C is the IC50, x is the logio of the concentration of the competing compound and D is the slope of the curve (the Hill Coefficient). From these curves the IC50 (inhibition concentration at which 50% specific binding of the radioligand was displaced) and Hill coefficient were determined. The affinity constant (K1) was calculated using the Cheng- Prusoff equation K1 = (IC5o/l+([L]/Kd), where [L] is the concentration of radioligand and Kd is the dissociation constant of the radioligand at the receptor as determined by the saturation isotherm.
The compounds of the present invention are selective dual modulators of the serotonin 5-HT2A and dopamine D3 receptors as this is shown with the activity table hereinafter which gives the K1 values in μM for the human serotonin 5-HT2A, human dopamine D3 and human dopamine D2 receptors for some examples of the compounds of the present invention:
Activity table
Figure imgf000035_0001
Figure imgf000036_0001
Figure imgf000037_0001
Figure imgf000038_0001
Figure imgf000039_0001
Figure imgf000040_0001
Figure imgf000041_0001
Figure imgf000042_0001
Figure imgf000043_0001
Figure imgf000044_0001
Figure imgf000045_0001
Figure imgf000046_0001
Figure imgf000047_0001
Figure imgf000048_0001
Figure imgf000049_0001
Figure imgf000050_0001
Figure imgf000051_0001
Figure imgf000052_0001
Figure imgf000053_0001
The compounds of formula (I) and pharmaceutically acceptable salts thereof can be used as medicaments, e.g. in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions. However, the administration can also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.
The compounds of formula (I) and pharmaceutically acceptable salts thereof can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts and the like can be used, for example, as such as carriers for tablets, coated tablets, dragees and hard gelatine capsules. Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like; depending on the nature of the active substance no carriers are, however, usually required in the case of soft gelatine capsules. Suitable carriers for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar, glucose and the like. Adjuvants, such as alcohols, polyols, glycerol, vegetable oils and the like, can be used for aqueous injection solutions of water-soluble salts of compounds of formula (I), but as a rule are not necessary. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.
In addition, the pharmaceutical preparations can contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
As mentioned earlier, medicaments containing a compound of formula (I) or pharmaceutically acceptable salts thereof and a therapeutically inert excipient are also an object of the present invention, as is a process for the production of such medicaments which comprises bringing one or more compounds of formula (I) or pharmaceutically acceptable salts thereof and, if desired, one or more other therapeutically valuable substances into a galenical dosage form together with one or more therapeutically inert carriers.
The dosage can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case. In general, the effective dosage for oral or parenteral administration is between 0.01-20 mg/kg/day, with a dosage of 0.1-10 mg/ kg/day being preferred for all of the indications described. The daily dosage for an adult human being weighing 70 kg accordingly lies between 0.7-1400 mg per day, preferably between 7 and 700 mg per day.
The following examples illustrate the present invention without limiting it.
Example A
Film coated tablets containing the following ingredients can be manufactured in a conventional manner:
Figure imgf000055_0001
The active ingredient is sieved and mixed with micro crystalline cellulose and the mixture is granulated with a solution of polyvinylpyrrolidone in water. The granulate is mixed with sodium starch glycolate and magnesiumstearate and compressed to yield kernels of 120 or 350 mg respectively. The kernels are lacquered with an aqueous solution / suspension of the above mentioned film coat.
Example B
Capsules containing the following ingredients can be manufactured in a conventional manner:
Figure imgf000055_0002
The components are sieved and mixed and filled into capsules of size 2. Example C
Injection solutions can have the following composition:
Figure imgf000056_0001
Example D
Soft gelatin capsules containing the following ingredients can be manufactured in a conventional manner:
Figure imgf000056_0002
The active ingredient is dissolved in a warm melting of the other ingredients and the mixture is filled into soft gelatin capsules of appropriate size. The filled soft gelatin capsules are treated according to the usual procedures. Example E
Sachets containing the following ingredients can be manufactured in a conventional manner:
Figure imgf000057_0003
The active ingredient is mixed with lactose, microcrystalline cellulose and sodium carboxymethyl cellulose and granulated with a mixture of polyvinylpyrrolidone in water. The granulate is mixed with magnesium stearate and the flavoring additives and filled into sachets.
The following examples 1 to 119 are provided for illustration of the invention. They should not be considered as limiting the scope of the invention, but merely as being representative thereof.
Example 1
N-trans-{4-[2-f4-benzo[dlisoxazol-3-yl-piperazin-l-yl)-ethyll-cvclohexyl}-3-methoxy-
Figure imgf000057_0001
Step 1 : trans-{4-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-l-yl)-ethyl]-cyclohexyl}- carbamic acid tert-butyl ester
Figure imgf000057_0002
A mixture of 3-piperazin-l-yl-l,2-benzisoxazole (1 g, 4.92 mmol), trans-[4-(2-oxo- ethyl)-cyclohexyl]-carbamic acid tert-butyl ester {Intermediate A) (1.3 g, 5.41 mmol), in dichloromethane (15 ml) was stirred for 15 minutes at room temperature and sodium triacetoxyborohydride (1.88 g, 8.86 mmol) was added slowly and the resulting solution was stirred for 12 hours until the TLC indicated completion of the reaction. The mixture was extracted with saturated NaHCO3-solution and two times dichloromethane. The organic layers were dried over sodium sulfate, filtrated and concentrated to dryness. The crude product was purified with column chromatography on silica gel using heptane : ethyl acetate 80:20 -> 10:90. The product fractions were concentrated to give 1.34 g (64% yield) of a white solid. MS (m/e): 429.4 (M+H+).
Step 2: trans-4-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-l-yl)-ethyl]-cyclohexylamine hydrochloride
Figure imgf000058_0001
Trans- {4-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-l-yl)-ethyl]-cyclohexyl}-carbamic acid tert-butyl ester (1.3 g, 3.03 mmol) was dissolved in 3 ml dichloromethane and 4N HCl in dioxane (15.2 ml, 60.7 mmol) was added. The white suspension was stirred for 4 hours at room temperature, diluted with diisopropylether and filtered. The crystals were washed with diisopropylether and dried for 1 hour at 500C and <20 mbar, to get the desired salt as a white solid (1.2 g, quant.) [MS: m/e = 329.2 (M+H+)].
Step 3 : N-trans- {4-[2-(4-benzo[d]isoxazol-3-yl-piperazin- 1 -yl)-ethyl]-cyclohexyl} -3- methoxy-propionamide
Figure imgf000058_0002
Trans-4-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-l-yl)-ethyl]-cyclohexylamine hydrochloride (100 mg, 0.27 mmol), 3-methoxypropionic acid (31 mg, 0.30 mmol) and N- ethyldiisopropylamine (140 μl, 0.820 mmol) were dissolved in DMF (2 ml). 2-(1H- benzotriazol-l-yl)-l, 1, 3, 3-tetramethyl uranium tetrafluoroborate (TBTU) (100 mg, 0.32 mmol) was added and the mixture was stirred for 12 hours at room temperature. The mixture was extracted with two times ethyl acetate and saturated NaHCO3-solution/water. The organic layers were dried over sodium sulfate, filtrated and concentrated to dryness. The crude product was purified with column chromatography on silica gel using dichloromethane : methanol 100:0 -> 90:10. The product fractions were concentrated to give 57 mg (50% yield) of a white solid. MS (m/e): 415.4 (M+H+).
Example 2 N-trans-{4-[2-f4-benzo[dlisoxazol-3-yl-piperazin-l-yl)-ethyll-cvclohexyl}-acetamide
Figure imgf000059_0001
The title compound, MS: m/e = 371.3 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from trans-4-[2-(4-benzo[d]isoxazol-3-yl- piperazin-l-yl)-ethyl]-cyclohexylamine hydrochloride (examplel, step 2) and acetic acid.
Example 3 N-trans-{4-[2-f4-Benzo[dlisoxazol-3-yl-piperazin-l-yl)-ethyll-cvclohexyl}-2-trans-f3- methoxy-cyclopentvD-acetamide
Figure imgf000059_0002
trans-(3-Methoxy-cyclopentyl)-acetic acid methyl ester {intermediate C) (71 mg, 0.41 mmol) was dissolved in 2 ml dichloromethane. Potassium trimethylsilanolate KOlSiMe3 (105 mg, 0.82 mmol) was added and the suspension stirred for 16 hours at room temperature. The solvent was evaporated and trans-4-[2-(4-benzo[d]isoxazol-3-yl- piperazin-l-yl)-ethyl]-cyclohexylamine hydrochloride (examplel, step 2) (150 mg, 0.41 mmol) in 1 ml DMF was added. N,N-Diisopropylethylamine (280 μl, 1.65 mmol) and 2- (lH-benzotriazol-l-yl)-l, 1, 3, 3-tetramethyl uranium tetrafluoroborate TBTU (158 mg, 0.49 mmol) were added and the reaction stirred for 2 hours at room temperature. The reaction mixture was quenched with saturated NaHCO3-solution and extracted with dichloromethane. The organic extract was washed with brine, dried with sodium sulfate, filtered and evaporated. The crude product was purified by flash chromatography on silica gel (dichloromethane / methanol 100:0 -> 90:10 gradient). The desired compound was obtained as a white solid (76 mg, 40%), MS: m/e = 469.3 (M+H+). Example 4
N-trans-{4-[2-f4-Benzo[dlisoxazol-3-yl-piperazin-l-yl)-ethyll-cvclohexyl}-2-hydroxy-
Figure imgf000060_0001
The title compound, MS: m/e = 387.3 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from trans-4-[2-(4-benzo[d]isoxazol-3-yl- piperazin-l-yl)-ethyl]-cyclohexylamine hydrochloride (example 1, step 2) and hydro xy- acetic acid.
Example 5 N-trans-f4-{2-[4-f5-Fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)-3- methoxy-propionamide
Figure imgf000060_0002
The title compound, MS: m/e = 433.4 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5-fluoro-benzo[d]isoxazol-3- yl)-piperazin-l-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate D) and 3- methoxypropionic acid.
Example 6
N-trans-f4-{2-[4-f5-Fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)-2- trans-f4-methoxy-cvclohexyl)-acetamide
Figure imgf000060_0003
The title compound, MS: m/e = 501.4 (M+H+), can be prepared in accordance with the general method of example 3 from 4-trans-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)- piperazin-1-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate D) and trans-(4- methoxy-cyclohexyl)-acetic acid methyl ester {intermediate B).
Example 7
Tetrahydro-pyran-4-carboxylic acid-trans-(4- {2- \4-( 5-fluoro-benzo [dl isoxazol-3-yl)- piperazin-l-yll-ethyll-cyclohexyD-amide
Figure imgf000061_0001
The title compound, MS: m/e = 459.5 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5-fluoro-benzo[d]isoxazol-3- yl)-piperazin-l-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate D) and tetrahydro- pyran-4-carboxylic acid.
Example 8
N-trans-f4-{2-[4-f5-Fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)-2- (tetrahvdro-pyran-4-yl)-acetamide
Figure imgf000061_0002
The title compound, MS: m/e = 473.3 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5-fluoro-benzo[d]isoxazol-3- yl)-piperazin-l-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate D) and (tetrahydro- pyran-4-yl)-acetic acid. Example 9
N-trans-f4-{2-[4-f5-Fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)-2- methoxy-acetamide
Figure imgf000062_0001
The title compound, MS: m/e = 419.3 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5-fluoro-benzo[d]isoxazol-3- yl)-piperazin-l-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate D) and methoxyacetic acid.
Example 10
N-trans-f4-{2-[4-f5-Fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)-2-
(^-isopropoxy-cvclohexvD-acetamide
Figure imgf000062_0002
Step 1 : 4-Isopropoxy-cvclohexanone
Figure imgf000062_0003
The title compound can be prepared in accordance with the literature in the patent WO 2007107566, description 42.
Step 2: (4-Isopropoxy-cyclohexylidene)-acetic acid methyl ester
Figure imgf000063_0001
Trimethylphosphono acetate (700 mg, 3.87 mmol) was solved in 10 ml of THF and added into a cold (0-50C) mixture of sodium hydride (169 mg, 3.87 mmol, 55%) in 10 ml THF. After 1 hour stirring at 0-50C 4-isopropoxy-cyclohexanone (550 mg, 3.5 mmol) in 5 ml THF was added drop wise. The reaction mixture was quenched after 1 hour at room temperature with saturated NaHCO3-solution and extracted two times with ethyl acetate. The organic extracts were washed with brine, dried with sodium sulfate, filtered and evaporated. The crude product was purified with column chromatography on silica gel using heptane : ethyl acetate 90:10 -> 20:80. The product fractions were concentrated to give 550 mg (74% yield) of a colorless liquid. MS (m/e): 213.3 (M+H+).
Step 3 : rac-(4-Isopropoxy-cyclohexyl)-acetic acid methyl ester
Figure imgf000063_0002
Prepared from (4-isopropoxy-cyclohexylidene)-acetic acid methyl ester (0.500 g, 2.36 mmol) by hydrogenation 16 hours at room temperature using Pd/C (10%) (50 mg) in ethylacetate (15 ml), cis/trans mixture. MS (m/e): 215.4 (M+H+).
Step 4: N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(4-isopropoxy-cyclohexyl)-acetamide
Figure imgf000063_0003
The title compound, MS: m/e = 529.3 (M+H+), can be prepared in accordance with the general method of example 3 from 4-trans-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)- piperazin-1-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate D) and rac-(4- isopropoxy-cyclohexyl)-acetic acid methyl ester.
Example 11
N-trans-f4-{2-[4-f5-Fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)-3- hvdroxv-3-methvl-butyramide
Figure imgf000065_0001
The title compound, MS: m/e = 447.1 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5-fluoro-benzo[d]isoxazol-3- yl)-piperazin-l-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate D) and 3-hydroxy- 3 -methyl-butyric acid.
Example 12
2-Ethoxy-N-trans-f4-{2-[4-f5-fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cyclohexvD-acetamide
Figure imgf000065_0002
The title compound, MS: m/e = 433.5 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5-fluoro-benzo[d]isoxazol-3- yl)-piperazin-l-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate D) and ethoxyacetic acid. Example 13
4-Methoxy-cvclohexanecarboxylic acid N-trans-(4- {2- \4-( 5-fluoro-benzo [dl isoxazol-3- vD-piperazin-l-yll-ethyll-cyclohexyD-amide
Figure imgf000066_0001
The title compound, MS: m/e = 447.1 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5-fluoro-benzo[d]isoxazol-3- yl)-piperazin-l-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate D) and 4-methoxy- cyclohexanecarboxylic acid.
Example 14 N-trans-f4-{2-[4-f5-Fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)- methanesulfonamide
Figure imgf000066_0002
4-Trans-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexylamine hydrochloride (intermediate D) (100 mg, 0.26 mmol) was solved in dichloromethane (2 ml), methanesulfonyl chloride (33 mg, 0.29 mmol) was added followed by triethylamine (80 μl, 0.57 mmol) and the solution was stirred overnight at room temperature. The reaction mixture was quenched with saturated NaHCO3-solution and extracted with dichloromethane. The organic extracts were washed with brine, dried with sodium sulfate, filtered and evaporated. The crude product was purified with column chromatography on silica gel using dichloromethane / methanol 100:0 -> 90:20. The product fractions were concentrated to give 88 mg (79% yield) of a white solid. MS (m/e): 425.2 (M+H+). Example 15
2- [ 1 ,41 Dioxan-2-yl-N-trans-( 4- {2- \4-( 5-fluoro-benzo [dl isoxazol-3-yl)-piperazin- 1-yll - ethylj-cyclohexyD-acetamide
Figure imgf000067_0001
Step 1 : ri,41Dioxan-2-yl-acetic acid ethyl ester
Figure imgf000067_0002
The title compound can be prepared in accordance with the literature in the patents WO 9857968 and US9811409.
Step 2: 2-[1.41Dioxan-2-yl-N-trans-(4-(2-[4-(5-fluoro-benzo[dlisoxazol-3-yl)- piperazin- 1 -yll -ethyl) -cyclohexyD-acetamide
Figure imgf000067_0003
The title compound, MS: m/e = 475.3 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5-fluoro-benzo[d]isoxazol-3- yl)-piperazin-l-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate D) and [l,4]dioxan- 2-yl-acetic acid (can be prepared by LiOH hydrolysis of [ 1 ,4]dioxan-2-yl-acetic acid ethyl ester). Example 16
3-Methoxy-cvclohexanecarboxylic acid N-trans-( 4- {2- \4-( 5-fluoro-benzo [dl isoxazol-3- vD-piperazin-l-yll-ethyll-cyclohexyD-amide
Figure imgf000068_0001
The title compound, MS: m/e = 487.4 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5-fluoro-benzo[d]isoxazol-3- yl)-piperazin-l-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate D) and 3- methoxycyclohexanecarboxylic acid.
Example 17
N-trans-f4-{2-[4-f5-Fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)- malonamide
Figure imgf000068_0002
The title compound, MS: m/e = 432.4 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5-fluoro-benzo[d]isoxazol-3- yl)-piperazin-l-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate D) and malonamic acid (can be prepared by LiOH hydrolysis of the commercially available malonamic acid ethyl ester). Example 18 rac-2-f2,2-Dimethyl-tetrahvdro-pyran-4-yl)-N-trans-f4-{2-[4-f5-fluoro- benzordlisoxazol-S-vD-piperazin-l-yll-ethyll-cvclohexyD-acetamide
Figure imgf000069_0001
The title compound, MS: m/e = 501.4 (M+H+), can be prepared in accordance with the general method of example 3 from 4-trans-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)- piperazin-1-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate D) and (2,2-dimethyl- tetrahydro-pyran-4-yl)-acetic acid methyl ester.
Example 19 N-trans-f4-{2-[4-f5-Fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)-2- αR,4S)-7-oxa-bicvclo[2.2.11hept-2-vl-acetamide
Figure imgf000069_0002
Step 1 : 7-Oxa-bicyclo[2.2.1]hept-5-en-2-one
The title compound can be prepared in accordance with literature Lit. : Helvetica Chimica ACTA -Vol. 66, Fasc.6(1983-Nr.l82), S1865-1871.
Step 2: (lS.4R)-[7-Oxa-bicvclo[2.2.11hept-(2E)-ylidenel-acetic acid methyl ester
The title compound, MS: m/e = 169.0 (M+H+), can be prepared in accordance with the general method of example 10, step 2 from 7-oxa-bicyclo[2.2.1]hept-5-en-2-one.
Step 3: (lS.4R)-(7-Oxa-bicvclor2.2.11hept-2-yl)-acetic acid methyl ester The title compound, MS: m/e = 171.2 (M+H+), can be prepared in accordance with the general method of example 10, step 3 from (lS,4R)-[7-oxa-bicyclo[2.2.1]hept-(2E)- ylidene] -acetic acid methyl ester.
Step 4: N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(lR,4S)-7-oxa-bicyclo[2.2.1]hept-2-yl-acetamide
The title compound, MS: m/e = 485.4 (M+H+), can be prepared in accordance with the general method of example 3 from 4-trans-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)- piperazin-1-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate D) and (lS,4R)-(7-oxa- bicyclo[2.2.1]hept-2-yl)-acetic acid methyl ester.
Example 20
N-trans-f4-{2-[4-f5-Fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)-2- trans-O-hydroxymethyl-cyclobutyD-acetamide
Figure imgf000070_0001
The title compound, MS: m/e = 473.4 (M+H+), can be prepared in accordance with the general method of example 3 from 4-trans-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)- piperazin-1-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate D) and trans-(3- hydroxymethyl-cyclobutyl)-acetic acid methyl ester (intermediate E, step 5).
Example 21
N-trans-f4-{2-[4-f5-Fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)-2- (3-methyl-oxetan-3-yl)-acetamide
Figure imgf000070_0002
Step 1 : Oxetan-3-ylidene-acetic acid methyl ester
Figure imgf000071_0001
Oxetan-3-one (commercially available) (50 mg, 0.69 mmol) was solved in 1 ml dichloromethane and cooled to 0-50C. (Methoxycarbonylmethylene) triphenylphosphorane (255 mg, 0.76 mmol) was added and the mixture stirred for 15 minutes. The mixture was directly purified with column chromatography on silica gel using heptane : ethyl acetate 100:0 -> 0:100. The product fractions were concentrated to give 57 mg (64% yield) of a white solid.
Step 2: (3-Methyl-oxetan-3-yl)-acetic acid methyl ester
Figure imgf000071_0002
Chlorotrimethylsilane (74 μl, 0.58 mmol) was solved in 1.5 ml THF. Copper(I) iodide
(7 mg, 0.04 mmol) and oxetan-3-ylidene-acetic acid methyl ester (50 mg, 0.39 mmol) in 0.5 ml THF were added at room temperature and the mixture was stirred for 15 minutes at room temperature. The reaction mixture was cooled to -15°C and 3N methylmagnesiumchloride-solution (0.52 ml, 1.56 mmol) was added drop wise. The reaction mixture was stirred for 1 hour at room temperature, quenched then with saturated NH4Cl-solution and extracted with dichloromethane. The organic extracts were washed with brine, dried with sodium sulfate, filtered and evaporated to give 65 mg (92%) light yellow oil. The crude product was used for the next step without further purification.
Step 3 : N-trans-(4- {2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin- 1 -yl]-ethyl} - cvclohexyl)-2-(3 -methyl-oxetan-3 -yl)-acetamide
Figure imgf000071_0003
The title compound, MS: m/e = 459.4 (M+H+), can be prepared in accordance with the general method of example 3 from 4-trans-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)- piperazin-1-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate D) and (3-methyl- oxetan-3-yl)-acetic acid methyl ester. Example 22
2-αS)-2,2-Dimethyl-tetrahvdro-pyran-4-yl)-N-trans-(4-{2-r4-(5-fluoro- benzordlisoxazol-S-vD-piperazin-l-yll-ethyll-cvclohexyD-acetamide
Figure imgf000072_0001
The title compound, MS: m/e = 501.3 (M+H+), was obtained from separation of rac-
2-(2,2-Dimethyl-tetrahydro-pyran-4-yl)-N-trans-(4-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)- piperazin-1-yl] -ethyl} -cyclohexyl)-acetamide (example 18) using a chiral column (chiralpak AD).
Example 23
2-qR)-2,2-Dimethyl-tetrahvdro-pyran-4-yl)-N-trans-(4-{2-r4-(5-fluoro- benzordlisoxazol-S-vD-piperazin-l-yll-ethyll-cvclohexyD-acetamide
Figure imgf000072_0002
The title compound, MS: m/e = 501.3 (M+H+), was obtained from separation of rac- 2-(2,2-Dimethyl-tetrahydro-pyran-4-yl)-N-trans-(4-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)- piperazin-1-yl] -ethyl} -cyclohexyl)-acetamide (example 18) using a chiral column (chiralpak AD). Example 24
2- [ 1 ,31 Dioxan-2-yl-N-trans-( 4- {2- \4-( 5-fluoro-benzo [dl isoxazol-3-yl)-piperazin- 1-yll - ethylj-cyclohexyD-acetamide
Figure imgf000073_0001
Step 1 : [l,3]Dioxan-2-yl-acetic acid methyl ester
O O^
Propane- 1,-3-diol (2.45 ml, 36 mmol) was dissolved in 100 ml THF and cooled to 0-5 0C. Sodium hydride (1.43 g, 40 mmol, 55%) was added and the reaction mixture stirred for 15 minutes at 0-5 0C. Propyonic acid methyl ester (2.97 ml, 36 mmol) dissolved in 10 ml THF was added drop wise and stirred for 3 hours at 0-50C. The reaction mixture was quenched with 2N HCl-solution and extracted two times with ethyl acetate. The organic extracts were washed with brine, dried with sodium sulfate, filtered and evaporated. The crude product was purified by flash chromatography on silica gel (dichloromethane). The desired compound was obtained as a colourless liquid (2.96 g, 52%).
Step 2: 2-[1.31Dioxan-2-yl-N-trans-(4-(2-[4-(5-fluoro-benzo[dlisoxazol-3-yl)- piperazin- 1 -yl] -ethyl} -cyclohexyD-acetamide
Figure imgf000073_0002
The title compound, MS: m/e = 475.3 (M+H+), can be prepared in accordance with the general method of example 3 from 4-trans-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)- piperazin-1-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate D) and [l,3]dioxan-2- yl-acetic acid methyl ester. Example 25
N-trans-f4-{2-[4-f5-Fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)-2-
(4-methoxy-piperidin-l-vl)-acetamide
Figure imgf000074_0001
Step 1 : (4-Hydroxy-piperidin-l-yl)-acetic acid methyl ester xα ,(0
The title compound can be prepared in accordance with the literature in the patent WO2007127726, preparation 34.
Step 2: (4-Methoxy-piperidin-l-yl)-acetic acid methyl ester
^x
The title compound can be prepared in accordance with the general method of intermediate B, step 3 from (4-hydroxy-piperidin-l-yl)-acetic acid methyl ester.
Step 2: N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(4-methoxy-piperidin- 1 -yl)-acetamide
Figure imgf000074_0002
The title compound, MS: m/e = 502.4 (M+H+), can be prepared in accordance with the general method of example 3 from 4-trans-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)- piperazin-1-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate D) and (4-methoxy- piperidin-l-yl)-acetic acid methyl ester. Example 26
N-trans-f4-{2-[4-f5-Fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)-
3,3-dimethoxy-propionamide
Figure imgf000075_0001
The title compound, MS: m/e = 463.3 (M+H+), can be prepared in accordance with the general method of example 3 from 4-trans-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)- piperazin-1-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate D) and methyl 3,3- dimethoxypropionate.
Example 27
N-trans-f4-{2-[4-f5-Fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)-2- trans-^-methoxymethyl-cyclobutyP-acetamide
Figure imgf000075_0002
The title compound, MS: m/e = 487.5 (M+H+), can be prepared in accordance with the general method of example 3 from 4-trans-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)- piperazin-1-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate D) and trans-(3- methoxymethyl-cyclobutyl)-acetic acid methyl ester (intermediate E). Example 28
N-trans-f4-{2-[4-f5-Fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)-
4,4-dimethoxv-butyramide
Figure imgf000076_0001
The title compound, MS: m/e = 477.3 (M+H+), can be prepared in accordance with the general method of example 3 from 4-trans-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)- piperazin-1-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate D) and methyl 4,4- dimethoxybutyrate.
Example 29 N-trans-f4-{2-[4-f6-Chloro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)-
3-methoxy-propionamide
Figure imgf000076_0002
The title compound, MS: m/e = 449.3/451.1 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(6-chloro- benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate F) and 3-methoxypropionic acid. Example 30 N-trans-f4-{2-[4-f6-Chloro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)-
Figure imgf000077_0001
The title compound, MS: m/e = 405.4 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(6-chloro-benzo[d]isoxazol-3- yl)-piperazin-l-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate F) and acetic acid.
Example 31
N-trans-f4-{2-[4-f6-Chloro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)- 2-trans-(4-methoxy-cvclohexyr)-acetamide
Figure imgf000077_0002
The title compound, MS: m/e = 516.9 (M+H+), can be prepared in accordance with the general method of example 3 from 4-trans-{2-[4-(6-chloro-benzo[d]isoxazol-3-yl)- piperazin-1-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate F) and trans-(4- methoxy-cyclohexyl)-acetic acid methyl ester {intermediate B).
Example 32
Tetrahvdro-pyran-4-carboxylic acid-trans-( 4- {2- \4-( 6-chloro-benzo [dl isoxazol-3-vD- piperazin-l-yll-ethyll-cyclohexyD-amide
Figure imgf000077_0003
The title compound, MS: m/e = 475.3 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(6-chloro-benzo[d]isoxazol-3- yl)-piperazin-l-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate F) and tetrahydro- pyran-4-carboxylic acid. Example 33 rac-N-trans-f4-{2-[4-f6-Chloro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cyclohexyl)- 3-,3i3-trifluoro-2-hvdroxy-propionamide
Figure imgf000078_0001
The title compound, MS: m/e = 489.4 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(6-chloro-benzo[d]isoxazol-3- yl)-piperazin-l-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate F) and rac-3,3,3- trifluoro-2-hydroxy-propionic acid.
Example 34 Tetrahydro-furan-3-carboxylic acid N-trans-( 4- {2- \4-( 6-chloro-benzo [dl isoxazol-3-yl)- piperazin-l-yll-ethyll-cvclohexvD-amide
Figure imgf000078_0002
The title compound, MS: m/e = 461.3 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(6-chloro-benzo[d]isoxazol-3- yl)-piperazin-l-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate F) and tetrahydro- furan-3-carboxylic acid.
Example 35
N-trans-f4-{2-[4-f6-Chloro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)-
2-(tetrahvdro-pyran-2-vl)-acetamide
Figure imgf000079_0001
The title compound, MS: m/e = 489.4 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(6-chloro-benzo[d]isoxazol-3- yl)-piperazin-l-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate F) and (tetrahydro- pyran-2-yl)-acetic acid.
Example 36
N-trans-f4-{2-[4-f6-Chloro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)- 2-trans-f3-methoxy-cvclopentyl)-acetamide
Figure imgf000079_0002
The title compound, MS: m/e = 503.4 (M+H+), can be prepared in accordance with the general method of example 3 from 4-trans-{2-[4-(6-chloro-benzo[d]isoxazol-3-yl)- piperazin-1-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate F) and trans-(3- methoxy-cyclopentyl)-acetic acid methyl ester (intermediate C).
Example 37 N-trans-f4-{2-[4-f6-Chloro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)-
3-methoxy-butyramide
Figure imgf000079_0003
Step 1 : 3-Methoxy-butyric acid methyl ester o o^
The title compound can be prepared in accordance with the preparation described in the literature Journal of Organic Chemistry (1995), 60(11), 3529-32.
Step 2: N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3 -methoxy-butyramide
Figure imgf000080_0001
The title compound, MS: m/e = 463.3 (M+H+), can be prepared in accordance with the general method of example 3 from 4-trans-{2-[4-(6-chloro-benzo[d]isoxazol-3-yl)- piperazin-1-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate F) and 3-methoxy- butyric acid methyl ester.
Example 38 l-Hydroxy-cyclopropanecarboxylic acid N-trans-f4-{2-[4-f6-chloro-benzo[dlisoxazol- 3-yl)-piperazin-l-yll-ethyl}-cyclohexyl)-amide
Figure imgf000080_0002
The title compound, MS: m/e = 447.1 (M+H+), can be prepared in accordance with the general method of example 3 from 4-trans-{2-[4-(6-chloro-benzo[d]isoxazol-3-yl)- piperazin-1-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate F) and 1 -hydro xy- cyclopropanecarboxylic acid.
Example 39 N-trans-f4-{2-[4-f6-Chloro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cyclohexyl)-
2-f4-methoxy-4-methyl-cyclohexyl)-acetamide
Figure imgf000081_0001
Step 1 : (4-Methoxy-4-methyl-cyclohexyl)-acetic acid methyl ester
Figure imgf000081_0002
The title compound, MS: m/e = 201.2 (M+H+), can be prepared in accordance with the general method of example 10, step 1 and step 2 from 4-methoxy-4-methyl- cyclohexanone (described in literatures).
Step 2: N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cvclohexyl)-2-(4-methoxy-4-methyl-cvclohexyl)-acetamide
Figure imgf000082_0001
The title compound, MS: m/e = 531.3 (M+H+), can be prepared in accordance with the general method of example 3 from 4-trans-{2-[4-(6-chloro-benzo[d]isoxazol-3-yl)- piperazin-1-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate F) and (4-methoxy-4- methyl-cyclohexyl)-acetic acid methyl ester.
Example 40 N-trans-f4-{2-[4-f6-Chloro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)- 2-(tetrahydro-pyran-4-yl)-acetamide
Figure imgf000082_0002
The title compound, MS: m/e = 489.4 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(6-chloro-benzo[d]isoxazol-3- yl)-piperazin-l-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate F) and (tetrahydro- pyran-4-yl)-acetic acid.
Example 41
N-trans-f4-{2-[4-f6-Chloro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)- propionamide
Figure imgf000082_0003
The title compound, MS: m/e = 419.4 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(6-chloro-benzo[d]isoxazol-3- yl)-piperazin-l-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate F) and propionic acid.
Example 42
N-trans-f4-{2-[4-f6-Chloro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)-
2-hvdroxy-acetamide
Figure imgf000083_0001
The title compound, MS: m/e = 421.3 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(6-chloro-benzo[d]isoxazol-3- yl)-piperazin-l-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate F) and hydro xy- acetic acid.
Example 43
N-trans-f4-{2-[4-f6-Chloro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)-
2-trans-(4-hvdroxy-cvclohexyl)-acetamide
Figure imgf000083_0002
The title compound, MS: m/e = 503.4 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(6-chloro-benzo[d]isoxazol-3- yl)-piperazin-l-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate F) and trans-(4- hydroxy-cyclohexyl)-acetic acid (intermediate B, step I).
Example 44
N-trans-f4-{2-[4-f6-Chloro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)- 3-hydroxy-3-methyl-butyramide
Figure imgf000084_0001
The title compound, MS: m/e = 463.3 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(6-chloro-benzo[d]isoxazol-3- yl)-piperazin-l-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate F) and 3-hydroxy-3- methyl-butyric acid.
Example 45
(S)-N-trans-(4-{2-r4-(6-Chloro-benzordlisoxazol-3-yl)-piperazin-l-yll-ethvU- cvclohexvl)-3-hvdroxv-butyramide
Figure imgf000084_0002
The title compound, MS: m/e = 449.1 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(6-chloro-benzo[d]isoxazol-3- yl)-piperazin-l-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate F) and (S)-(+)-3- hydroxylbutyric acid.
Example 46 ( S)-Tetrahydro-furan-3-carboxylic acid-N-trans-( 4- {2- \4-( 6-chloro-benzo [dl isoxazol-
3-yl)-piperazin-l-yll-ethvl}-cvclohexyl)-amide
Figure imgf000084_0003
The title compound, MS: m/e = 461.4 (M+H+), was obtained from separation of tetrahydro-furan-3-carboxylic acid N-trans-(4- (2-[4-(6-chloro-benzo[d]isoxazol-3-yl)- piperazin-1-yl] -ethyl} -cyclohexyl)-amide (example 34) using a chiral column (chiralpak AD).
Example 47
N-trans-f4-{2-[4-f6-Chloro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)-
Figure imgf000086_0001
Step 1 : Oxetan-3-ylidene-acetic acid methyl ester
Figure imgf000086_0002
Oxetan-3-one (commercially available) (50 mg, 0.69 mmol) was solved in 1 ml dichloromethane and cooled to 0-50C. (Methoxycarbonylmethylene) triphenylphosphorane (255 mg, 0.76 mmol) was added and the mixture stirred for 15 minutes. The mixture was directly purified with column chromatography on silica gel using heptane : ethyl acetate 100:0 -> 0:100. The product fractions were concentrated to give 57 mg (64% yield) of a white solid.
Step 2: Oxetan-3-yl-acetic acid methyl ester
Figure imgf000086_0003
The title compound can be prepared in accordance with the general method of example 10, step 2 from oxetan-3-ylidene-acetic acid methyl ester.
Step 3 : N-trans-(4- {2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin- 1 -yl]-ethyl} - cvclohexyl)-2-oxetan-3-yl-acetamide
Figure imgf000087_0001
The title compound, MS: m/e = 461.1 (M+H+), can be prepared in accordance with the general method of example 3 from 4-trans-{2-[4-(6-chloro-benzo[d]isoxazol-3-yl)- piperazin-1-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate F) and oxetan-3-yl- acetic acid methyl ester.
Example 48
N-trans-f4-{2-[4-f6-Chloro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)- l-trans-O-methoxymethyl-cyclobutyD-acetamide
Figure imgf000087_0002
The title compound, MS: m/e = 503.0 (M+H+), can be prepared in accordance with the general method of example 3 from 4-trans-{2-[4-(6-chloro-benzo[d]isoxazol-3-yl)- piperazin-1-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate F) and trans-(3- methoxymethyl-cyclobutyl)-acetic acid methyl ester (intermediate E).
Example 49 N-trans-f4-{2-[4-f6-Chloro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)-
2-(R)-tetrahvdro-pyran-2-vl-acetamide
Figure imgf000087_0003
Step 1 : N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-tetrahydro-pwan-2-yl-acetamide
The title compound, MS: m/e = 489.4 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(6-chloro-benzo[d]isoxazol-3- yl)-piperazin-l-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate F) and 2- (tetrahydro-pyran-2-yl)-acetic acid.
Step 2: N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(R)-tetrahydro-pyran-2-yl-acetamide
The title compound, MS: m/e = 489.4 (M+H+), was obtained from separation of N- trans-(4-{2-[4-(6-chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2- tetrahydro-pyran-2-yl-acetamide (example 49, step I) using a chiral column (chiralpak AD).
Example 50
N-trans-f4-{2-[4-f6-Chloro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)-
2-(S)-tetrahvdro-pyran-2-vl-acetamide
Figure imgf000089_0001
The title compound, MS: m/e = 489.4 (M+H+), was obtained from separation of N- trans-(4-{2-[4-(6-chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-2- tetrahydro-pyran-2-yl-acetamide (example 49, step I) using a chiral column (chiralpak AD).
Example 51
N-trans-f4-{2-[4-f6-Chloro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)- 2-(4-isopropoxy-cvclohexyl)-acetamide
Figure imgf000089_0002
The title compound, MS: m/e = 545.4 (M+H+), can be prepared in accordance with the general method of example 3 from 4-trans-{2-[4-(6-chloro-benzo[d]isoxazol-3-yl)- piperazin-1-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate F) and rac-(4- isopropoxy-cyclohexyl)-acetic acid methyl ester (example 10, step 3).
Example 52
N-trans-(4-{244-(6-Chloro-benzo[dlisoxazol-3-γl)-piperazin-l-γll-ethγl}- cvclohexyl)-2-cvclopropyl-acetamide
Figure imgf000090_0001
The title compound, MS: m/e = 445.3 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(6-chloro-benzo[d]isoxazol-3- yl)-piperazin-l-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate F) and cyclopropyl- acetic acid.
Example 53
N-trans-f4-{2-[4-f6-Chloro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)-
3-,3i3-trifluoro-propionamide
Figure imgf000090_0002
The title compound, MS: m/e = 473.2 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(6-chloro-benzo[d]isoxazol-3- yl)-piperazin-l-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate F) and 3,3,3- trifluoro -propionic acid. Example 54
4-trans-Methoxy-cvclohexanecarboxylic acid N-trans-(4- {2- \4-( 6-chloro- benzordlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)-amide
Figure imgf000091_0001
The title compound, MS: m/e = 503.3/505.2 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(6-chloro- benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate F) and 4-methoxycyclohexanecarboxylic acid and by separation of the two stereoisomers using a chiral column (chiralpak AD).
Example 55
N-trans-(4-{2-[4-(6-Chloro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cyclohexyl)-
3,3-dimethoxy-propionamide
Figure imgf000091_0002
The title compound, MS: m/e = 479.2 (M+H+), can be prepared in accordance with the general method of example 3 from 4-trans-{2-[4-(6-chloro-benzo[d]isoxazol-3-yl)- piperazin-1-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate F) and methyl 3,3- dimethoxypropionate. Example 56
N-trans-f4-{2-[4-f5.,6-Difluoro-benzo[(ilisoxazol-3-yl)-piperazin-l-yll-ethyl}- cyclohexvD-acetamide
Figure imgf000092_0001
The title compound, MS: m/e = 407.3 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5,6-difluoro-benzo[d]isoxazol- 3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate G) and acetic acid.
Example 57 N-trans-f4-{2-[4-f5.,6-Difluoro-benzo[(ilisoxazol-3-yl)-piperazin-l-yll-ethyl}- cyclohexyl)-3-methoxy-propionamide
Figure imgf000092_0002
The title compound, MS: m/e = 451.2 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5,6-difluoro-benzo[d]isoxazol- 3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate G) and 3- methoxypropionic acid. Example 58
N-trans-f4-{2-[4-f5.,6-Difluoro-benzo[(ilisoxazol-3-yl)-piperazin-l-yll-ethyl}- cvclohexyD-2-trans-(4-methoxy-cvclohexyD-acetamide
Figure imgf000093_0001
The title compound, MS: m/e = 519.4 (M+H+), can be prepared in accordance with the general method of example 3 from 4-trans-{2-[4-(5,6-difluoro-benzo[d]isoxazol-3-yl)- piperazin-1-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate G) and trans-(4- methoxy-cyclohexyl)-acetic acid methyl ester {intermediate B).
Example 59 N-trans-f4-{2-[4-f5.,6-Difluoro-benzo[(ilisoxazol-3-yl)-piperazin-l-yll-ethyl}- cyclohexvD-propionamide
Figure imgf000093_0002
The title compound, MS: m/e = 421.2 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5,6-difluoro-benzo[d]isoxazol- 3-yl)-piperazin-l-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate G) and propionic acid.
Example 60
N-trans-f4-{2-[4-f5.,6-Difluoro-benzo[(ilisoxazol-3-yl)-piperazin-l-yll-ethyl}- cvclohexyl)-2-methoxv-acetamide
Figure imgf000094_0001
The title compound, MS: m/e = 437.2 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5,6-difluoro-benzo[d]isoxazol- 3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate G) and methoxyacetic acid.
Example 61 N-trans-f4-{2-[4-f5.,6-Difluoro-benzo[(ilisoxazol-3-yl)-piperazin-l-yll-ethyl}- cvclohexyl)-2-f4-hvdroxy-tetrahvdro-pyran-4-yl)-acetamide
Figure imgf000094_0002
The title compound, MS: m/e = 507.3 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5,6-difluoro-benzo[d]isoxazol- 3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate G) and (4- hydroxy-tetrahydro-pyran-4-yl)-acetic acid (can be prepared in accordance with the patent WO2007006534).
Example 62
N-trans-f4-{2-[4-f5.,6-Difluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cvclohexyl)-2-f4-methoxy-tetrahydro-pyran-4-vl)-acetamide
Figure imgf000095_0001
The title compound, MS: m/e = 521.4 (M+H+), can be prepared in accordance with the general method of example 3 from 4-trans-{2-[4-(5,6-difluoro-benzo[d]isoxazol-3-yl)- piperazin-1-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate G) and (4-methoxy- tetrahydro-pyran-4-yl)-acetic acid methyl ester (can be prepared in accordance with the general method of intermediate B, step 2 and step 3 from (4-hydroxy-tetrahydro-pyran-4- yl)-acetic acid (WO2007006534).
Example 63
N-trans-f4-{2-[4-f5.,6-Difluoro-benzo[(ilisoxazol-3-yl)-piperazin-l-yll-ethyl}- cvclohexyl)-2-ftetrahvdro-pyran-4-vl)-acetamide
Figure imgf000095_0002
The title compound, MS: m/e = 491.2 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5,6-difluoro-benzo[d]isoxazol- 3-yl)-piperazin-l-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate G) and tetrahydropyran-4-yl-acetic acid.
Example 64
N-trans-f4-{2-[4-f5.,6-Difluoro-benzo[(ilisoxazol-3-yl)-piperazin-l-yll-ethyl}- cvclohexyl)-3-hvdroxv-3-methvl-butyramide
Figure imgf000096_0001
The title compound, MS: m/e = 465.3 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5,6-difluoro-benzo[d]isoxazol- 3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate G) and beta- hyroxyisovaleric acid.
Example 65
N-trans-f4-{2-[4-f5.,6-Difluoro-benzo[(ilisoxazol-3-yl)-piperazin-l-yll-ethyl}- cvclohexyl)-2-trans-(3-methoxy-cvclopentyl)-acetamide
Figure imgf000097_0001
The title compound, MS: m/e = 505.3 (M+H+), can be prepared in accordance with the general method of example 3 from 4-trans-{2-[4-(5,6-difluoro-benzo[d]isoxazol-3-yl)- piperazin-1-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate G) and trans-(3- methoxy-cyclopentyl)-acetic acid methyl ester (intermediate C).
Example 66 4-Methoxy-cvclohexanecarboxylic acid N-trans(4-{2-[4-(5.,6-difluor()- benzordlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)-amide
Figure imgf000097_0002
The title compound, MS: m/e = 505.3 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5,6-difluoro-benzo[d]isoxazol- 3-yl)-piperazin-l-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate G) and 4- methoxy-cyclohexanecarboxylic acid.
Example 67
Tetrahydro-pyran-4-carboxylic acid N-trans-( 4- {2- \4-( 5,6-difluoro-benzo [dl isoxazol- 3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)-amide
Figure imgf000098_0001
The title compound, MS: m/e = 477.2 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5,6-difluoro-benzo[d]isoxazol- 3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate G) and tetrahydro-pyran-4-carboxylic acid.
Example 68 Ethanesulfonic acid N-trans-( 4- {2- \4-( 5-,6-difluoro-benzo [dl isoxazol-3-yl)-piperazin- 1- yll-ethyll-cvclohexvD-amide
Figure imgf000098_0002
The title compound, MS: m/e = 457.4 (M+H+), can be prepared in accordance with the general method of example 14 from 4-trans-{2-[4-(5,6-difluoro-benzo[d]isoxazol-3-yl)- piperazin-1-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate G) and ethanesulfonyl chloride.
Example 69
N-trans-f4-{2-[4-f5.,6-Difluoro-benzo[(ilisoxazol-3-yl)-piperazin-l-yll-ethyl}- cvclohexyl)-2-ri.,31dioxan-2-vl-acetamide
Figure imgf000099_0001
The title compound, MS: m/e = 493.3 (M+H+), can be prepared in accordance with the general method of example 3 from 4-trans-{2-[4-(5,6-difluoro-benzo[d]isoxazol-3-yl)- piperazin-1-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate G) and [l,3]dioxan-2- yl-acetic acid methyl ester (example 24, step I).
Example 70
N-trans-f4-{2-[4-f6-Chloro-5-fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cyclohexvD-propionamide
Figure imgf000099_0002
The title compound, MS: m/e = 437.2 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(6-chloro-5-fluoro- benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate H) and propionic acid. Example 71 N-trans-f4-{2-[4-f6-Chloro-5-fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cyclohexyl)-3-methoxy-propionamide
Figure imgf000100_0001
The title compound, MS: m/e = 467.3 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(6-chloro-5-fluoro- benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate H) and 3-methoxypropionic acid.
Example 72 N-trans-f4-{2-[4-f6-Chloro-5-fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cyclohexyl)-2-ftetrahvdro-pyran-4-yl)-acetamide
Figure imgf000100_0002
The title compound, MS: m/e = 507.3 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(6-chloro-5-fluoro- benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate H) and (tetrahydro-pyran-4-yl)-acetic acid. Example 73 N-trans-f4-{2-[4-f5-Chloro-6-fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cyclohexyD-acetamide
Figure imgf000101_0001
The title compound, MS: m/e = 423.2 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5-chloro-6-fluoro- benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate I) and acetic acid.
Example 74 N-trans-f4-{2-[4-f5-Chloro-6-fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cvclohexyl)-3-methoxy-propionamide
Figure imgf000101_0002
The title compound, MS: m/e = 467.2 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5-chloro-6-fluoro- benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate I) and 3-methoxypropionic acid. Example 75 N-trans-f4-{2-[4-f5-Chloro-6-fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cyclohexyl)-2-cvclopropyl-acetamide
Figure imgf000102_0001
The title compound, MS: m/e = 463.3 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5-chloro-6-fluoro- benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate I) and cyclopropylacetic acid.
Example 76
N-trans-f4-{2-[4-f5-Chloro-6-fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cyclohexyD-2- [ 1 ,41 dioxan-2-yl-acetamide
Figure imgf000102_0002
The title compound, MS: m/e = 509.3 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5-chloro-6-fluoro- benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate I) and [l,4]dioxan-2-yl-acetic acid [can be prepared by LiOH hydrolysis of [l,4]dioxan-2- yl-acetic acid ethyl ester (example 15, step 1)]. Example 77 N-trans-f4-{2-[4-f5-Chloro-6-fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cvclohexyl)-2-[l,31dioxan-2-yl-acetamide
Figure imgf000103_0001
The title compound, MS: m/e = 509.3 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5-chloro-6-fluoro- benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate I) and [l,3]dioxan-2-yl-acetic acid methyl ester (example 24, step 1).
Example 78 N-trans-f4-{2-[4-f5-Chloro-6-fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cyclohexyl)-3.,3-dimethoxy-propionamide
Figure imgf000103_0002
The title compound, MS: m/e = 497.3 (M+H+), can be prepared in accordance with the general method of example 3 from 4-trans-{2-[4-(5-chloro-6-fluoro-benzo[d]isoxazol- 3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate I) and methyl 3,3- dimethoxypropionate. Example 79
N-trans-f4-{2-[4-f5-Chloro-6-fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cvclohexyl)-2-trans-f3-hvdroxymethyl-cvclobutyl)-acetamide
Figure imgf000104_0001
The title compound, MS: m/e = 507.3 (M+H+), can be prepared in accordance with the general method of example 3 from 4-trans-{2-[4-(5-chloro-6-fluoro-benzo[d]isoxazol- 3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate I) and trans-(3- hydroxymethyl-cyclobutyl)-acetic acid methyl ester (intermediate E, step 5).
Example 80
N-trans-f4-{2-[4-f5-Chloro-6-fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cvclohexyl)-2-trans-(3-methoxymethyl-cvclobutyl)-acetamide
Figure imgf000104_0002
The title compound, MS: m/e = 521.3 (M+H+), can be prepared in accordance with the general method of example 3 from 4-trans-{2-[4-(5-chloro-6-fluoro-benzo[d]isoxazol- 3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate I) and trans-(3- methoxymethyl-cyclobutyl)-acetic acid methyl ester (intermediate E).
Example 81
N-trans-f4-{2-[4-f5-Chloro-6-fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cvclohexyl)-3-methvlsulfanyl-propionamide
Figure imgf000105_0001
The title compound, MS: m/e = 483.3 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5-chloro-6-fluoro- benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate I) and 3-methylsulfanyl-propionic acid.
Example 82 N-trans-f4-{2-[4-f5-Chloro-6-fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cyclohexyD^-O-methyl-isoxazol-S-vD-acetamide
Figure imgf000105_0002
The title compound, MS: m/e = 504.3 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5-chloro-6-fluoro- benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate I) and (3-methyl-isoxazol-5-yl)-acetic acid.
Example 83 3-Chloro-cvclobutanecarboxylic acid N-trans-(4-{2-r4-(5-chloro-6-fluoro- benzordlisoxazol-S-vD-piperazin-l-yll-ethyll-cyclohexyD-amide
Figure imgf000106_0001
The title compound, MS: m/e = 497.2 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5-chloro-6-fluoro- benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate I) and 3-chloro-cyclobutanecarboxylic acid.
Example 84 S-Chloro-thiophene-l-carboxylic acid N-trans-(4-{2-r4-(5-chloro-6-fluoro- benzordlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)-amide
Figure imgf000107_0001
The title compound, MS: m/e = 525.3 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5-chloro-6-fluoro- benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate I) and 5-chloro-thiophene-2-carboxylic acid.
Example 85 S-Methoxy-thiophene-l-carboxylic acid N-trans-( 4- {2- \4-( 5-chloro-6-fluoro- benzordlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)-amide
Figure imgf000107_0002
The title compound, MS: m/e = 521.3 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5-chloro-6-fluoro- benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate I) and 5-methoxy-thiophene-2-carboxylic acid. Example 86 N-trans-f4-{2-[4-f5-Chloro-6-fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cyclohexyD-propionamide
Figure imgf000108_0001
The title compound, MS: m/e = 437.3 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5-chloro-6-fluoro- benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate I) and propionic acid.
Example 87 N-trans-f4-{2-[4-f5-Chloro-6-fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cyclohexyl)-2-hydroxy-acetamide
Figure imgf000108_0002
The title compound, MS: m/e = 439.3 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5-chloro-6-fluoro- benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate I) and glycolic acid.
Example 88
N-trans-f4-{2-[4-f5-Chloro-6-fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cyclohexyl)-2-trans-(4-methoxy-cvclohexyl)-acetamide
Figure imgf000109_0001
The title compound, MS: m/e = 535.4 (M+H+), can be prepared in accordance with the general method of example 3 from 4-trans-{2-[4-(5-chloro-6-fluoro-benzo[d]isoxazol- 3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate I) and trans-(4- methoxy-cyclohexyl)-acetic acid methyl ester {intermediate B).
Example 89
N-trans-f4-{2-[4-f5-Chloro-6-fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cyclohexyD-l-methanesulfonyl-acetamide
Figure imgf000109_0002
The title compound, MS: m/e = 501.2 (M+H+), can be prepared in accordance with the general method of example 3 from 4-trans-{2-[4-(5-chloro-6-fluoro-benzo[d]isoxazol- 3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate I) and methanesulfonyl-acetic acid methyl ester.
Example 90 N-trans-f4-{2-[4-f5-Chloro-6-fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cvclohexyl)-3-methanesulfonyl-propionamide
Figure imgf000110_0001
The title compound, MS: m/e = 515.5 (M+H+), can be prepared in accordance with the general method of example 3 from 4-trans-{2-[4-(5-chloro-6-fluoro-benzo[d]isoxazol- 3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate I) and 3- methanesulfonyl-propionic acid methyl ester.
Example 91 N-trans-f4-{2-[4-f5-Chloro-6-fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cyclohexyD-carbamic acid methyl ester
Figure imgf000111_0001
The title compound, MS: m/e = 439.4/441.2(M+H+), can be prepared in accordance with the general method of intermediate A, step 3 from 4-trans-{2-[4-(5-chloro-6-fluoro- benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate I) and methylchloro formate.
Example 92 C yclobutanecarboxylic acid N-trans-( 4- {2- \4-( 5-chloro-6-fluoro-benzo [dl isoxazol-3- yl)-piperazin-l-yll-ethyl}-cyclohexyl)-amide
Figure imgf000111_0002
The title compound, MS: m/e = 463.3/465.4 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5-chloro-6-fluoro- benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate I) and cyclobutanecarboxylic acid. - I l l -
Example 93
N-trans-f4-{2-[4-f5-Chloro-6-fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cyclohexyl)-3.,3i3-trifluoro-propionamide
Figure imgf000112_0001
The title compound, MS: m/e = 491.3/493.3 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5-chloro-6-fluoro- benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate I) and 3,3,3-trifluoro-propionic acid.
Example 94 N-trans-f4-{2-[4-f5.,6-Dichloro-benzo[(ilisoxazol-3-yl)-piperazin-l-yll-ethyl}- cyclohexvl)-3-methoxv-propionamide
Figure imgf000112_0002
The title compound, MS: m/e = 483.4 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5,6-dichloro-benzo[d]isoxazol-3- yl)-piperazin-l-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate J) and 3- methoxypropionic acid. Example 95 Tetrahydro-pyran-4-carboxylic acid N-trans-(4- {2- \4-( 5,6-dichloro-benzo [dl isoxazol-
3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)-amide
Figure imgf000113_0001
The title compound, MS: m/e = 509.4 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5,6-dichloro-benzo[d]isoxazol- 3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate J) and tetrahydro- pyran-4-carboxylic acid.
Example 96 N-trans-f4-{2-[4-f5.,6-Dichloro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cvclohexyl)-2-trans-(4-methoxy-cvclohexyl)-acetamide
Figure imgf000113_0002
The title compound, MS: m/e = 551.3 (M+H+), can be prepared in accordance with the general method of example 3 from 4-trans-{2-[4-(5,6-dichloro-benzo[d]isoxazol-3-yl)- piperazin-1-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate J) and trans-(4- methoxy-cyclohexyl)-acetic acid methyl ester {intermediate B).
Example 97 N-trans-f4-{2-[4-f5.,6-Dichloro-benzo[(ilisoxazol-3-yl)-piperazin-l-yll-ethyl}- cvclohexyl)-2-ftetrahvdro-pyran-4-yl)-acetamide
Figure imgf000114_0001
The title compound, MS: m/e = 523.3 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5,6-dichloro-benzo[d]isoxazol- 3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate J) and (tetrahydro-pyran-4-yl)-acetic acid.
Example 98 3-Methoxy-N-trans-f4-{2-[4-f6-methyl-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cyclohexvD-propionamide
Figure imgf000114_0002
The title compound, MS: m/e = 429.5 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(6-methyl-benzo[d]isoxazol-3- yl)-piperazin-l-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate K) and 3- methoxypropionic acid.
Example 99
N-trans-f4-{2-[4-f6-Methyl-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)- propionamide
Figure imgf000115_0001
The title compound, MS: m/e = 399.2 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(6-methyl-benzo[d]isoxazol-3- yl)-piperazin-l-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate K) and propionic acid.
Example 100
2-trans-( 4-Methoxy-cvclohexyl)-N-trans-( 4- {2- \4-( 6-methyl-benzo [dl isoxazol-3-yl)- piperazin-l-yll-ethylj-cyclohexyD-acetamide
Figure imgf000115_0002
The title compound, MS: m/e = 497.4 (M+H+), can be prepared in accordance with the general method of example 3 from 4-trans-{2-[4-(6-methyl-benzo[d]isoxazol-3-yl)- piperazin-1-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate K) and trans-(4- methoxy-cyclohexyl)-acetic acid methyl ester {intermediate B).
Example 101
2- [ 1 ,31 Dioxan-2-yl-N-trans-( 4- {2- \4-( 6-methyl-benzo [dl isoxazol-3-yl)-piperazin- 1-yll - ethylj-cyclohexyP-acetamide
Figure imgf000115_0003
The title compound, MS: m/e = 471.3 (M+H+), can be prepared in accordance with the general method of example 3 from 4-trans-{2-[4-(6-methyl-benzo[d]isoxazol-3-yl)- piperazin-1-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate K) and [l,3]dioxan-2- yl-acetic acid methyl ester (example 24, step 1).
Example 102
2- [ 1 ,41 Dioxan-2-yl-N-trans-( 4- {2- \4-( 6-methyl-benzo [dl isoxazol-3-yl)-piperazin- 1-yll - ethylj-cyclohexyD-acetamide
Figure imgf000117_0001
The title compound, MS: m/e = 471.3 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(6-methyl-benzo[d]isoxazol-3- yl)-piperazin-l-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate K) and [l,4]dioxan- 2-yl-acetic acid (can be prepared by LiOH hydrolysis of [l,4]dioxan-2-yl-acetic acid ethyl ester, example 15, step 1).
Example 103
3,3-Dimethoxy-N-trans-f4-{2-[4-f6-methyl-benzo[dlisoxazol-3-yl)-piperazin-l-yll- ethyl}-cyclohexyl)-propionamide
Figure imgf000117_0002
The title compound, MS: m/e = 459.5 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(6-methyl-benzo[d]isoxazol-3- yl)-piperazin-l-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate K) and 3,3- dimethoxy-propionic acid. Example 104
3-Methoxy-N-trans-f4-{2-[4-f5-methyl-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cyclohexyD-propionamide
Figure imgf000118_0001
The title compound, MS: m/e = 429.3 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(5-methyl-benzo[d]isoxazol-3- yl)-piperazin-l-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate L) and 3- methoxypropionic acid.
Example 105 2-Methanesulfonyl-N-trans-( 4- {2- \4-( 6-methyl-benzo [dl isoxazol-3-yl)-piperazin- 1-yll - ethylj-cyclohexyD-acetamide
Figure imgf000118_0002
The title compound, MS: m/e = 463.3 (M+H+), can be prepared in accordance with the general method of example 3 from 4-trans-{2-[4-(6-methyl-benzo[d]isoxazol-3-yl)- piperazin-1-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate K) and methanesulfonyl-acetic acid methyl ester. Example 106
N-trans-f4-{2-[4-f6-Fluoro-5-methyl-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cyclohexvD-acetamide
Figure imgf000119_0001
The title compound, MS: m/e = 403.3 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(6-fluoro-5-methyl- benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate M) and acetic acid.
Example 107
N-trans-f4-{2-[4-f6-Fluoro-5-methyl-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cyclohexyl)-2-methoxv-acetamide
Figure imgf000119_0002
The title compound, MS: m/e = 433.5 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(6-fluoro-5-methyl- benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate M) and methoxyacetic acid. Example 108
N-trans-f4-{2-[4-f6-Fluoro-5-methyl-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cvclohexyl)-3-methoxy-propionamide
Figure imgf000120_0001
The title compound, MS: m/e = 447.4 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(6-fluoro-5-methyl- benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate M) and 3-methoxypropionic acid.
Example 109
2-C vclopropyl-N-trans-( 4- {2- \4-( 6-fluoro-5-methyl-benzo [dl isoxazol-3-yl)-piperazin-
1-yll-ethyll-cyclohexyD-acetamide
Figure imgf000120_0002
The title compound, MS: m/e = 443.3 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(6-fluoro-5-methyl- benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate M) and cyclopropyl-acetic acid. Example 110
2-Ethoxy-N-trans-( 4- {2- \4-( 6-fluoro-5-methyl-benzo [dl isoxazol-3-yl)-piperazin- 1-yll - ethylj-cyclohexyD-acetamide
Figure imgf000121_0001
The title compound, MS: m/e = 447.5 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(6-fluoro-5-methyl- benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate M) and ethoxyacetic acid.
Example 111
2- [ 1 ,31 Dioxan-2-yl-N-trans-( 4- {2- \4-( 6-fluoro-5-methyl-benzo [dl isoxazol-3-yl)- piperazin-l-yll-ethyl}-cyclohexyl)-acetamide
Figure imgf000121_0002
The title compound, MS: m/e = 489.5 (M+H+), can be prepared in accordance with the general method of example 3 from 4-trans-{2-[4-(6-fluoro-5-methyl-benzo[d]isoxazol- 3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate M) and [l,3]dioxan-2-yl-acetic acid methyl ester (example 24, step I). Example 112
N-trans-f4-{2-[4-f6-Fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexyl)-2-
(tetrahydro-pvran-4-vl)-acetamide
Figure imgf000122_0001
The title compound, MS: m/e = 473.4 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(6-fluoro-benzo[d]isoxazol-3- yl)-piperazin-l-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate N) and (tetrahydro- pyran-4-yl)-acetic acid.
Example 113 2- [ 1 ,41 Dioxan-2-yl-N-trans-( 4- {2- \4-( 6-fluoro-5-methyl-benzo [dl isoxazol-3-vD- piperazin-l-yll-ethyll-cyclohexyD-acetamide
Figure imgf000122_0002
The title compound, MS: m/e = 489.4 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(6-fluoro-5-methyl- benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate M) and [l,4]dioxan-2-yl-acetic acid [can be prepared by LiOH hydrolysis of [l,4]dioxan-2- yl-acetic acid ethyl ester (example 15, step 1)]. Example 114
2-(R)- [ 1 ,41 Dioxan-2-yl-N-trans-( 4- {2- \4-( 6-fluoro-5-methyl-benzo [dl isoxazol-3-yl)- piperazin-l-yll-ethyll-cyclohexyD-acetamide
Figure imgf000123_0001
The title compound, MS: m/e = 489.4 (M+H+), was obtained from separation of 2-
[ 1 ,4]Dioxan-2-yl-N-(4- {2-[4-(6-fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin- 1 -yl]- ethyl}-cyclohexyl)-acetamide (example 113, step 1) using a chiral column (Reprosil Chiral NR).
Example 115 2-(S)- [ 1 ,41 Dioxan-2-yl-N-trans-(4- {2- r4-(6-fluoro-5-methyl-benzo [dl isoxazol-3-vD- piperazin-l-yll-ethyll-cyclohexyD-acetamide
Figure imgf000123_0002
The title compound, MS: m/e = 489.4 (M+H+), was obtained from separation of 2- [ 1 ,4]Dioxan-2-yl-N-(4- {2-[4-(6-fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin- 1 -yl]- ethyl} -cyclohexyl)-acetamide (example 113, step 1) using a chiral column (Reprosil Chiral NR). Example 116
( S)-4,4,4-Trifluoro-N-trans-f 4- {2- \4-( 6-fluoro-5-methyl-benzo [dl isoxazol-3-vD- piperazin-l-yll-ethyl}-cvclohexyl)-3-hvdroxy-butyramide
Figure imgf000124_0001
The title compound, MS: m/e = 500.53 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(6-fluoro-benzo[d]isoxazol-3- yl)-piperazin-l-yl] -ethyl} -cyclohexylamine hydrochloride (intermediate N) and (S)-4,4,4- Trifluoro-3-hydroxybutyric acid.
Example 117
N-trans-f4-{2-[4-f6-Fluoro-5-methyl-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cyclohexyl)-2-ftetrahvdro-pyran-2-vl)-acetamide
Figure imgf000124_0002
The title compound, MS: m/e = 487.5 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(6-fluoro-5-methyl- benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate M) and (Tetrahydro-pyran-2-yl)-acetic acid. Example 118
N-trans-f4-{2-[4-f6-Fluoro-5-methyl-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cvclohexyl)-2-ftetrahydro-furan-2-vl)-acetamide
Figure imgf000125_0001
The title compound, MS: m/e = 487.5 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(6-fluoro-5-methyl- benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate M) and (Tetrahydro-furan-2-yl)-acetic acid.
Example 119
N-trans-f4-{2-[4-f6-Fluoro-5-methyl-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cvclohexyl)-2-methoxv-propionamide
Figure imgf000125_0002
The title compound, MS: m/e = 487.5 (M+H+), can be prepared in accordance with the general method of example 1, step 3 from 4-trans-{2-[4-(6-fluoro-5-methyl- benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexylamine hydrochloride (intermediate M) and 2-methoxypropionic acid (can be prepared by LiOH hydrolysis of [l,4]dioxan-2-yl- acetic acid ethyl ester, example 15, step 1). Synthesis of intermediates
Intermediate A Trans- [4-f2-Oxo-ethyl)-cvclohexyll-carbamic acid tert-butyl ester
Figure imgf000126_0001
Step 1 : trans-(4-Amino-cyclohexyl)- acetic acid
(4-Nitro-phenyl)-acetic acid (5Og, 276 mmol) was added to a stirred solution of 22.08g of 50% sodium hydroxide solution in 45OmL deionizated water. The clear yellow solution is transferred into a high-pressure autoclave that it charged with 3Og (511 mmol) of water- wet sponge nickel catalyst. The autoclave is sealed, flushed with nitrogen and then pressurized to 115 bar with hydrogen. The reaction mixture is stirred and heated to 125°C for 48h. At that time the autoclave is cooled, vented and charged under nitrogen with another 30g (511 mmol) of the sponge nickel catalyst. The autoclave is flushed again with nitrogen and then pressurized to 115 bar and the vessel is heated to 1300C while stirring (a maximum pressure of 130 bars is observed). Hydro genation is continued for 5 days to 1300C. The autoclave is then cooled, vented and flushed with nitrogen and the contents are removed and filtered through filter aid to remove catalyst. After removal of the solvent 74g of crude material was obtained. The intermediated is used directly in the next step without purification. MS (m/e): 158.3 (M+H+).
Step 2: Trans-(4-amino-cyclohexyl)-acetic acid ethyl ester
A solution of the trans-(4-amino-cyclohexyl)- acetic acid obtained (74g, 476mmol) is adjusted to pH 5 with 25% HCl. The mixture was evaporated to dryness and dried under vacuum overnight. The residue was suspended in 146mL of a 6.5N ethanolic HCl solution and 0.6L of ethanol were added to the mixture. After 4 h refluxing, the mixture is cooled and filtered and the filtrate is concentrated to dryness under vacuum. The residue is dissolved in ethanol, treated with ether and cooled overnight in the refrigerator, to give the trans-(4-amino-cyclohexyl)-acetic acid ethyl ester hydrochloride (19.7 g, 32% on the two steps ) as a white solid which was filtered and dried under vacuum. MS (m/e): 186.1 (M+H+).
Step 3: trans-(4-tert-Butoxycarbonylamino-cyclohexyl)-acetic acid ethyl ester
To a solution of trans-(4-amino-cyclohexyl)-acetic acid ethyl ester (1.28 g, 7 mmol), in dichloromethane (15ml), di-tert-butyl-dicarbonate (2,26 g, lOmmol), triethylamine (0.699 ml, 7mmol) and 4-dimethylaminopyridine (0.042mL, 0.35mmol) were added. The mixture was stirred for 8h until TLC indicated completion of the reaction. Water was added and the solution was extracted three times with dichloromethane. The combined organic layers were washed with water and brine, dried over magnesium sulfate, filtered and evaporated. The crude product was purified by flash-chromatography on silica gel with hexane : ethyl acetate (4:2 to 3:2) to give 1.2 g (60%) of the product as a white solid. MS (m/e): 284.4 (M-H+).
Step 4: trans-[4-(2-Oxo-ethyl)-cyclohexyl]-carbamic acid tert-butyl ester
To a solution of trans-(4-tert-butoxycarbonylamino-cyclohexyl)-acetic acid ethyl ester (1.04 g, 4 mmol), in toluene (10 ml) at -78°C a 1.2M solution of DIBAL-H (5. ImI, 6 mmol) in toluene was added. The mixture was stirred at -78°C until TLC after 0.5h indicated completion of the reaction. Water was added and the solution was extracted three times with dichloromethane. The combined organic layers were washed with water and brine, dried over magnesium sulfate, filtered and evaporated. The crude product was used without purification on the next step. MS (m/e): 242.3 (M+H+).
Intermediate B trans-(4-Methoxy-cvclohexyl)-acetic acid methyl ester
Figure imgf000127_0001
Step 1 : trans-(4-Hydroxy-cyclohexyl)-acetic acid
o ^V0
O KK>
The title compound can be prepared in accordance with literature Journal of the American Chemical Society (1948), 70 1898-9.
Step 2: trans-(4-Hydroxy-cyclohexyl)-acetic acid methyl ester
Figure imgf000127_0002
The ester can be prepared by refluxing the corresponding acid in methanol and catalytic sulfuric acid for 4 hours. Step 3 : trans-(4-Methoxy-cyclohexyl)-acetic acid methyl ester
trans-(4-Hydroxy-cyclohexyl)-acetic acid methyl ester (500 mg, 2.90 mmol) were dissolved in 1.5 ml DMF and cooled to 0-5 0C. Sodium hydride (190 mg, 4.35 mmol, 55%) and iodomethane (3.62 ml, 23.2 mmol) were added and the reaction mixture stirred for 4 hours at 0-5 0C. The reaction mixture was quenched with saturated NaHCO3-solution and extracted with dichloromethane. The organic extract was washed with brine, dried with sodium sulfate, filtered and evaporated. The crude product (561 mg, quant.) was obtained as a colourless oil and used without any further purification for the next step.
Intermediate C Trans-(3-Methoxy-cvclopentyl)-acetic acid methyl ester
^O JUO 1O
Step 1 : Trans-(3 -Hydro xy-cyclopentyl)-acetic acid methyl ester
The title compound can be prepared in accordance with literature Helvetica Chimica Acta - Vol. 75 (1992) Page 1945 and 1950.
Step 2: Trans-(3-Methoxy-cyclopentyl)-acetic acid methyl ester
The title compound was prepared in accordance with the general method of intermediate B, step 3 from rac-trans-(3 -hydro xy-cyclopentyl)-acetic acid methyl ester.
Intermediate D
4-Trans-{2-[4-f5-Fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cyclohexylamine; hydrochloride
Figure imgf000128_0001
Step 1 : 2,5-Difluoro-benzaldehyde oxime
Figure imgf000128_0002
2,5-Difluorobenzaldehyde (28.5 g, 0.20 mol) was dissolved in 30 ml EtOH. 80 ml water, 80 g crushed ice and hydroxylamine hydrochloride (15.3 g, 0.22 mol) were added. 250 ml (0.50 mol) 2N NaOH were added drop wise and the yellow solution was stirred for 3 hours at room temperature. The reaction mixture was neutralized to pH 6 with acetic acid. The formed suspension was diluted with water and filtered. The crystals were washed with water and dried 2 hours at 500C and <20mbar to obtain the desired product as a white solid (26.1 g, 83%). MS (m/e): 156.0 (M-H+).
Step 2: 4-{(2,5-Difluoro-phenyl)-[(E)-hydroxyimino]-methyl}-piperazine-l- carboxylic acid tert-butyl ester
Figure imgf000129_0001
2,5-Difluoro-benzaldehyde oxime (26.1 g, 0.17 mol) was dissolved in 250 ml ACN and heated to 35-40 0C. N-Chlorosuccinimide (23.3 g, 0.174 mmol) was added in portions (exothermic!) and the reaction mixture stirred for 30 minutes at 30-400C. The reaction mixture was quenched with water and extracted two times with ethyl acetate. The organic extracts were washed with brine, dried with sodium sulfate, filtered and evaporated. The residue was dissolved in 400 ml dichloromethane and Et3N (24.2 ml, 0.174 mmol) was added. Tert. -Butyl- 1-piperazinecarboxylate (34.1 g, 0.183 mmol) was added and the mixture stirred for 30 minutes at room temperature. The reaction mixture was quenched with saturated NaHCO3-solution and extracted with dichloromethane. The organic extracts were dried with sodium sulfate, filtered and evaporated. The crude product (61.9 g light yellow solid) was used without purification on the next step. MS (m/e): 342.2 (M+H+).
Step 3: 4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazine-l-carboxylic acid tert-butyl ester
Figure imgf000129_0002
4- {(2,5-Difluoro-phenyl)-[(E)-hydroxyimino]-methyl} -piperazine- 1 -carboxylic acid tert-butyl ester (28.3 g, 82.9 mmol) was suspended in 200 ml dioxane and stirred together with 300 ml 30% KOH in water for 16 hours at reflux. The reaction mixture was cooled and extracted two times with dichloromethane. The organic extracts were dried with sodium sulfate, filtered and evaporated. The crude product was purified by flash- chromatography on silica gel with hexane : ethyl acetate (95:5 to 40:60) to give 22.7 g (85%) of the product as a white solid. MS (m/e): 322.2 (M-H+).
Step 4: 5-Fluoro-3-piperazin-l-yl-benzo[d]isoxazole hydrochloride
Figure imgf000131_0001
4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazine-l-carboxylic acid tert-butyl ester (22.7 g, 70.6 mmol) was dissolved in 40 ml dichloromethane and 4N HCl in dioxane (264 ml, 1.06 mol) was added. The white suspension was stirred for 16 hours at room temperature, diluted with diisopropylether and filtered. The crystals were washed with diisopropylether and dried for 1 hour at 500C and <20 mbar, to get the desired salt as a white solid (18.2 g, quant.) [MS: m/e = 222.3 (M+H+)].
Step 5 : Trans-(4- {2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin- 1 -yl]-ethyl} - cvclohexyD-carbamic acid tert-butyl ester
Figure imgf000131_0002
The title compound, MS: m/e = 447.1 (M+H+), can be prepared in accordance with the general method of example 1, step 1 from 5-fluoro-3-piperazin-l-yl-benzo[d]isoxazole hydrochloride and trans-[4-(2-oxo-ethyl)-cyclohexyl]-carbamic acid tert-butyl ester (intermediate A).
Step 6: 4-Trans-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexylamine hydrochloride
The title compound, MS: m/e = 347.1 (M+H+), can be prepared in accordance with the general method of example 1, step 2 from trans-(4-{2-[4-(5-fluoro-benzo[d]isoxazol-3- yl)-piperazin- 1 -yl] -ethyl} -cyclohexyl)-carbamic acid tert-butyl ester.
Intermediate E Trans-(3-Methoxymethyl-cvclobutyl)-acetic acid methyl ester
Figure imgf000131_0003
Step 1 : S-Benzyloxymethyl-cyclobutanone
Figure imgf000132_0001
The title compound can be prepared in accordance with the literature in the patent WO2006063281.
Step 2: (3-Benzyloxymethyl-cvclobutylidene)-acetic acid methyl ester
Figure imgf000132_0002
The title compound, MS: m/e = 247.4 (M+H+), can be prepared in accordance with the general method of example 10, step 2 from S-benzyloxymethyl-cyclobutanone.
Step 3: Q-Benzyloxymethyl-cvclobutyD-acetic acid methyl ester
Figure imgf000132_0003
(3-Benzyloxymethyl-cyclobutylidene)-acetic acid methyl ester (5.4 g, 21.9 mmol) were dissolved in 80 ml methanol and cooled to 0-5 0C. NiCl2 (2.53 g, 19.5 mmol) and NaBH4 (4.14 g, 109.6 mmol) were added slowly and the reaction mixture stirred for 1 hour at 0-5 0C. The reaction mixture was quenched with IN HCl and extracted two times with dichloromethane. The organic extract was washed with brine, dried with sodium sulfate, filtered and evaporated. The crude product (3.0 g, 55 %) was obtained as a colourless liquid and used without any further purification for the next step. MS: m/e = 249.1 (M+H+).
Step 4: Trans-(3-Benzyloxymethyl-cvclobutyl)-acetic acid methyl ester
Figure imgf000132_0004
The title compound, MS: m/e = 249.1 (M+H+), was obtained from separation of (3- benzyloxymethyl-cyclobutyl)-acetic acid methyl ester using a chiral column (chiralpak AD). Step 5: Trans-(3 -Hydro xymethyl-cyclobutyD-acetic acid methyl ester
Figure imgf000133_0001
Prepared from trans-(3-berιzylo xymethyl-cyclobutyD-acetic acid methyl ester (980 mg, 3.95 mmol) by hydrogenation 16 hours at room temperature using Pd/C (10%) (420 mg) in ethylacetate (20 ml).
Step 6: Trans-(3-Metho xymethyl-cyclobutyD-acetic acid methyl ester
The title compound can be prepared in accordance with the general method of intermediate B, step 3 from trans-(3 -hydro xymethyl-cyclobutyD-acetic acid methyl ester.
Intermediate F 4-trans-{2-[4-f6-Chloro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexylamine hydrochloride
Figure imgf000133_0002
The title compound, MS: m/e = 363.3 (M+H+), can be prepared in accordance with the general method of intermediate D starting from 4-chloro-2-fluorobenzaldehyde.
Intermediate G
4-trans-{2-[4-f5-,6-Difluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cyclohexylamine hydrochloride
Figure imgf000133_0003
The title compound, MS: m/e = 365.2 (M+H+), can be prepared in accordance with the general method of intermediate D starting from 2,4,5-trifluorobenzaldehyde. Intermediate H
4-trans-{2-[4-f6-Chloro-5-fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cyclohexylamine hydrochloride
Figure imgf000134_0001
The title compound, MS: m/e = 381.3 (M+H+), can be prepared in accordance with the general method of intermediate D starting from 4-chloro-2,5-difluorobenzaldehyde.
Intermediate I
4-trans-{2-[4-f5-Chloro-6-fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cyclohexylamine hydrochloride
Figure imgf000134_0002
The title compound, MS: m/e = 381.3 (M+H+), can be prepared in accordance with the general method of intermediate D starting from 5-chloro-2,4-difluorobenzaldehyde.
Intermediate J
4-trans-{2-[4-f5.,6-Dichloro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cyclohexylamine hydrochloride
Figure imgf000134_0003
The title compound, MS: m/e = 397.1 (M+H+), can be prepared in accordance with the general method of intermediate D starting from 4,5-dichloro-2-fluorobenzaldehyde.
Intermediate K
4-trans-{2-[4-f6-Methyl-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexylamine hydrochloride
Figure imgf000135_0001
The title compound, MS: m/e = 343.3 (M+H+), can be prepared in accordance with the general method of intermediate D starting from 4-methyl-2-fluorobenzaldehyde.
Intermediate L
4-trans-{2-[4-f5-Methyl-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexylamine hydrochloride
Figure imgf000135_0002
The title compound, MS: m/e = 343.3 (M+H+), can be prepared in accordance with the general method of intermediate D starting from 5-methyl-2-fluorobenzaldehyde.
Intermediate M 4-trans-{2-[4-f6-Fluoro-5-methyl-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}- cyclohexylamine hydrochloride
Figure imgf000135_0003
The title compound, MS: m/e = 361.3 (M+H+), can be prepared in accordance with the general method of intermediate D starting from 5-methyl-2,4-difluorobenzaldehyde.
Intermediate N
4-trans-{2-[4-f6-Fluoro-benzo[dlisoxazol-3-yl)-piperazin-l-yll-ethyl}-cvclohexylamine hydrochloride
Figure imgf000136_0001
The title compound, MS: m/e = 347.3 (M+H+), can be prepared in accordance with the general method of intermediate D starting from 2,4-difluorobenzaldehyde.

Claims

Claims
1. A compound of formula (I) :
Figure imgf000137_0001
wherein:
X is independently of each other halogen or Ci-6-alkyl;
n is 0, 1, or 2;
R1 is -COR2 or-SO2-Ci_6-alkyl;
R2 is Ci-6-alkyl, Ci-6-haloalkyl, Ci-6-hydroxyalkyl, Ci-6-alkoxy, 3 to 10 membered cycloalkyl, 4 to 10 membered heterocycloalkyl, or 5 to 10 membered heteroaryl, which are optionally substituted by one or more substituents selected from the group consisting of: halo, hydroxy,
Ci-e-alkyl, Ci-6-haloalkyl,
Ci-6-hydroxyalkyl,
Ci-6-alkoxy,
Ci-6-alkoxy optionally substituted by one or more Ra,
-S-Ci_6-alkyl, -SO2-Ci_6-alkyl,
-CONH2,
-CHO,
3 to 10 membered cycloalkyl optionally substituted by one or more Ra,
4 to 10 membered heterocycloalkyl optionally substituted by one or more Ra, and
5 to 10 membered heteroaryl optionally substituted by one or more Ra;
wherein Ra is selected from the group consisting of: halo, hydroxy, Ci-e-alkyl, Ci-6-hydroxyalkyl, Ci-6-haloalkyl, and > Ci-6-alkoxy;
as well as pharmaceutically acceptable salts thereof.
2. A compound of formula (F) according to claim 1 :
Figure imgf000138_0001
x. (r) wherein X, R1 and n are defined as in claim 1.
3. A compound of formula (I) according to claim 1 wherein R1 is -COR2; and wherein X, R2 and n are defined as in claim 1.
4. A compound of formula (F) according to claim 2, wherein R1 is -COR2; and wherein X, R2 and n are defined as in claim 1.
5. A compound of formula (Ia) according to claim 1 :
Figure imgf000138_0002
Xn (Ia)
wherein:
X and n are defined as in claim 1 ;
R4 is hydrogen, hydroxyl, Ci-e-alkyl, Ci-6-hydroxyalkyl, Ci-6-alkoxy, 3 to 6-membered cycloalkyl optionally substituted by one or more Rb, or
4 to 7-membered hetero cycloalkyl optionally substituted by one or more Rb,
wherein Rb is selected from the group consisting of: hydroxy, Ci-e-alkyl, Ci-6-hydroxyalkyl, and
Ci-6-alkoxy.
6. A compound of formula (Ia') according to claim 5:
Figure imgf000139_0001
wherein X, R4 and n are defined as in claim 1.
7. A compound of formula (Ia') according to claim 6 wherein X and n are defined as in claim 1; and R4 is Ci_6-alkoxy or Ci_6-alkoxy-Ci_6-alkyl.
8. A compound of formula (Ia') according to claims 6 or 7 selected from the group consisting of:
N-trans- {4- [2-(4-benzo [d]isoxazol-3 -yl-piperazin- 1 -yl)-ethyl] -cyclohexyl} -3 - methoxy-propionamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3 -methoxy-propionamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-methoxy-acetamide;
2-Ethoxy-N-trans-(4-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3,3-dimethoxy-propionamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-4,4-dimethoxy-butyramide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3-methoxy-propionamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3 -methoxy-butyramide; N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3,3-dimethoxy-propionamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3-methoxy-propionamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-methoxy-acetamide;
N-trans-(4-{2-[4-(6-Chloro-5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3-methoxy-propionamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3-methoxy-propionamide; N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3,3-dimethoxy-propionamide;
N-trans-(4-{2-[4-(5,6-Dichloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3-methoxy-propionamide;
3 -Methoxy-N-trans-(4- {2- [4-(6-methyl-benzo [d]isoxazol-3 -yl)-piperazin- 1 -yl] -ethyl} - cyclohexyl)-propionamide;
3,3-Dimethoxy-N-trans-(4-{2-[4-(6-methyl-benzo[d]isoxazol-3-yl)-piperazin-l-yl]- ethyl} -cyclohexyl)-propionamide;
3 -Methoxy-N-trans-(4- {2- [4-(5 -methyl-benzo [d]isoxazol-3 -yl)-piperazin- 1 -yl] -ethyl} - cyclohexyl)-propionamide; N-trans-(4-{2-[4-(6-Fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-methoxy-acetamide;
N-trans-(4-{2-[4-(6-Fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3 -methoxy-propionamide; and
2-Ethoxy-N-trans-(4-{2-[4-(6-fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-l- yl]-ethyl} -cyclohexy^-acetamide.
9. A compound of formula (Ia') according to claim 6 wherein:
X and n are defined as in claim 1 ;
R4 is 3 to 6-membered cycloalkyl optionally substituted by one or more Rb, or
4 to 7-membered hetero cycloalkyl optionally substituted by one or more Rb;
wherein Rb is selected from the group consisting of: hydroxy, C^-alkyl,
Ci-6-hydroxyalkyl, and Ci-6-alkoxy.
10. A compound of formula (Ia') according to claim 6 or 9 selected from the group consisting of:
N-trans-{4-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-l-yl)-ethyl]-cyclohexyl}-2-trans- (3-methoxy-cyclopentyl)-acetamide; N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-trans-(4-methoxy-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(tetrahydro-pyran-4-yl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(4-isopropoxy-cyclohexyl)-acetamide;
2-[ 1 ,4]Dioxan-2-yl-N-trans-(4- {2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)-piperazin- 1 - yl] -ethyl} -cyclohexyl)-acetamide;
Rac-2-(2,2-Dimethyl-tetrahydro-pyran-4-yl)-N-trans-(4-{2-[4-(5-fluoro- benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-acetamide; N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(lR,4S)-7-oxa-bicyclo[2.2.1]hept-2-yl-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-trans-(3-hydroxymethyl-cyclobutyl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(3 -methyl-oxetan-3 -yl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-((S)-2,2,4-trimethyl-tetrahydro-pyran-4-yl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-((R)-2,2,4-trimethyl-tetrahydro-pyran-4-yl)-acetamide; 2-[ 1 ,3]Dioxan-2-yl-N-trans-(4- {2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)-piperazin- 1 ■ yl] -ethyl} -cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(4-methoxy-piperidin- 1 -yl)-acetamide; N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-trans-(3-methoxymethyl-cyclobutyl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-trans-(4-methoxy-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(tetrahydro-pyran-2-yl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-trans-(3-methoxy-cyclopentyl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(4-methoxy-4-methyl-cyclohexyl)-acetamide; N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(tetrahydro-pyran-4-yl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-trans-(4-hydroxy-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-oxetan-3 -yl-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-trans-(3-methoxymethyl-cyclobutyl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(R)-tetrahydro-pyran-2-yl-acetamide; N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(S)-tetrahydro-pyran-2-yl-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(4-isopropoxy-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-cyclopropyl-acetamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-trans-(4-methoxy-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(4-hydroxy-tetrahydro-pyran-4-yl)-acetamide; N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(4-methoxy-tetrahydro-pyran-4-yl)-acetamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(tetrahydro-pyran-4-yl)-acetamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-trans-(3-methoxy-cyclopentyl)-acetamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-[ 1 ,3]dioxan-2-yl-acetamide;
N-trans-(4-{2-[4-(6-Chloro-5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(tetrahydro-pyran-4-yl)-acetamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-cyclopropyl-acetamide; N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-[ 1 ,4]dioxan-2-yl-acetamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-[ 1 ,3]dioxan-2-yl-acetamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-trans-(3 -hydro xymethyl-cyclobutyl)-acetamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-trans-(3-methoxymethyl-cyclobutyl)-acetamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-trans-(4-methoxy-cyclohexyl)-acetamide; N-trans-(4-{2-[4-(5,6-Dichloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-trans-(4-methoxy-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(5,6-Dichloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(tetrahydro-pyran-4-yl)-acetamide;
2-trans-(4-Methoxy-cyclohexyl)-N-trans-(4-{2-[4-(6-methyl-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl] -ethyl} -cyclohexyl)-acetamide;
2-[ 1 ,3]Dioxan-2-yl-N-trans-(4- {2-[4-(6-methyl-benzo[d]isoxazol-3-yl)-piperazin- 1 - yl] -ethyl} -cyclohexyFj-acetamide;
2-[ 1 ,4]Dioxan-2-yl-N-trans-(4- {2-[4-(6-methyl-benzo[d]isoxazol-3-yl)-piperazin- 1 - yl] -ethyl} -cyclohexyFj-acetamide; 2-Cyclopropyl-N-trans-(4-{2-[4-(6-fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-
1 -yl] -ethyl} -cyclohexyFj-acetamide;
2-[l,3]Dioxan-2-yl-N-trans-(4-{2-[4-(6-fluoro-5-methyl-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl] -ethyl} -cyclohexyFj-acetamide; and
N-trans-(4-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(tetrahydro-pyran-4-yl)-acetamide.
11. A compound of formula (Ib) according to claim 1 :
Figure imgf000144_0001
wherein:
X and n are defined as in claim 1 ; and
R5 is 4 to 7-membered heterocycloalkyl; or
3 to 6-membered cycloalkyl optionally substituted by one or more halogen, hydroxyl or Ci-6-alkoxy.
12. A compound of formula (Ib') according to claim 11 wherein
Figure imgf000144_0002
wherein X, R5 and n are defined as in claim 11.
13. A compound of formula (Ib') according to claim 12 selected from the group consisting of: 4-Methoxy-cyclohexanecarboxylic acid N-trans-(4-{2-[4-(5-fluoro-benzo[d]isoxazol-
3 -yl)-piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide;
3-Methoxy-cyclohexanecarboxylic acid N-trans-(4- {2-[4-(5-fluoro-benzo[d]isoxazol-
3 -yl)-piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide;
Tetrahydro-pyran-4-carboxylic acid N-trans-(4- {2-[4-(6-chloro-benzo[d]isoxazol-3- yl)-piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide;
Tetrahydro-furan-3-carboxylic acid N-trans-(4- {2-[4-(6-chloro-benzo[d]isoxazol-3- yl)-piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide;
1 -Hydro xy-cyclopropanecarboxylic acid N-trans-(4- {2-[4-(6-chloro- benzo[d]isoxazol-3-yl)-piperazin- 1 -yl]-ethyl} -cyclohexyl)-amide;
(S)-Tetrahydro-furan-3-carboxylic acid (4- (2-[4-(6-chloro-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide;
4-trans-Methoxy-cyclohexanecarboxylic acid N-trans-(4- {2-[4-(6-chloro- benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-amide;
4-Methoxy-cyclohexanecarboxylic acid N-trans(4- {2-[4-(5,6-difluoro- benzo[d]isoxazol-3-yl)-piperazin- 1 -yl]-ethyl} -cyclohexyl)-amide;
Tetrahydro-pyran-4-carboxylic acid N-trans-(4- {2-[4-(5,6-difluoro-benzo[d]isoxazol-
3 -yl)-piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide; 1 -Chloro-cyclobutanecarboxylic acid N-trans-(4- {2-[4-(5-chloro-6-fluoro- benzo[d]isoxazol-3-yl)-piperazin- 1 -yl]-ethyl} -cyclohexyl)-amide;
Cyclobutanecarboxylic acid N-trans-(4- {2-[4-(5-chloro-6-fluoro-benzo[d]isoxazol-3- yl)-piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide;
Tetrahydro-pyran-4-carboxylic acid N-trans-(4- {2-[4-(5,6-dichloro-benzo[d]isoxazol- 3-yl)-piperazin- 1 -yl]-ethyl} -cyclohexyl)-amide.
14. The compound according to claim 1, wherein the piperazinyl-ethyl moiety and the N- amide moiety are attached to the cyclohexyl-ring in a trans-configuration.
15. The compound according to any one of claims 1 and 14, wherein X is fluoro or methyl.
16. The compound according to any one of claims 1 and 14 to 15, wherein n is 1 or 2.
17. The compound according to any one of claims 1 and 14 to 16, wherein R2 is Ci-6-alkyl which is optionally substituted by one substituent selected from the group consisting of Ci-6-alkoxy, -SO2-Ci_6-alkyl and 6 membered heterocycloalkyl.
18. The compound according to any one of claims 1 and 14 to 17, wherein R2 is methyl, methyl substituted by methanesulfonyl or [ 1 ,4]dioxin-2-yl or ethyl substituted by methoxy.
19. A compound of formula (I) according to claim 1 selected from the group consisting of:
N-trans- {4- [2-(4-benzo [d]isoxazol-3 -yl-piperazin- 1 -yl)-ethyl] -cyclohexyl} -3 - methoxy-propionamide;
N-trans- {4-[2-(4-benzo[d]isoxazol-3-yl-piperazin-l-yl)-ethyl]-cyclohexyl}-acetamide;
N-trans- {4-[2-(4-Benzo[d]isoxazol-3-yl-piperazin- 1 -yl)-ethyl] -cyclohexyl} -2-trans-
(3-methoxy-cyclopentyl)-acetamide;
N-trans- {4-[2-(4-Benzo[d]isoxazol-3-yl-piperazin-l-yl)-ethyl]-cyclohexyl} -2- hydroxy-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3-methoxy-propionamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-trans-(4-methoxy-cyclohexyl)-acetamide; Tetrahydro-pyran-4-carboxylic acid-trans-(4- (2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(tetrahydro-pyran-4-yl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-methoxy-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(4-isopropoxy-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3 -hydro xy-3 -methyl-butyramide; 2-Ethoxy-N-trans-(4-{2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-acetamide;
4-Methoxy-cyclohexanecarboxylic acid N-trans-(4- {2-[4-(5-fluoro-benzo[d]isoxazol-
3 -yl)-piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-methanesulfonamide;
2-[ 1 ,4]Dioxan-2-yl-N-trans-(4- {2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)-piperazin- 1 - yl] -ethyl} -cyclohexyl)-acetamide;
3-Methoxy-cyclohexanecarboxylic acid N-trans-(4- {2-[4-(5-fluoro-benzo[d]isoxazol-
3 -yl)-piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide; N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-malonamide;
Rac-2-(2,2-Dimethyl-tetrahydro-pyran-4-yl)-N-trans-(4-{2-[4-(5-fluoro- benzof^isoxazol-S-y^-piperazin-l-ylJ-ethyll-cyclohexy^-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(lR,4S)-7-oxa-bicyclo[2.2.1]hept-2-yl-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-trans-(3 -hydro xymethyl-cyclobutyFj-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(3 -methyl-oxetan-3 -yl)-acetamide;
2-((S)-2,2-Dimethyl-tetrahydro-pyran-4-yl)-N-trans-(4-{2-[4-(5-fluoro- benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-acetamide; 2-((R)-2,2-Dimethyl-tetrahydro-pyran-4-yl)-N-trans- (4- {2-[4-(5-fluoro- benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-acetamide;
2-[ 1 ,3]Dioxan-2-yl-N-trans-(4- {2-[4-(5-fluoro-benzo[d]isoxazol-3-yl)-piperazin- 1 - yl] -ethyl} -cyclohexyFj-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(4-methoxy-piperidin- 1 -yl)-acetamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3,3-dimethoxy-propionamide;
N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-trans-(3-methoxymethyl-cyclobutyl)-acetamide; N-trans-(4-{2-[4-(5-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-4,4-dimethoxy-butyramide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3-methoxy-propionamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-trans-(4-methoxy-cyclohexyl)-acetamide;
Tetrahydro-pyran-4-carboxylic acid N-trans-(4- {2-[4-(6-chloro-benzo[d]isoxazol-3- yl)-piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide; N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-rac-3,3,3-trifluoro-2-hydroxy-propionamide;
Tetrahydro-furan-3-carboxylic acid N-trans-(4- {2-[4-(6-chloro-benzo[d]isoxazol-3- yl)-piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(tetrahydro-pyran-2-yl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-trans-(3-methoxy-cyclopentyl)-acetamide; N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3 -methoxy-butyramide;
1 -Hydro xy-cyclopropanecarboxylic acid N-trans-(4- {2-[4-(6-chloro- benzo[d]isoxazol-3-yl)-piperazin- 1 -yl]-ethyl} -cyclohexyl)-amide; N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(4-methoxy-4-methyl-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(tetrahydro-pyran-4-yl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-propionamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-hydroxy-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-trans-(4-hydroxy-cyclohexyl)-acetamide; N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3 -hydro xy-3 -methyl-butyramide;
(S)-N-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-
3 -hydro xy-butyramide;
(S)-Tetrahydro-furan-3-carboxylic acid (4- (2-[4-(6-chloro-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-oxetan-3-yl-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-trans-(3-methoxymethyl-cyclobutyl)-acetamide; N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(R)-tetrahydro-pyran-2-yl-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(S)-tetrahydro-pyran-2-yl-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(4-isopropoxy-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-cyclopropyl-acetamide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3,3,3-trifluoro-propionamide; 4-trans-Methoxy-cyclohexanecarboxylic acid N-trans-(4-{2-[4-(6-chloro- benzo[d]isoxazol-3-yl)-piperazin- 1 -yl]-ethyl} -cyclohexyl)-amide;
N-trans-(4-{2-[4-(6-Chloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3,3-dimethoxy-propionamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3 -methoxy-propionamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-trans-(4-methoxy-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-propionamide; N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-methoxy-acetamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(4-hydroxy-tetrahydro-pyran-4-yl)-acetamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(4-methoxy-tetrahydro-pyran-4-yl)-acetamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(tetrahydro-pyran-4-yl)-acetamide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3 -hydro xy-3 -methyl-butyramide; N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-trans-(3-methoxy-cyclopentyl)-acetamide;
4-Methoxy-cyclohexanecarboxylic acid N-trans(4- {2-[4-(5,6-difluoro- benzo[d]isoxazol-3-yl)-piperazin- 1 -yl]-ethyl} -cyclohexyl)-amide;
Tetrahydro-pyran-4-carboxylic acid N-trans-(4- {2-[4-(5,6-difluoro-benzo[d]isoxazol- 3 -yl)-piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide;
Ethanesulfonic acid N-trans-(4- {2-[4-(5,6-difluoro-benzo[d]isoxazol-3-yl)-piperazin-
1 -yl] -ethyl} -cyclohexyl)-amide;
N-trans-(4-{2-[4-(5,6-Difluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-[ 1 ,3]dioxan-2-yl-acetamide; N-trans-(4-{2-[4-(6-Chloro-5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-propionamide;
N-trans-(4-{2-[4-(6-Chloro-5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3-methoxy-propionamide;
N-trans-(4-{2-[4-(6-Chloro-5-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(tetrahydro-pyran-4-yl)-acetamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-acetamide; N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3-methoxy-propionamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-cyclopropyl-acetamide; N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-[ 1 ,4]dioxan-2-yl-acetamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-[ 1 ,3]dioxan-2-yl-acetamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3,3-dimethoxy-propionamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-trans-(3-hydroxymethyl-cyclobutyl)-acetamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-trans-(3-methoxymethyl-cyclobutyl)-acetamide; N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3-methylsulfanyl-propionamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(3-methyl-isoxazol-5-yl)-acetamide;
3-Chloro-cyclobutanecarboxylic acid N-trans-(4- {2-[4-(5-chloro-6-fluoro- benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}-cyclohexyl)-amide;
5-Chloro-thiophene-2-carboxylic acid N-trans-(4- {2-[4-(5-chloro-6-fluoro- benzo[d]isoxazol-3-yl)-piperazin- 1 -yl]-ethyl} -cyclohexyl)-amide;
5-Methoxy-thiophene-2-carboxylic acid N-trans-(4- {2-[4-(5-chloro-6-fluoro- benzo[d]isoxazol-3-yl)-piperazin- 1 -yl]-ethyl} -cyclohexyl)-amide; N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-propionamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-hydroxy-acetamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-trans-(4-methoxy-cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-methanesulfonyl-acetamide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3-methanesulfonyl-propionamide; N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-carbamic acid methyl ester;
Cyclobutanecarboxylic acid N-trans-(4- {2-[4-(5-chloro-6-fluoro-benzo[d]isoxazol-3- yl)-piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide;
N-trans-(4-{2-[4-(5-Chloro-6-fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3,3,3-trifluoro-propionamide;
N-trans-(4-{2-[4-(5,6-Dichloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3 -methoxy-propionamide;
Tetrahydro-pyran-4-carboxylic acid N-trans-(4- {2-[4-(5,6-dichloro-benzo[d]isoxazol-
3 -yl)-piperazin- 1 -yl] -ethyl} -cyclohexyl)-amide;
N-trans-(4-{2-[4-(5,6-Dichloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-trans-(4-methoxy-cyclohexyl)-acetamide; N-trans-(4-{2-[4-(5,6-Dichloro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(tetrahydro-pyran-4-yl)-acetamide;
3 -Methoxy-N-trans-(4- {2- [4-(6-methyl-benzo [d]isoxazol-3 -yl)-piperazin- 1 -yl] -ethyl} - cyclohexyl)-propionamide;
N-trans-(4-{2-[4-(6-Methyl-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-propionamide;
2-trans-(4-Methoxy-cyclohexyl)-N-trans-(4-{2-[4-(6-methyl-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl] -ethyl} -cyclohexyl)-acetamide;
2-[ 1 ,3]Dioxan-2-yl-N-trans-(4- {2-[4-(6-methyl-benzo[d]isoxazol-3-yl)-piperazin- 1 - yl] -ethyl} -cyclohexyTj-acetamide; 2-[ 1 ,4]Dioxan-2-yl-N-trans-(4- {2-[4-(6-methyl-benzo[d]isoxazol-3-yl)-piperazin- 1 - yl] -ethyl} -cyclohexyTj-acetamide;
3,3-Dimethoxy-N-trans-(4-{2-[4-(6-methyl-benzo[d]isoxazol-3-yl)-piperazin-l-yl]- ethyl} -cyclohexyl)-propionamide;
3 -Methoxy-N-trans-(4- {2- [4-(5 -methyl-benzo [d]isoxazol-3 -yl)-piperazin- 1 -yl] -ethyl} - cyclohexyl)-propionamide;
N-trans-(4-{2-[4-(6-Fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(6-Fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-methoxy-acetamide; N-trans-(4-{2-[4-(6-Fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3-methoxy-propionamide;
2-Cyclopropyl-N-trans-(4-{2-[4-(6-fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-
1 -yl] -ethyl} -cyclohexyl)-acetamide;
2-Ethoxy-N-trans-(4-{2-[4-(6-fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-l- yl]-ethyl} -cyclohexyl)-acetamide;
2-[l,3]Dioxan-2-yl-N-trans-(4-{2-[4-(6-fluoro-5-methyl-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl] -ethyl} -cyclohexyl)-acetamide; N-trans-(4-{2-[4-(6-Fluoro-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(tetrahydro-pyran-4-yl)-acetamide.
20. A compound of formula (I) according to claim 1 selected from the group consisting of:
2-Methanesulfonyl-N-trans-(4-{2-[4-(6-methyl-benzo[d]isoxazol-3-yl)-piperazin-l- yl] -ethyl} -cyclohexyl)-acetamide;
2-[l,4]Dioxan-2-yl-N-trans-(4-{2-[4-(6-fluoro-5-methyl-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl] -ethyl} -cyclohexyl)-acetamide; 2-(R)-[l,4]Dioxan-2-yl-N-trans-(4-{2-[4-(6-fluoro-5-methyl-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl] -ethyl} -cyclohexyl)-acetamide;
2-(S)-[l,4]Dioxan-2-yl-N-trans-(4-{2-[4-(6-fluoro-5-methyl-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl] -ethyl} -cyclohexyl)-acetamide;
(S)-4,4,4-Trifluoro-N-trans-(4-{2-[4-(6-fluoro-5-methyl-benzo[d]isoxazol-3-yl)- piperazin- 1 -yl] -ethyl} -cyclohexyl)-3 -hydro xy-butyramide;
N-trans-(4-{2-[4-(6-Fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(tetrahydro-pyran-2-yl)-acetamide;
N-trans-(4-{2-[4-(6-Fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-(tetrahydro-furan-2-yl)-acetamide; and N-trans-(4-{2-[4-(6-Fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-2-methoxy-propionamide.
21. A compound of formula (I) according to claim 1 selected from the group consisting of: 2-Methanesulfonyl-N-trans-(4-{2-[4-(6-methyl-benzo[d]isoxazol-3-yl)-piperazin-l- yl] -ethyl} -cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(6-Fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-acetamide;
N-trans-(4-{2-[4-(6-Fluoro-5-methyl-benzo[d]isoxazol-3-yl)-piperazin-l-yl]-ethyl}- cyclohexyl)-3-methoxy-propionamide; and
2-(R)-[l,4]Dioxan-2-yl-N-trans-(4-{2-[4-(6-fluoro-5-methyl-benzo[d]isoxazol-3-yl)- piperazin- 1 -yTJ-ethyl} -cyclohexy^-acetamide.
22. A process for preparing a compound of formula (I) as defined in any of claims 1 - 21, wherein R1, X and n have meanings as given in claim 1, comprising one of the following steps:
a) reductive amination of aldehyde of formula (1-1) with 3-piperazine-l-yl-l,2- benzisoxazole of formula (1-2) in the presence of a reducing agent,
Figure imgf000153_0001
removing the protecting group G under acidic conditions to yield amine intermediate of formula (1-3),
Figure imgf000153_0002
Xπ (1-3)
b) and coupling of amine intermediate of formula (1-3) with a carboxylic acid R2-
COOH, acid chloride R2-COC1, or sulfonyl chloride R3-SO2C1 to yield compound o f formula (I) ,
wherein X, n and R2 are as given in claim 1 and R3 is Ci-6-alkyl.
23. Compounds according to any of claims 1 - 21, obtainable by the process of claim 24.
24. Compounds according to any of claims 1 - 21 for the use as a medicament.
25. A medicament comprising one or more compounds as claimed in any one of claims 1 to 21 and pharmaceutically acceptable excipients for the treatment and/or the prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions.
26. A pharmaceutical compositions comprising a compound as claimed in any one of claims 1 to 21 and a pharmaceutically acceptable carrier and/or adjuvant.
27. A pharmaceutical compositions comprising a compound as claimed in any one of claims 1 to 21 and a pharmaceutically acceptable carrier and/or adjuvant for the use in the treatment and/or the prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions.
28. Compounds according to any of claims 1 - 21 as well as its pharmaceutically acceptable salt for use as therapeutically active substances.
29. Compounds according to any of claims 1 - 21 as well as its pharmaceutically acceptable salt for use as therapeutically active substances for the treatment or prevention of diseases which are related to the serotonin 5-HT2a and dopamine D3 receptors.
30. Compounds according to any of claims 1 - 21 as well as its pharmaceutically acceptable salt for use as therapeutically active substances for the treatment and/or the prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions.
31. A method for the treatment or prevention of diseases which are related to the serotonin 5-HT2a and dopamine D3 receptors, which method comprises administering a compound according to any of claims 1 - 21 as well as its pharmaceutically acceptable salt to a human being or animal.
32. A method for the treatment and/or the prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions, which method comprises administering a compound according to any of claims 1 - 21 as well as its pharmaceutically acceptable salt to a human being or animal.
33. A compound in accordance with any one of claims 1 to 21 as well as its pharmaceutically acceptable salt for use in the treatment or prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions.
34. The use of compounds according to any of claims 1 - 21 as well as its pharmaceutically acceptable salt for the manufacture of medicaments for the treatment or prevention of diseases which are modulated by ligands for serotonin 5-HT2a and dopamine D3 receptors.
35. The use of a compound in accordance with any one of claims 1 to 21 as well as its pharmaceutically acceptable salt for the manufacture of medicaments for the treatment and/or the prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions.
36. The invention as hereinbefore described.
PCT/EP2009/061788 2008-09-22 2009-09-11 Piperazine d3 and 5-ht2a receptor modulators WO2010031735A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
ES09782901T ES2402875T3 (en) 2008-09-22 2009-09-11 D3 and 5-HT2a receptor modulators
CA2735400A CA2735400A1 (en) 2008-09-22 2009-09-11 Piperazine d3 and 5-ht2a receptor modulators
EP09782901A EP2334657B1 (en) 2008-09-22 2009-09-11 Piperazine d3 and 5-ht2a receptor modulators
MX2011002628A MX2011002628A (en) 2008-09-22 2009-09-11 Piperazine d3 and 5-ht2a receptor modulators.
BRPI0918949A BRPI0918949A2 (en) 2008-09-22 2009-09-11 5-ht2a and piperazine d3 receptor modulators
KR1020117006453A KR101329548B1 (en) 2008-09-22 2009-09-11 Piperazine d3 and 5-ht2a receptor modulators
CN2009801369519A CN102159557A (en) 2008-09-22 2009-09-11 Piperazine d3 and 5-ht2a receptor modulators
JP2011527297A JP5367824B2 (en) 2008-09-22 2009-09-11 Piperazine D3 and 5-HT2A receptor modulators
AU2009294695A AU2009294695B2 (en) 2008-09-22 2009-09-11 Piperazine D3 and 5-HT2a receptor modulators
IL210769A IL210769A0 (en) 2008-09-22 2011-01-20 Piperazine d3 and 5-ht2a receptor modulators

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08164802.4 2008-09-22
EP08164802 2008-09-22

Publications (1)

Publication Number Publication Date
WO2010031735A1 true WO2010031735A1 (en) 2010-03-25

Family

ID=41226238

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/061788 WO2010031735A1 (en) 2008-09-22 2009-09-11 Piperazine d3 and 5-ht2a receptor modulators

Country Status (14)

Country Link
US (1) US7858630B2 (en)
EP (1) EP2334657B1 (en)
JP (1) JP5367824B2 (en)
KR (1) KR101329548B1 (en)
CN (1) CN102159557A (en)
AR (1) AR073622A1 (en)
AU (1) AU2009294695B2 (en)
BR (1) BRPI0918949A2 (en)
CA (1) CA2735400A1 (en)
ES (1) ES2402875T3 (en)
IL (1) IL210769A0 (en)
MX (1) MX2011002628A (en)
TW (1) TW201016687A (en)
WO (1) WO2010031735A1 (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011161009A1 (en) 2010-06-21 2011-12-29 F. Hoffmann-La Roche Ag Anellated pyridine compounds as dual modulators of the 5-ht2a and d3 receptors
WO2012004206A1 (en) * 2010-07-06 2012-01-12 F. Hoffmann-La Roche Ag Anellated pyridine compounds
WO2012110470A1 (en) 2011-02-17 2012-08-23 F. Hoffmann-La Roche Ag Novel benzodioxole piperazine compounds
WO2013026695A1 (en) 2011-08-25 2013-02-28 Syngenta Participations Ag Isoxazoline derivatives as insecticidal compounds
WO2013026930A1 (en) 2011-08-25 2013-02-28 Syngenta Participations Ag Process for the preparation of thietane derivatives
WO2013026933A1 (en) 2011-08-25 2013-02-28 Syngenta Participations Ag Isoxazoline derivatives as insecticidal compounds
WO2013026929A1 (en) 2011-08-25 2013-02-28 Syngenta Participations Ag Dihydropyrrole derivatives as insecticidal compounds
WO2013026931A1 (en) 2011-08-25 2013-02-28 Syngenta Participations Ag Isoxazoline derivatives as insecticidal compounds
US8598357B2 (en) 2011-03-03 2013-12-03 Hoffmann-La Roche Inc. Benzodioxole piperidine compounds
US8877778B2 (en) 2010-12-15 2014-11-04 Hoffmann-La Roche Inc. Benzofurane compounds
WO2014180165A1 (en) * 2013-05-08 2014-11-13 上海医药工业研究院 Benzoisothiazole compounds and use in preparation of antipsychotic drugs
US8921397B2 (en) 2011-05-04 2014-12-30 Hoffmann-La Roche Inc. Benzofurane-piperidine compounds
US10870660B2 (en) 2016-07-28 2020-12-22 Shionogi & Co., Ltd. Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect
WO2021083246A1 (en) 2019-10-29 2021-05-06 上海翰森生物医药科技有限公司 Modifier of four-membered ring derivative, preparation method and application thereof
WO2021088920A1 (en) 2019-11-05 2021-05-14 上海翰森生物医药科技有限公司 Benzothiophene derivative regulator, preparation method therefor and use thereof
US11447484B2 (en) 2018-01-26 2022-09-20 Shionogi & Co., Ltd. Cyclic compound having dopamine D3 receptor antagonistic effect
WO2022228447A1 (en) 2021-04-28 2022-11-03 上海翰森生物医药科技有限公司 Salt containing piperazine polycyclic derivative, crystal form thereof, preparation method therefor, and use thereof
US11578084B2 (en) 2018-01-26 2023-02-14 Shionogi & Co., Ltd. Condensed ring compounds having dopamine D3 receptor antagonistic effect

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000032987A (en) * 1998-07-16 2000-02-02 Dai Ichi Seiyaku Co Ltd Dna
CN101778844B (en) * 2007-07-26 2013-01-02 弗·哈夫曼-拉罗切有限公司 Dual modulators of 5-ht2a and d3 receptors
EP2337783A1 (en) * 2008-09-23 2011-06-29 F. Hoffmann-La Roche AG Isoxazolo[4,5]pyridin-3-yl-piperazin derivatives useful as modulatorsof dopamine d3 receptors
JP5964615B2 (en) * 2011-03-28 2016-08-03 住友化学株式会社 Positive resist composition
UY35420A (en) * 2013-03-15 2014-10-31 Abbvie Inc ACILAMINOCICLOALQUILO COMPOUNDS APPROPRIATE TO TREAT DISORDERS THAT RESPOND TO THE MODULATION OF DOPAMINE D3 RECEIVER
CN106518841B (en) * 2015-09-15 2019-03-05 浙江京新药业股份有限公司 Cyclohexane derivant or its stereoisomer or salt and its preparation and application
WO2017045599A1 (en) * 2015-09-15 2017-03-23 浙江京新药业股份有限公司 Cyclohexane derivative or stereoisomer or salt thereof, and preparation and use thereof
CN107793350B (en) * 2016-09-05 2021-06-04 上海医药工业研究院 Arylethylpiperidinyl derivatives and their use for the treatment of schizophrenia
CN107793408B (en) * 2016-09-05 2020-12-08 上海医药工业研究院 Piperidine amino derivatives and their use for the treatment of schizophrenia
CN106543017B (en) * 2016-11-10 2018-04-06 中国科学院青岛生物能源与过程研究所 A kind of preparation method of 4 aminocyclohexyl acetic acid
CN110872272A (en) * 2018-08-30 2020-03-10 浙江京新药业股份有限公司 Salt of cyclohexane derivative

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011680A1 (en) 1993-10-28 1995-05-04 Hoechst-Roussel Pharmaceuticals Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgetics
WO2004026864A1 (en) 2002-09-17 2004-04-01 Warner-Lambert Company Llc Heterocyclic substituted piperazines for the treatment of schizophrenia
WO2004100954A1 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Treatment of psychotic and depressive disorders
WO2004100955A1 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Anxiety treatments with ziprasidone
WO2009013212A2 (en) * 2007-07-26 2009-01-29 F. Hoffmann-La Roche Ag Dual modulators of 5-ht2a and d3 receptors
WO2009101321A2 (en) 2008-02-04 2009-08-20 L'oreal Cationic surfactant compounds, use thereof as conditioner, cosmetic treatment method, and cosmetic or pharmaceutical compositions comprising same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1362039B1 (en) 2001-02-16 2005-12-21 Aventis Pharmaceuticals Inc. Heterocyclic substituted carbonyl derivatives and their use as dopamine d3 receptor ligands
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
CN1701072A (en) * 2002-09-17 2005-11-23 沃纳-兰伯特公司 Heterocyclic substituted piperazines for the treatment of schizophrenia
CA2505397A1 (en) * 2002-11-08 2004-05-21 Warner-Lambert Company Llc Phenylalkyl and pyridylalkyl piperazine derivatives
CN101384581B (en) * 2006-02-17 2013-09-18 弗·哈夫曼-拉罗切有限公司 Benzoyl-piperidine derivatives as 5HT2/D3 modulators
BRPI0707960A2 (en) 2006-02-17 2011-05-10 Hoffmann La Roche benzoyl piperidine derivatives as 5ht2 / d3 modulators, medicament and use thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011680A1 (en) 1993-10-28 1995-05-04 Hoechst-Roussel Pharmaceuticals Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgetics
WO2004026864A1 (en) 2002-09-17 2004-04-01 Warner-Lambert Company Llc Heterocyclic substituted piperazines for the treatment of schizophrenia
WO2004100954A1 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Treatment of psychotic and depressive disorders
WO2004100955A1 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Anxiety treatments with ziprasidone
WO2009013212A2 (en) * 2007-07-26 2009-01-29 F. Hoffmann-La Roche Ag Dual modulators of 5-ht2a and d3 receptors
WO2009101321A2 (en) 2008-02-04 2009-08-20 L'oreal Cationic surfactant compounds, use thereof as conditioner, cosmetic treatment method, and cosmetic or pharmaceutical compositions comprising same

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ASHBY ET AL.: "Acute administration of the selective D3 receptor antagonist SB-277011-A blocks the acquisition and expression of the conditioned place preference response to heroin in male rats", SYNAPSE, vol. 48, 2003, pages 154 - 156
CAMPOS, A. C. ET AL.: "The dopamine D3 receptor antagonist SB277011A antagonizes nicotine-enhanced brain-stimulation reward in rat", SOC. NEUROSCI. ABSTR., vol. 322, 2003, pages 8
DE ANGELIS, L.: "5-HT2A antagonists in psychiatric disorders", CURR. OPIN. INVESTIG. DRUGS, vol. 3, 2002, pages 106 - 112
DRESCHER, K. ET AL.: "In vivo effects of the selective dopamine D3 receptor antagonist A-437203", AM. SOC. NEUROSCI., vol. 894, 2002, pages 6
HARRISON, P. J.: "Neurochemical alterations in schizophrenia affecting the putative receptor targets of atypical antipsychotics. Focus on dopamine (D 1, D3, D4) and 5-HT2A receptors", BR. J. PSYCHIATRY SUPPL., vol. 38, 1999, pages 12 - 22
JOYCE, J. N.; MILLAN, M. J.: "Dopamine D3 receptor antagonists as therapeutic agents", DRUG DISCOVERY TODAY, vol. 10, no. 13, 1 July 2005 (2005-07-01), pages 917 - 25
MELTZER, H. Y. ET AL.: "Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values", J. PHARMACOL. EXP. THER., vol. 251, 1989, pages 238 - 246
PORRAS, G. ET AL.: "5-HT2A and 5-HT2C/28 receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum", NEUROPSYCHOPHARMACOLOGY, vol. 26, 2002, pages 311 - 324
REAVILL-C ET AL.: "Pharmacological actions of a novel, high-affinity, and selective human dopamine D3 receptor antagonist, SB-277011-A", JPET, vol. 294, 2000, pages 1154 - 1165
VOREL, S. R. ET AL.: "Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats", J. NEUROSCI., vol. 22, 2002, pages 9595 - 9603

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011161009A1 (en) 2010-06-21 2011-12-29 F. Hoffmann-La Roche Ag Anellated pyridine compounds as dual modulators of the 5-ht2a and d3 receptors
JP2013529610A (en) * 2010-06-21 2013-07-22 エフ．ホフマン−ラ ロシュ アーゲー Fused pyridine compounds as dual modulators of 5-HT2A and D3 receptors
US8586579B2 (en) 2010-06-21 2013-11-19 Hoffmann-La Roche Inc. Anellated pyridine compounds
CN102947310A (en) * 2010-06-21 2013-02-27 霍夫曼-拉罗奇有限公司 Anellated pyridine compounds as dual modulators of the 5-HT2A and D3 receptors
CN102947310B (en) * 2010-06-21 2015-11-25 霍夫曼-拉罗奇有限公司 As the condensed pyridine compound of the dual modulators of 5-HT2A and D3 acceptor
CN102958936B (en) * 2010-07-06 2015-10-21 霍夫曼-拉罗奇有限公司 The pyridine compounds condensed
WO2012004206A1 (en) * 2010-07-06 2012-01-12 F. Hoffmann-La Roche Ag Anellated pyridine compounds
JP2013533872A (en) * 2010-07-06 2013-08-29 エフ．ホフマン−ラ ロシュ アーゲー Fused pyridine compound
CN102958936A (en) * 2010-07-06 2013-03-06 霍夫曼-拉罗奇有限公司 Anellated pyridine compounds
US8470828B2 (en) 2010-07-06 2013-06-25 Hoffmann-La Roche Inc. Anellated pyridine compounds
US8877778B2 (en) 2010-12-15 2014-11-04 Hoffmann-La Roche Inc. Benzofurane compounds
US8722683B2 (en) 2011-02-17 2014-05-13 Hoffmann La-Roche Inc. Benzodioxole piperazine compounds
CN103380122A (en) * 2011-02-17 2013-10-30 霍夫曼-拉罗奇有限公司 Novel benzodioxole piperazine compounds
WO2012110470A1 (en) 2011-02-17 2012-08-23 F. Hoffmann-La Roche Ag Novel benzodioxole piperazine compounds
US8598357B2 (en) 2011-03-03 2013-12-03 Hoffmann-La Roche Inc. Benzodioxole piperidine compounds
US8921397B2 (en) 2011-05-04 2014-12-30 Hoffmann-La Roche Inc. Benzofurane-piperidine compounds
WO2013026931A1 (en) 2011-08-25 2013-02-28 Syngenta Participations Ag Isoxazoline derivatives as insecticidal compounds
WO2013026933A1 (en) 2011-08-25 2013-02-28 Syngenta Participations Ag Isoxazoline derivatives as insecticidal compounds
WO2013026930A1 (en) 2011-08-25 2013-02-28 Syngenta Participations Ag Process for the preparation of thietane derivatives
WO2013026695A1 (en) 2011-08-25 2013-02-28 Syngenta Participations Ag Isoxazoline derivatives as insecticidal compounds
WO2013026929A1 (en) 2011-08-25 2013-02-28 Syngenta Participations Ag Dihydropyrrole derivatives as insecticidal compounds
WO2014180165A1 (en) * 2013-05-08 2014-11-13 上海医药工业研究院 Benzoisothiazole compounds and use in preparation of antipsychotic drugs
EP2995617A4 (en) * 2013-05-08 2016-12-14 Shanghai Inst Pharmaceutical Ind Benzoisothiazole compounds and use in preparation of antipsychotic drugs
US9550741B2 (en) 2013-05-08 2017-01-24 Shanghai Institute Of Pharmaceutical Industry Benzoisothiazole compounds and methods of treating schizophrenia
US10870660B2 (en) 2016-07-28 2020-12-22 Shionogi & Co., Ltd. Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect
US11897899B2 (en) 2016-07-28 2024-02-13 Shionogi & Co., Ltd. Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect
US11345716B2 (en) 2016-07-28 2022-05-31 Shionogi & Co., Ltd. Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect
US11578084B2 (en) 2018-01-26 2023-02-14 Shionogi & Co., Ltd. Condensed ring compounds having dopamine D3 receptor antagonistic effect
US11447484B2 (en) 2018-01-26 2022-09-20 Shionogi & Co., Ltd. Cyclic compound having dopamine D3 receptor antagonistic effect
WO2021083246A1 (en) 2019-10-29 2021-05-06 上海翰森生物医药科技有限公司 Modifier of four-membered ring derivative, preparation method and application thereof
WO2021088920A1 (en) 2019-11-05 2021-05-14 上海翰森生物医药科技有限公司 Benzothiophene derivative regulator, preparation method therefor and use thereof
EP4056568A4 (en) * 2019-11-05 2024-02-28 Shanghai Hansoh Biomedical Co., Ltd. Benzothiophene derivative regulator, preparation method therefor and use thereof
WO2022228447A1 (en) 2021-04-28 2022-11-03 上海翰森生物医药科技有限公司 Salt containing piperazine polycyclic derivative, crystal form thereof, preparation method therefor, and use thereof

Also Published As

Publication number Publication date
MX2011002628A (en) 2011-04-05
US20100075983A1 (en) 2010-03-25
IL210769A0 (en) 2011-03-31
EP2334657A1 (en) 2011-06-22
US7858630B2 (en) 2010-12-28
KR101329548B1 (en) 2013-11-18
CA2735400A1 (en) 2010-03-25
EP2334657B1 (en) 2013-03-06
BRPI0918949A2 (en) 2019-09-24
AU2009294695B2 (en) 2012-09-13
AU2009294695A1 (en) 2010-03-25
ES2402875T3 (en) 2013-05-10
JP2012502944A (en) 2012-02-02
TW201016687A (en) 2010-05-01
JP5367824B2 (en) 2013-12-11
AR073622A1 (en) 2010-11-17
KR20110045071A (en) 2011-05-03
CN102159557A (en) 2011-08-17

Similar Documents

Publication Publication Date Title
EP2334657B1 (en) Piperazine d3 and 5-ht2a receptor modulators
EP2183245B1 (en) Dual modulators of 5-ht2a and d3 receptors
JP4855485B2 (en) Benzoyl-piperidine derivatives as 5HT2 / D3 modulators
AU2009296045B2 (en) Benzo[d]isoxazol-3-yl-piperazin derivatives useful as modulators of dopamine D3 receptors
AU2008285729B2 (en) Benzoyl-piperidine derivatives as dual modulators of the 5-HT2a and D3 receptors
US7795437B2 (en) Ether derivatives
Gobbi et al. D3 and 5-HT2A Receptor Modulators
Gobbi et al. Dual modulators of 5HT 2A and D 3 receptors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980136951.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09782901

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009782901

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009294695

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2735400

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009294695

Country of ref document: AU

Date of ref document: 20090911

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/002628

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1880/CHENP/2011

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2011527297

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20117006453

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: PI0918949

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110321